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Abstract
Cell tracking offers the opportunity to study migration and localization of cells in vivo, allowing investigations
of disease mechanisms and drug efficacy. Monocytes play a key role in the progression of atherosclerotic
plaques in the coronary arteries. While x-ray computed tomography (CT) is commonly used to clinically
assess coronary plaque burden, cell tracking with CT is mostly unexplored. The establishment of monocyte
cell tracking tools would allow for the direct investigation of gene and drug therapies aimed at monocyte
recruitment in atherosclerosis. In this thesis, we present the design and optimization of gold nanoparticles as
CT contrast agents for cell tracking of monocyte recruitment to atherosclerotic plaques. Gold nanoparticle
polymer constructs with controlled localization are evaluated as potential monocyte labels. However,
cytotoxic effects were observed at concentrations necessary for cell labeling. Therefore, variations in physical
and chemical properties of gold nanoparticles were explored as cell labels for monocyte tracking. Each
formulation was screened for effects on cell viability, cell function and uptake in monocytes. The uptake in
monocytes revealed a complex relationship with nanoparticle size behavior dependent on the surface ligand
used. This led to the selection of an optimal size and coating for monocyte labeling, 11-mercaptoundecanoic
acid coated 15 nm gold nanoparticles. This formulation was further investigated for cell viability, function, and
uptake with isolated primary monocytes. Moreover, primary monocytes labeled with this formulation were
used to observe monocyte recruitment in atherosclerotic mice. Mice with early atherosclerotic plaques
received intravenously injections of gold labeled monocytes and their recruitment to plaques were observed
over 5 days with CT. Increases in CT attenuation in the plaque and transmission electron microscopy of
plaque sections indicated the presence of gold labeled monocytes in the plaque. These results demonstrate the
feasibility of using CT to track ex-vivo labeled cells non-invasively with CT and could further be used to
investigate drugs aimed at modulating monocyte recruitment in the treatment of atherosclerosis. This work
expands the applications of cell tracking and may lead to additional uses in other diseases.
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ABSTRACT 
 
DESIGN AND SYNTHESIS OF GOLD NANOPARTICLE 
CONTRAST AGENTS FOR ATHEROSCLEROSIS IMAGING WITH 
COMPUTED TOMOGRAPHY 
 
 
Peter Chhour 
 
 
David P. Cormode, D.Phil. 
 
Cell tracking offers the opportunity to study migration and localization of cells in 
vivo, allowing investigations of disease mechanisms and drug efficacy. Monocytes play a 
key role in the progression of atherosclerotic plaques in the coronary arteries. While x-
ray computed tomography (CT) is commonly used to clinically assess coronary plaque 
burden, cell tracking with CT is mostly unexplored. The establishment of monocyte cell 
tracking tools would allow for the direct investigation of gene and drug therapies aimed 
at monocyte recruitment in atherosclerosis. In this thesis, we present the design and 
optimization of gold nanoparticles as CT contrast agents for cell tracking of monocyte 
recruitment to atherosclerotic plaques. Gold nanoparticle polymer constructs with 
controlled localization are evaluated as potential monocyte labels. However, cytotoxic 
effects were observed at concentrations necessary for cell labeling. Therefore, variations 
in physical and chemical properties of gold nanoparticles were explored as cell labels for 
monocyte tracking. Each formulation was screened for effects on cell viability, cell 
function and uptake in monocytes. The uptake in monocytes revealed a complex 
relationship with nanoparticle size behavior dependent on the surface ligand used. This 
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led to the selection of an optimal size and coating for monocyte labeling, 11-
mercaptoundecanoic acid coated 15 nm gold nanoparticles. This formulation was further 
investigated for cell viability, function, and uptake with isolated primary monocytes. 
Moreover, primary monocytes labeled with this formulation were used to observe 
monocyte recruitment in atherosclerotic mice. Mice with early atherosclerotic plaques 
received intravenously injections of gold labeled monocytes and their recruitment to 
plaques were observed over 5 days with CT. Increases in CT attenuation in the plaque 
and transmission electron microscopy of plaque sections indicated the presence of gold 
labeled monocytes in the plaque. These results demonstrate the feasibility of using CT 
to track ex-vivo labeled cells non-invasively with CT and could further be used to 
investigate drugs aimed at modulating monocyte recruitment in the treatment of 
atherosclerosis. This work expands the applications of cell tracking and may lead to 
additional uses in other diseases. 
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Chapter 1: Introduction to cardiovascular disease, computed 
tomography and nanoparticle contrast agents 
 
1.1 Introduction 
The development of nanotechnology has presented new potential solutions to 
biomedical problems. Via control over a nanoparticle’s physical and chemical properties, 
it can be specifically tailored to a given biomedical application. These properties 
influence how the nanoparticles interact with cells and the surrounding biological 
environment. As a result, nanotechnology has been involved in applications for drug 
delivery, gene delivery, adjuvants for cancer therapy and medical imaging. In particular, 
cell tracking has emerged as a methodology to observe cell behavior in vivo. The ability 
to detect migration, viability and localization of nanoparticle labeled cells has become of 
interest with the emergence of stem cell and immuno-cell therapy. Additionally, cell 
tracking presents an opportunity to study specific disease mechanisms in conditions 
such as cardiovascular disease (CVD).  
X-ray computed tomography is the most commonly used imaging modality to 
detect and diagnose CVD in patients due to its high spatial and temporal resolution. 
However, the current CT contrast agents used for CVD imaging have a number of 
limitations including fast clearance, potential adverse reactions, and non-specific 
localization. The use of iodinated nano-structures and inorganic nanocrystals has shown 
initial success in mitigating the issues mentioned above. Furthermore, the use of CT 
contrast agents for cell tracking remains largely unexplored, prompting the need to 
develop cell tracking CT contrast agents for investigating CVD.  
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Herein, we propose and evaluate the design of gold nanoparticle formulations for 
optimal labeling of monocytes for non-invasively tracking of their recruitment into 
atherosclerotic plaques with CT. Complications from atherosclerosis remain the leading 
cause of death in CVD and monocyte recruitment into plaques plays a large role in the 
progression of the disease. We hypothesized that large nanoparticles with high payloads 
would be effective for giving monocytes high loading, to allow their detection with CT. 
We therefore developed and characterized large (~500 nm) polyphosphazene 
nanospheres containing high payloads of nanocrystals including gold and iron 
nanoparticles. We found loading of the nanocrystals could be selectively localized to the 
core or surface without disrupting the diagnostic function of the nanoparticle (Chapter 2). 
However at incubation concentrations necessary for sufficient cell loading for in vivo 
detection with CT, cytotoxicity towards monocytes was observed. We next sought to 
investigate the potential of gold nanoparticles that were not encapsulated in 
polyphosphazene for labeling monocytes. We studied the effect of gold nanoparticle size 
and coating on monocyte labeling (Chapter 3). We synthesized particles ranging from 15 
to 150 nm and characterized their viability and uptake in monocytes. We found the 
coating of the gold nanoparticle affected the relationship between size and gold uptake 
in monocytes suggesting a unique size relationship for each coating examined. Since 
maximal cell loading could be achieved with 15 nm gold nanoparticles, we chose them 
for further study. We investigated the biocompatibility of 15 nm gold nanoparticle 
formulations with both a monocyte cell line and primary monocytes. After selecting an 
optimal formulation, we were able to detect the recruitment of gold labeled monocytes to 
atherosclerotic plaques in mice using x-ray computed tomography (Chapter 4). The 
results indicate the feasibility of non-invasively tracking the localization of gold labeled 
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cells using computed tomography. In this chapter, we detail the progression of 
atherosclerosis, the current state of CT technology, and the state of the art use of 
nanoparticles as CT contrast agents.        
 
1.2 Background 
1.2.1 Cardiovascular disease 
1.2.1a Overview 
Cardiovascular diseases (CVD) are the leading cause of death, accounting for 
nearly 1 in 3 deaths in the developed world today. Worldwide, CVD accounted for 17.3 
million deaths in 2013 which is expected to increase to 23.6 million by 2030.1 In the 
United States, approximately 35.1% of adults have at least one cardiovascular disease, 
and this number is expected to rise to 43.9% by 2030.2 This rise in prevalence is 
expected due to increase of factors such as physical inactivity, poor nutrition, and 
obesity. Cardiovascular disease is a broad definition that covers several pathologies 
including stroke, high blood pressure, heart failure, and coronary artery disease (CAD). 
Nearly half of the total deaths from CVD arise from CAD which includes angina pectoris 
(chest pain), atherosclerosis of the coronary arteries, myocardial infarction, and ischemic 
heart disease.3 These underlying causes of these conditions is the development of 
atherosclerosis in the coronary arteries that lead to narrowing of the arteries and 
potential blockage from rupture.  
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1.2.1b Coronary arterial disease 
Coronary artery disease is the progression of atherosclerosis in the coronaries 
such that it leads to clinical manifestations, i.e. ischemic heart disease and myocardial 
infarction. Atherosclerosis is prevalent in areas of high oscillatory flow and low 
endothelial shear stress, indicating that initiation of atherosclerosis may be due to 
localized mechanical stresses.4-5 These local flow conditions allow for the accumulation 
of circulating low density lipoproteins (LDL) into the intima. Oxidation of these LDL 
particles leads to the activation of the endothelium, increasing the expression of surface 
adhesion molecules.6-7 Increased expression of vascular cell adhesion molecule (VCAM) 
and intercellular adhesion molecules (ICAM) promote the adherence of circulating 
leukocytes.8-10 Subsequently, a chemokine gradient drives the migration of these 
adhered leukocytes into intima. Inflammatory monocytes play a key role in the 
progression of atherosclerosis and have been found to be recruited into the intima 
through chemokine gradients for MCP-1 (CCR2 receptor), fractalkine (CX3CR1 
receptor), and CCL5 (CCR5 receptor).11-13 In the intima, monocytes differentiate into 
phenotypical macrophages and begin engulfing oxidized LDL particles. These lipid 
particles accumulate in the macrophages, eventually becoming foam cells, which are 
thus named due to their appearance under microscopy.14 Foam cells promote the 
destabilization of the surrounding extracellular matrix (ECM) through the release of 
proteolytic enzymes, including matrix metalloproteinases (MMP) and cathepsins.15 The 
chronic build up of foam cells and other cells, such as altered smooth muscle cells 
migrating from the media, increases the chances of plaque rupture.16 
The development of plaques may eventually lead to their rupture, which releases 
the contents of the plaque into the circulation as depicted in Figure 1.1. The contents of 
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the plaque such as necrotic cells and cell debris induce the formation of a thrombus, 
which can occlude the artery.17 Such an occlusion occurring in the coronary artery can 
result in an acute myocardial infarction (MI). The myocardium downstream of the 
occlusion may become ischemic, which can lead to necrosis. Resolution of the occlusion 
can lead to increased incidence of a secondary cardiac event for patients resulting from 
weaken structural integrity of the affected myocardium. Management of wound healing 
after a MI is critical for improved prognosis for patients.     
 
Figure 1.1 Progression of atherosclerosis in artery. 
Illustration of plaque build up and progression to stabilized plaque or rupture. Continued 
accumulation of lipids in the intima can lead to a thin fibrous cap, increasing risk of 
rupture. Plaque rupture in the coronary artery leads to the formation of thrombus and an 
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occlusion of the artery i.e. myocardial infarction. Reproduced with permission from Libby 
et al. (2002).15 
 
1.2.1c The role of monocytes in coronary arterial disease  
Monocytes play a central role in both the progression of atherosclerosis in the 
coronary arteries and wound healing of the myocardium after a MI as shown in Figure 
1.2. In both instances, the function of the monocytes depends on their subtype. 
Monocytes are frequently divided into two subtypes via differential marker expression. In 
humans, classical inflammatory monocytes are described by the cell surface expression 
of CD14++CD16- markers.18 Conversely, resident monocytes are characterized by their 
expression CD14+CD16+.19 These two distinct monocyte subpopulations have been 
found to be conserved across species, with Ly6C+ and Ly6C- cell surface markers 
describing inflammatory and resident murine monocyte populations, respectively.20 
These subtypes are also classified by the relative expression of CCR2, a chemokine 
receptor involved in recruitment of inflammatory cells.21-22 This receptor plays a 
prominent role in the migration of inflammatory monocytes to inflamed tissue.      
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Figure 1.2 The role of monocytes in atherosclerosis progression. 
Monocytes are actively recruited into the arterial wall in developing plaques through 
active chemokine gradients. In the arterial wall, monocytes differentiate in macrophages 
and engulf LDL, becoming foam cells. Foam cells promote plaque destabilization and 
rupture. After rupture and occlusion of coronary arteries, monocytes are recruited to 
injured tissue for repair and wound healing. Reproduced with permission from Ghattas et 
al. (2013).23  
 
In the progression of arterial disease, the activation of the endothelium increases 
the adherence of circulating leukocytes including monocytes. Inflammatory monocytes 
migrate through the endothelium facilitated by the expression of surface receptors 
CCR2, CX3CR1 and CCR5.24-25 The release of chemokines corresponding to these 
receptors (MCP-1, fractalkine, CCL5) drives the chemokine gradients and subsequent 
migration. In the intima, monocytes differentiate into macrophages and begin engulfing 
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oxidized low density lipoproteins.26-27 The initial recruitment of monocytes populates 
lesional macrophages early in plaque formation. However in established plaques, the 
majority of the macrophages are due to local proliferation.28-29 With the accumulated 
LDL, the macrophages become phenotypical lipid-laden foam cells releasing cytokines 
and metalloproteinases that contribute to plaque destabilization.30-31 The accumulation of 
foam cells gives rise to lesion formation and eventual plaque rupture.  
A plaque rupture in the coronary arteries leads to the formation of a thrombus 
and potential occlusion of the vessel. The blockage of the coronary arteries is a 
myocardial infarction also known as a heart attack. The role of monocytes in wound 
healing after a myocardial infarct is critical to the long term clinical outcome. Monocytes 
are necessary to clear necrotic tissue from the site as well as promote the repair of the 
tissue. After an infarct monocytes are recruited from circulation to the injured area for 
repair for up to two weeks.32 The recruitment of monocytes has been hypothesized to be 
a biphasic response with separate monocyte subtypes dominating at each phase. 
Nahrendorf et al proposed that in the first 1-4 days following the infarct, inflammatory Ly-
6c+ monocytes are the major recruitment subtype, promoting clearance through 
phagocytosis and enzymatic digestion. Onward from day 4, reparative Ly-6c- monocytes 
appear to be the actively recruited subtype for wound healing through anti-inflammatory 
cytokines and growth factors.33 Similar to the recruitment to plaques, monocyte 
recruitment to the infarcted area is mediated through the chemokine receptors CCR2, 
CX3CR1, and CCR5. Moreover, it was proposed that the biphasic recruitment is due to a 
shift in the expression of ligands specific to these receptors by the infarct tissue. The 
production of MCP-1 (CCR2 ligand) promotes Ly-6c+ recruitment during “phase 1,” and 
fractalkine (CX3CR1 ligand) expression promotes Ly-6c- recruitment during “phase 2.”33 
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Studies have shown that  increased recruitment of Ly6c+ can lead to improper healing 
outcomes such as left ventricular dilation that can manifest into future clinical 
cardiovascular events.34-36 Therefore, proper accumulation of monocyte population in 
each phase after a myocardial infarct is critical to understanding infarct healing.  
 
1.2.2 Imaging of coronary arteries 
1.2.2a Introduction   
Coronary artery disease is a chronic condition, typically developing for decades 
before becoming symptomatic. While symptoms may differ in patients, a common early 
indicator for CAD is chest pain i.e. angina pectoris. Risk factors such as age, sex, 
weight, smoking, and hypertension are used to determine the risk of CAD for patients 
with chest pain.37 Patients with high risk undergo electrocardiography for evidence of 
ST-T wave changes or LV hypertrophy. If abnormalities are present, further evaluation is 
necessary to determine extent of the CAD and risk of a cardiac event.38-39 A coronary 
angiogram is a commonly used method to assess the location and severity of the arterial 
plaques. To perform a coronary angiogram, a catheter is fed to the coronary arteries and 
an iodinated dye is released. X-ray is used to observed the location and extent of 
stenosis in the coronary arteries. Coronary angiography also allows for stent and 
angioplasty intervention in the cases that call for revascularization. There is interest in 
developing imaging tools to non-invasively characterize plaque severity where magnetic 
resonance imaging (MRI), positron emission tomography (PET), and x-ray computed 
tomography (CT) are utilized.  
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MRI provides excellent soft tissue contrast, but suffers from long image 
acquisition times, preventing imaging of the coronary arteries from being performed in a 
single breath hold (which is needed to limit the impact of respiratory motion). Moreover, 
MRI of the coronary arteries lacks information on plaque calcification and cannot 
quantify the extent of the disease.40 MRI is not routinely used for coronary artery imaging 
in clinical practice. PET can provide functional cardiac information with the use of 
radioisotope contrast agents.41 Radiolabeled contrast agents typically have short-half-
lives, which increases the complexity of their distribution from production centers. The 
use of PET for coronary artery disease in the research field continues to expand, but still 
remains extremely limited clinically.42 18F-fluorodeoxyglucose (18F-FDG) has been used 
as a macrophage marker and subsequent marker of inflammation in atherosclerosis.43 
However, the low spatial resolution of PET has caused concern about reliability when 
quantifying 18F-FDG uptake in the coronary plaque.44 18F-sodium fluoride has also 
been explored as a PET marker for arterial calcification.45 For both contrast agents, low 
spatial resolution, motion and off-target uptake typically limits PET studies to evaluation 
of plaque only in larger arteries such as the carotids or thoracic aorta. As we will explain 
below, the modality of choice for clinical imaging of coronary artery disease is CT. 
   
1.2.2b CT principles  
CT has unique advantages for visualizing the coronary arteries that make it an 
excellent modality for this application. CT relies on x-rays that are produced by 
accelerating electrons from a cathode towards an anode, which is typically made of 
tungsten. The impact of the electrons, depending on their energy, produces x-rays in the 
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form of bremsstrahlung and characteristic radiation. In bremsstrahlung radiation, the 
incoming electron path is diverted by interaction with the nuclei, converting lost kinetic 
energy into an x-ray. In the case of characteristic radiation, the incoming electron ejects 
an inner-orbital electron of the atom. An electron from an outer orbital fills the vacancy 
while releasing a characteristic x-ray. For imaging applications, x-rays from the 
generating source interact with the object of interest in two primary mechanisms, 
Compton scattering and the photoelectric effect (Figure 1.3a). For Compton scattering, 
the incoming x-ray transfers a portion of its energy to an outer shell electron which 
causes the x-ray to scatter in a different direction. For CT energy levels, the primary form 
of interaction between x-rays and the subject is the photoelectric effect. The incoming x-
ray ejects an inner shell electron of the atom, typically of the k or l shell. An outer shell 
electron fills the inner-shell vacancy and produces a characteristic x-ray. The 
photoelectric effect occurs when the energy of the incoming x-ray is higher than the 
binding energy of the inner-shell electron, also known as the k-edge or l-edge energy. 
The photoelectric effect produces a significant jump in mass attenuation, improving 
contrast for imaging (Figure 1.3b). For CT contrast agents, imaging with peak voltages 
higher than the k-edge energy of the x-ray attenuating agent improves contrast 
enhancement between the agent and surrounding tissue. X-ray attenuation is quantified 
by the Hounsfield scale which defines Hounsfield units (HU) = 1000 * (µ- µwater)/(µwater - 
µair), where µ is the linear attenuation coefficient of the corresponding material. The 
Hounsfield scale standardizes the attenuation of a material in reference to the 
attenuation of water (HU= 0) and air (HU= -1000). 
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Figure 1.3 X-ray interaction with materials. 
(a) Incoming x-rays interact with matter via coherent scattering, Compton scattering, and 
photoelectron effect depending on the energy of the incident x-ray. At CT energy levels, 
the primary interaction is the photoelectron effect, where inner shell electrons are 
ejected and characteristic x-rays are produced. (b) For high Z-elements, ejection of inner 
shell (k or l shells) electron produces a spike in attenuation of x-ray, allowing for strong 
discrepancy between materials. Reproduced from with permission from Lee et al. 
(2013).46   
 
1.2.2c Current CT technologies 
Due to its non-invasive qualities and comparable effectiveness in predicting CAD 
in patients, the use of CT angiography has begun to rival coronary angiography in the 
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emergency room.47-48 The coronary arteries in humans are approximately 4-5 mm in 
diameter proximally, tapering rapidly to less than 1 mm, mandating high spatial 
resolution for imaging. A variety of adjustable factors, including slice thickness, 
reconstruction parameters, and field of view can affect spatial resolution in CT; most 
modern scanners are capable of producing resolution of 0.5 mm or less in each 
dimension.49 Moreover, cardiac and respiratory motion can be overcome by the fast 
temporal resolution of CT and a volume coverage allowing imaging of the entire heart to 
be acquired in a single breath hold. Increases in the number of detectors and 
improvement in gantry rotation speed in CT scanners has considerably improved the 
temporal resolution over the past two decades. Modern clinical 64-detector CT systems 
are capable of sub-200 ms resolution,50 while the newest CT scanners are capable of 
sub-100 ms temporal resolution.51 Synchronization of the acquisition to the 
electrocardiogram (ECG) signal can be used to reduce artifacts from heart motion.52 
ECG synchronization can be performed using two methods, prospective triggering and 
retrospective gating. Prospective triggering acquires images at a pre-defined portion of 
the R-R interval, while retrospective gating acquires images throughout the cardiac 
cycle, allowing for image reconstruction at any phase of the heartbeat, but at the cost of 
a higher radiation dose.  
 CT can quickly image the coronary arteries and exclude coronary artery disease 
from patients presenting with chest pain.53-55 CT allows for post-processing of cross-
sectional scans to create improved visual information, such as 3D renderings of 
coronary arteries.56 The applications of cardiac CT for plaque characterization include 
calcium scoring, determination of non-calcified plaque volume and extent of stenosis.57 
These parameters can be assessed with CT angiography (CTA), a non-invasive CT 
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scan using contrast agents to visualize arterial flow. The plaque characteristics that can 
be derived from CTA can be used to identify patients at high risk of a significant cardiac 
event. High risk plaque features that can be visualized with CTA include stenosis ≥ 50%, 
positive remodeling, low HU, napkin ring sign, and spotty calcium.58 A novel application 
of cardiac CT angiography is noninvasive determination of the hemodynamic 
significance of an observed stenosis. Fractional flow reserve (FFR) describes the 
pressure difference across an arterial stenosis as compared to the pressure in the 
absence of a stenosis and can be measured directly with catheter angiography.59 
However, advancements in computer modeling has allowed calculations of fluid 
dynamics from CTA scans for accurate determination of coronary flow and pressure 
without the need for an invasive procedure. CTA-derived computational models of FFR 
have been shown to have higher accuracy of determining the impact of stenoses than 
CTA based measurements of stenosis dimensions alone.60 The myocardium can also be 
visualized with high resolution allowing for detection of abnormal morphology in the 
chambers of the heart and valves.61 Moreover, the degree of injured myocardium after 
an infarct can be determined due to the changes in the thickness and/or scar formation 
of the myocardium.62  
 
1.2.2d Developing CT technologies 
 Advancements in x-ray CT technology are allowing for new potential clinical 
indications. Most commonly, CT images have been reconstructed using back filtered 
projection to create 3D datasets. With increases in computing power, iterative 
reconstruction methods have become available, allowing for improved signal to noise 
 
15 
 
ratios (SNR) as compared to current reconstruction methods i.e. back filtered 
projection.63 With improved SNR, similar image quality compared to back filtered 
projection reconstructions are achievable with less radiation dose.64 Various models of 
iterative reconstruction have been compared to filtered back projection, and lower image 
noise was consistently observed for identical CT imaging parameters.65 Iterative 
reconstruction could therefore be a boon for cardiothoracic imaging where image quality 
can suffer from motion artifacts, obese patients, calcium artifacts, and blooming from 
stents.66 Researchers have found that the improved image quality leads to more 
accurate diagnoses with iterative reconstruction compared to filtered back projection for 
coronary CT angiography.67-68 While various iterative reconstruction models are 
available, further experimental validation is needed before wider adoption. There is also 
current exploration for the use of iterative reconstruction methods to improve CT 
sensitivity towards contrast agents.69 Improving CT sensitivity to contrast agents may 
further enable CT applications such as cell tracking. 
 Multi-color or spectral computed tomography is an emerging CT technology 
capable of distinguishing different elements based on their x-ray absorption at different 
energies. This technology works by exploiting the x-ray absorption at the k-edge of high 
Z-elements and creating discrete photon energy bins.70 By separating the incoming 
photons by energy, multiple materials can distinguished in a single scan.71 This 
technology allows for material decomposition which results in material-specific images, 
providing additional information compared with current CT scanners. Additionally, 
spectral CT can offer new benefits for CT contrast agents due to material 
discrimination.72-73 Specifically, this technology allows for quantification of localized 
contrast agents and the possibility of discriminating multiple contrast agents in a single 
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scan.74-75 The use of contrast agents for CT can benefit from both of these emerging 
technologies, with the aim to improve CT sensitivity for contrast agents and expand 
detection capabilities of current CT scanners.    
      
1.2.3 CT cardiovascular contrast agents 
1.2.3a Introduction 
CT contrast agents play a key role in cardiovascular CT scans; the use of 
contrast agents in CT can improve the delineation between different soft tissues and is 
critical for highlighting blood vessels. The primary mechanism for x-ray attenuation in CT 
is the photoelectric effect. At CT energy levels (25-140 keV), incoming x-rays have 
enough energy to interact and eject inter-shell electrons (k or l shell) of the atom. 
Ejection of a k-shell electron produces a significant increase in x-ray attenuation and 
allows for increased separation between tissue and contrast media. For this reason, CT 
contrast agents are typically high atomic number elements such as iodine, barium, gold, 
bismuth, and lanthanides that have l and/or k edges that are at much higher energies 
than tissue and are closer to diagnostic x-ray energies (Table 1.1). However, CT suffers 
from low sensitivity to contrast agents, typically requiring millimolar local concentrations 
to produce contrast that can be distinguished from the background.76 
Table 1.1 Characteristics of elements commonly used to form CT contrast agents. 
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Clinically, iodinated contrast agents (ICA) can be used to visualize the 
vasculature as well as organs such as the brain, heart, liver, and kidneys.77-79 Clinical 
ICA are small molecules that are based on a tri-iodinated benzene ring (Figure 1.4). 
These types of structures have reduced osmolality and toxicity compared with iodide ion 
based agents. These iodinated rings are typically functionalized with amides and alcohol 
groups to provide water solubility, and can be monomers or dimers. These agents can 
be further categorized into ionic and non-ionic formulations which yield different 
properties in terms of toxicity and clearance from the blood stream. Regardless of the 
molecular structure of these agents, clinically approved ICA suffer from rapid renal 
clearance from the circulation after intravenous injection, on the order of minutes.80 
Given this rapid clearance, large amounts of contrast agent are often used for prolonged 
or multiple CT scans, with doses of 150 ml being used routinely.811 Injecting large 
volumes of ICA increases the chance of severe renal impairment, known as contrast 
induced nephropathy, in specific patient populations.82 Contrast-induced nephropathy is 
more likely in patients with pre-existing renal dysfunction,83 who now compose 26% of 
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the US population over 65.84 This proportion is expected to increase in the coming years, 
since renal dysfunction is common in diabetics and the prevalence of diabetes is 
predicted to rapidly rise.85-86 Iodinated contrast agents also can commonly cause 
adverse reactions in patients ranging from mild symptoms including nausea and 
vomiting to severe reactions such as anaphylaxis.87 
 
Figure 1.4 Common used iodinated small molecules. 
Tri-iodinated benzene ring based compounds that are clinically used as CT contrast 
agents. Variations include (a) ionic monomers, (b) non-ionic monomers, (c) ionic dimers 
and (d) non-ionic dimer. Reproduced from with permission from Lee et al (2013).46   
 
As mentioned, iodinated small molecule contrast agents are the most widely 
used class of agent in clinical CT scanning. While different formulations (ionic vs non-
ionic, dimer vs monomer) have slightly differing biocompatibility properties, they continue 
to suffer from rapid clearance and the risk of adverse reactions.87 Researchers have 
turned to nanotechnology to improve the properties of iodine-based agents. 
Incorporation of iodinated agents into nanoparticles such as nano-emulsions, micelles, 
liposomes, dendrimers have resulted in improvements in circulation time and 
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biocompatibility. The structures of some of the nanoparticle agents used as CT contrast 
agents are displayed in Figure 1.5. Long blood circulation times of contrast agents may 
help to improve the assessment of cardiovascular health. A long circulating agent can 
also decrease the total dose necessary for an imaging procedure, potentially reducing 
the burden of the agent on the patient. The use of a blood pool contrast agent for CT 
may provide information about coronary artery disease and progression, allowing 
visualization of the extent of stenosis in an artery as well as calcified and non-calcified 
plaques.88 Use of a contrast agent also allows for assessment of cardiac functions such 
as ejection fraction and stroke volume.49 In addition, contrast agents are needed to 
highlight blood vessels during stent placement procedures. Below, we further explore the 
current state of CT contrast agents including iodinated nanotechnologies and inorganic 
nanoparticles. 
 
Figure 1.5 Nanotechnologies used for contrast agent development. 
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Schematic representations of some of the nanoparticle platforms used to incorporate 
iodinated agents and inorganic nanocrystals for improved biocompatibility and biological 
function. Reproduced with permission from Mulder et al (2005).89 
 
1.2.3b Iodinated nanoparticle contrast agents 
To incorporate iodinated agents into nanoparticles, researchers have turned to a 
number of different nanotechnology platforms, each with their own advantages. 
Predominately, iodinated agents have been encapsulated or conjugated to oils and lipids 
to form these nanoparticles. One such platform is nano-emulsions, where the core of the 
particle contains iodinated oils. Nano-emulsions can be formed via simple methods that 
produce stable iodinated particles and have been an attractive choice for iodinated 
contrast agents. An emulsion is formed with a suitable amphiphilic surfactant 
encapsulating an iodinated oil core. An iodinated oil called Lipiodol (also known as 
Ethiodol) is FDA approved and consists of iodine combined with ethyl esters of poppy 
seed oil.90 Because Lipiodol is hydrophobic, it has limited clinical uses (it is used as an 
agent for lymphangiography and trans-arterial chemoembolization).91-92 To expand the 
applications of Lipiodol as a blood pool agent, Pluronic F127 and a polyethylene glycol 
(PEG) diamine was used to encapsulate Lipiodol into a nano-emulsion.93 These 
particles, 150 nm in diameter, were shown to be thermodynamically stable and produce 
vascular CT contrast in the ventricles and major arteries for up to 4 hours.  
Nano-emulsions have also been reported where a mixture of phospholipids and 
cholesterol was used to surround the hydrophobic core, which consisted of iodinated 
triglycerides. A nano-emulsion formed with endogenous oils and lipids was 
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demonstrated as an effective contrast agent for hepatic imaging and is available as a 
commercial product known as Fenestra LC®.94-95 The iodinated triglycerides making up 
the core of this nano-emulsion are rapidly metabolized by the liver.96 To provide longer 
circulation as a blood pool contrast agent, the agent has been reformulated with PEG 
included at the surface of the particle to reduce uptake by hepatocytes, which is known 
as Fenestra VC®.97-98 As a blood pool agent, Fenestra VC® has been used to study 
cardiac function in mice, quantifying ejection fraction, stroke volume, and cardiac 
output.99 In this study, Fenestra VC® provided vascular contrast for 3 hours with a nearly 
500 HU value difference between the blood and myocardium. Moreover, with the use of 
Fenestra VC®, Detombe et al., studied cardiac function and ventricular remodeling in a 
mouse model of myocardial infarction. The group was able to assess systolic and 
diastolic volumes and ejection fraction non-invasively over the course of 4 weeks after 
myocardial infarction.100 Both studies utilized cardiac gating with micro-CT to quantify 
cardiac function accurately.  
 While Fenestra formulations have been used successfully for cardiac 
applications, relatively poor inclusion of iodine by weight means that very large volume 
administrations of the agent are required (up to 40% of total blood volume). To 
overcome this issue, researchers have used denser iodinated oils to improve iodine 
content in the formulations. Using, a dense, tri-iodinated oil, de Vries et al., formed nano-
emulsions using the amphiphilic polymer, poly(butadiene)-b-poly(ethylene oxide) (PBD-
PEO).101 The agent was able to provide strong vascular contrast in the chambers of the 
heart of up to 220 HU directly after administration. Attenuation of the liver and spleen 
remained at high levels over the three hour observation period suggesting the 
mononuclear phagocytic system as the main clearance pathway for the agent. Novel 
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approaches to increasing the density of iodinated oils continue to be explored.102-103 For 
instance, Attia et al. reported agents that contain up to 65% wt. of iodine via use of a 
hexa-iodinated monoglyceride and a PEGylated nonionic surfactant.98 This formulation 
showed clear delineation of the major arteries and heart chambers post-injection with a 
long circulation half-life of 6.1 hours.            
Micelles are similar to nano-emulsions, in that they are self-assemblies of 
amphiphilic molecules where the hydrophilic head groups point outwards and the 
hydrophobic tails point inwards (Figure 1.5). The main difference between emulsions 
and micelles is that there is not an oil core for micelles. Therefore, to form micelle-based 
CT contrast agents, iodinated molecules are typically linked to the hydrophobic tails of 
the amphiphiles, concentrating the iodinated moieties into the center of the micelle. This 
allows for high iodine payloads.104 There have been several reports of iodinated micelles 
used as blood pool contrast agents.105 Torchilin et al. reported the synthesis of micelles 
using iodine containing poly-l-lysine (MPEG-iodolysine). The micelles were 
approximately 80 nm in diameter with 33.8% iodine content. The agent was injected 
intravenously and allowed for CT imaging of the aorta, heart, liver and spleen for up to 3 
hours post-injection in rats.106  
While nano-emulsions and micelles can carry hydrophobic contrast media, 
liposomes are versatile platforms that can carry both aqueous and hydrophobic 
payloads. Liposomes are synthesized through the use of amphiphilic lipids or polymers 
that self-assemble into bilayers. This architecture allows for encapsulation of hydrophilic 
agents in the core as well as hydrophobic agents in the bilayer. One of the first liposomal 
iodinated contrast agents was synthesized using L-α-phosphatidylcholine and was 
loaded with a number of different aqueous iodinated agents.107 The agent was injected 
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intravenously as a blood pool contrast agent. Uptake of the liposome was seen in the 
liver and spleen in a dose dependent manner with maximum attenuation of 240 HU seen 
at 1 hour. Because these early liposomes provided strong contrast of the liver and 
spleen, it was primarily used to visualize tumors in these organs.108-109  
With improvements to liposome design, most notably the modification of 
amphiphilic lipids/polymers with PEG, the diagnostic applications of liposomal contrast 
agents expanded. The addition of PEG to liposomal formulations allows for significantly 
increased blood circulation times improving their utility as blood pool agents.110-111 One 
of the earliest reports of PEGylated liposomes, PEG-phosphatidylethanolamine (PEG-
PE) liposomes, found that the addition of PEG increased the blood circulation time to up 
to 5 hours as compared to 30 minutes for non-PEGylated formulations.112 Iodinated 
PEGylated liposomes have been successful in providing strong vascular contrast of up 
to 900 HU in the aorta, as reported in a study by Mukundan et al.113  
 With the use of liposomes, a significant issue is the leakage of internal payloads 
through the lipid bilayer. Hydrophilic payloads have been found to diffuse through 
bilayers due to chemical gradients. To overcome this issue, some groups have added 
cholesterol to liposome formulations, which reduces the permeability of the liposome and 
thereby decreases payload leakage.114-115 Additionally, direct iodination of the lipids used 
to form the liposome can be used to prevent internal leakage, since covalently binding 
iodine onto lipid constrains the contrast generating material in the bilayer.116  
 Moreover by incorporating iodinated molecules into the lipid bilayer, the aqueous 
core can carry a separate payload including drugs for theranostics applications, another 
imaging agent for multi-modal imaging, or more of the same agent for increased payload 
delivery. A study by Kweon et al., reported liposomes that were simultaneously loaded 
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with iodinated contrast into both the core and lipid bilayer.117 1,2-dimyristoyl-sn-glycero-
3phosphocholine (DMPC), cholesterol, and Lipiodol were mixed together, freeze-dried 
and resuspended with a solution containing iopamidol to form the liposomes. As 
mentioned above, cholesterol increases the rigidity of the lipid membrane decreasing 
leakiness of the liposomes. This dual loading procedure produced particles about 280 
nm in diameter, and a solution whose iodine concentration was 49.2 mg/ml. Inclusion of 
both Lipiodol and iopamidol was found to improve iodine content in the nanoparticle 
solution over either payload alone. Intravenous injection of the liposome produced strong 
contrast in the aorta after injection and was observed for up to 2.5 hr. Because of the 
lack of PEG in the formulation, high uptake was seen in the liver and spleen, resulting in 
attenuation values of up to 684 HU for the spleen. This study demonstrates the 
versatility of liposomes for contrast agent delivery. 
 Dendrimers are another platform that has been used to develop contrast agents 
for computed tomography. Dendrimers are polymeric molecules formed through 
sequential branched growth steps termed “generations”. Each generation exponentially 
increases the number of branches, isolating the core from the external environment. 
Additionally, the last generation of the branched sequence can be functionalized to 
confer specific properties to the dendrimer. The branched structure provides excellent 
molecular stability and can provide many sites for functionalization at the ends of the 
branches.118 Dendrimers synthesized using poly(amido amine) (PAMAM) allow for 
functionalization through amine groups at the available termini of the molecule. By 
conjugating triiodobenzenepropanoic acid (DMAA-IPA) onto a PAMAM dendrimer, 
Yordanov et al. were able to incorporate up to 33% iodine content by weight.119 Large 
dendrimers are often quickly cleared through the mononuclear phagocytic system, 
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however Fu et al. reported dendrimer-based CT contrast agents with improved 
circulation times. These dendrimers were formed via the use of a large PEG core (6000-
12000 MW) and poly-L-lysine for branch generation.120 The amine termini of these 
dendrimers were functionalized with triiodophthalamide molecules to provide CT 
contrast.  
Nanotechnology offers several platforms upon which to develop contrast agents 
for CT as outlined above. Blood pool agents are useful to help visualize several 
pathologies in coronary artery disease and myocardial infarction, however specific 
targeting of contrast agents can allow single mechanisms or processes in cardiovascular 
disease to be probed. The progression of coronary artery disease occurs in many 
stages, providing numerous targets to study. Targeting can be accomplished by 
attaching ligands such as antibodies or peptides to the surface of the particle. Moreover, 
the use of native biological material such as lipoproteins (e.g LDL or high density 
lipoprotein) can provide targeting for cardiovascular disease. 
Pan et al., used poly(styrene-b-acrylic acid) to produce nano-emulsions with high 
payloads of Lipiodol (up to 37% wt of iodine) under 100 nm in diameter.121 Furthermore, 
the authors conjugated an anti-fibrin monoclonal antibody onto the particle using a 
modified avidin-biotin linker. Fibrin is generated during the coagulation cascade and is a 
key element in thrombus formation. It is a very high density target and therefore suitable 
for molecular imaging via CT (high density targets are needed due to the low sensitivity 
of CT). A fibrin targeted agent may reveal information on plaque rupture and subsequent 
thrombus formation. Using a fibrin clot phantom, the agent found a CNR value of 98 ± 12 
compared to the surrounding water. From rat experiments, the blood half-life of the 
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agent was found to be 56 minutes, although in vivo thrombus targeting experiments 
were not reported. 
 LDL is an attractive platform for targeted imaging due to its evasion of the 
immune system, biocompatibility, biodegradability, defined size and innate targeting. 
LDL infiltration in leaky endothelium is a key stage in early atherosclerosis development. 
A number of studies have attempted to use LDL as nanoparticle platform to carry 
imaging agents for detection of plaque for multi-modalities.122-124 For iodinated contrast 
agents, a study by Hill et al. demonstrated the feasibility of using LDL containing 
iodinated tri-glycerides to target liver cells (HepG2) that over express the LDL-
receptor.125 This in vitro study resulted in contrast enhancement of the cells, but would 
require further testing in vivo.  
 
1.2.3c Inorganic nanoparticle contrast agents 
While iodinated small molecules are the contrast agents used for x-ray computed 
tomography clinically, there has been significant pre-clinical interest in the development 
of inorganic nanoparticles as imaging agents. Inorganic nanoparticles can provide 
improved x-ray attenuation at CT energy ranges due to higher k-edge energy levels as 
compared to iodinated agents. Furthermore, the payloads of inorganic nanoparticles can 
be much higher than for iodine based agents, since the density of inorganic materials is 
often very high. For example, Brown et al., reported a solid bismuth core CT contrast 
agent (core density 9.8 g/ml) whose 76 nm cores carried a payload of 6 million Bi atoms 
each.126 Additionally, the use of inorganic nanocrystals may alleviate biocompatibility 
complications associated with iodinated agents as outlined above.  
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Of the various types of inorganic nanocrystals that have been proposed as CT 
contrast agents, gold nanoparticles (AuNP) have been the focus of most work. Gold 
nanoparticle syntheses allow for control of size, shape, and functionality of the particles. 
This precise control allows for specific tailoring of these particles for a given application. 
AuNP can be included in various nanotechnology platforms, i.e. micelles, liposomes, 
dendrimers, and as ligand stabilized crystalline nanoparticles.127-128 Gold nanoparticles 
are also well known for their biocompatible properties and have been used in a variety of 
biomedical applications such as drug delivery, imaging, biosensors, and photothermal 
ablation (Figure 1.6).129-133  
 
Figure 1.6 Biomedical applications of gold nanoparticles. 
 
28 
 
Gold nanoparticles can be synthesized in various shapes and sizes. Control over these 
properties in addition to control over chemical functionalization allow for tailoring of 
nanoparticles to specific biomedical applications. Reproduced with permission from 
Dreaden et al (2012).134 
 
 As a CT contrast agent, the physical parameters of the particle as well as its 
chemical properties can drastically influence the particle’s biological properties in terms 
of clearance and biocompatibility. One of the first AuNP developed as an x-ray contrast 
agent was a 1.9 nm spherical formulation, and was shown to provide strong 
enhancement of the major vessels. However, due to the small size of the agent, the 
particles were rapidly cleared through the renal system as evidenced by high attenuation 
in the bladder in images acquired 10 mins after injection.135 Increasing the size and/or 
modifying the surface functionality of AuNP has been shown to improve circulation time, 
as found in studies of AuNP whose core size was around 10 nm. After coating with PEG, 
the nanoparticles had an overall size of 38 nm. These nanoparticles were not renally 
cleared and provided vascular contrast over a period of 12-24 hours.136  
 A study by Kim et al., examined the effectiveness of AuNP as blood pool contrast 
agents after surface modification with PEG.137 AuNP 30 nm in diameter were 
synthesized through the reduction of gold chloride by sodium citrate using a modified 
Turkevich method.138-139 Ligand exchange was performed with 5000 molecular weight 
methoxy-PEG-thiol for stabilization and to provide a long circulation half-life. Cytotoxicity 
of the AuNP-PEG particles were evaluated in HepG2 (epithelial liver cell line). The 
particles were well tolerated up to 1000 µg/ml of Au. After intravenous injection of AuNP-
PEG, the agent yielded strong contrast in the heart and major arterial vessels (>100 
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HU). An increase in attenuation of roughly 100 HU in the heart and blood vessels was 
sustained for 4 hours post-injection. The attenuation of the liver and spleen was found to 
increase over the 24 hour period, indicating the major clearance pathways for the PEG 
coated AuNP. Due to the uptake of the particles by Kupffer cells and hepatocytes, the 
authors demonstrated visualization of a hepatoma in vivo in a rat model. In scans, 12 
hours post-injection, strong attenuation in the aorta was seen with clear delineation of 
the hepatoma. Other studies have focused on different AuNP structures (e.g. 
nanorods140-141), coatings (such as gum-arabic142-143) or incorporated gold into other 
platforms such as dendrimers.144-147 While AuNP have desirable properties for x-ray 
imaging, the cost of gold may be an issue for widespread adoption and scale up. Other 
high atomic number elements have been explored as CT contrast agents. For example, 
studies have shown bismuth nanoparticles as a possible CT blood pool contrast 
agent.148 Naha et al., reported the development of dextran coated bismuth-iron 
nanoparticles for in vivo blood contrast imaging with both CT and MRI.149 
Tantalum is another element that has been recently explored as a candidate for 
CT contrast agents due to the low toxicity of its oxide and strong x-ray absorption.150-151 
A group from General Electric have published on several tantalum oxide formulations 
where the overall nanoparticle size is below 5 nm, thus allowing for swift renal excretion. 
Due to the relative natural abundance of tantalum compared to gold, tantalum is an 
order of magnitude cheaper, which may facilitate widespread use. In another study, 
tantalum oxide nanocrystals were prepared using reverse emulsions and then surface 
functionalized with PEG and a fluorophore tag.152 This synthesis can be done on a bulk 
scale and allows the core size to be controlled in the 6-15 nm diameter range. As a 
blood pool agent, strong contrast enhancement of the heart and major blood vessels 
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could be seen for up to 3 hours post-injection, with eventual accumulation in the spleen 
and liver.  
Gadolinium chelates serve as MRI contrast agents for several biomedical 
applications including cancer and vascular imaging.153-154 Despite the toxicity concerns 
over non-chelated gadolinium and tissue retention, several studies have evaluated 
gadolinium as a potential CT contrast agent.155-156 Due to its unique properties for MRI, 
researchers have developed gadolinium nanoparticles for dual mode imaging with CT 
and MRI. The addition of gadolinium chelates to gold nanoparticles has been shown to 
provide significant contrast for both modalities.157-159 
A number of other high atomic number elements have shown promise as 
effective CT contrast agents. Gold and silver core-shell nanoparticles have been shown 
to produce stronger CT contrast than iodinated agents.160-162 A report by Chou et al., 
demonstrated the use of iron/platinum nanoparticles for dual CT and MRI molecular 
imaging after intravenous injection.163 Several studies have reported the use of tungsten 
nanoparticles as CT contrast agents that provide better enhancement compared to 
traditional iodinated agents.164-166 Moreover, ytterbium based nanoparticles have 
received attention as potential CT agents due to favorable x-ray absorption spectra and 
relative natural abundance compared to other potential elements mentioned.167-168 
Ytterbium based nanoparticles also present multi-modal opportunities through 
upconversion fluorescence imaging. Upconverting fluorescent probes allow for excitation 
at NIR-wavelengths for deep tissue penetration with reduced background tissue 
absorption. Liu et al., synthesized ytterbium based particles coated in PEG for use as a 
CT contrast agent.169 Xing et al., synthesized tri-modal nanoparticles for upconversion 
fluorescence, MR and CT imaging.170 The group synthesized gadolinium-based 
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upconverting nanoparticles (doped with yttrium, ytterbium, erbium, and thulium) that 
were also surface coated with gold nanoparticles. In vivo imaging of these trimodal 
particles was demonstrated with subcutaneous injection of the particles at tumor bearing 
locations in mice.  
 
1.2.3c Cell tracking agents 
 The use of nanoparticles as contrast agents provides unique advantages that 
can be exploited for specific biomedical applications. One such application is in vivo cell 
tracking, where a population of specific cells can be monitored in real time via imaging. 
Cell tracking offers the possibility of non-invasively observing cell behaviors such as 
migration, localization, and viability over a period of time.171 This technology has 
emerged as a particular area of interest since the development of adoptive cell therapy 
and stem cell transplantations.172 Both therapies involve the transplantation of 
endogenous cells that have been modified ex vivo. The fate of these transplanted cells is 
of high interest as it may provide information on the effectiveness of the therapies and 
the conditions that predict a successful treatment. Cell tracking has been explored with 
several imaging modalities including MRI, ultrasound, PET and optical imaging.173-174 
Contrast agents have developed for in a variety of cell tracking applications including 
neural stem cells,175 mesenchymal stem cells,176 hematopoietic progenitor cells,177 and 
cardiac applications.178-179  
 In cell tracking, coronary artery disease is of high interest due to the cells 
involved in the disease progression and regenerative opportunities after myocardial 
infarction. With injection of stem cells after myocardial infarction, there have been clinical 
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reports of improved left ventricle remodeling and function.180 However, concerns about 
cell fate, localization and safety need to resolved before further adoption of the therapy. 
Clinical imaging modalities are currently being explored as a method to address these 
issues.181 The use of MRI and MRI contrast agents have been the main focus due to 
high spatial resolution and reasonable contrast agent sensitivity. MRI contrast agents for 
cell tracking typically contain superparamagnetic (SPION) or ultra small paramagnetic 
(USPION) iron oxide particles.182 These agents primarily work by shortening T2 
relaxation (iron oxide) to produce hypo-contrast in the images (i.e. image darkening). 
There has a been a number of pre-clinical studies demonstrating success stem cell 
tracking in infarct models.183-185 A study Bulte et al., labeled autologous mesenchymal 
stem cells with Feridex (SPION) and directly injected the cells intra-myocardial into the 
infarct border zone in a canine model.186 The cells could be detected for up to 8 weeks 
post-injection with MRI and histology showed that the transplanted cells were indeed in 
the infarct region. While tracking stem cells with MRI can provide information about 
migration and localization, cell functionality can be difficult to assess. In a study by 
Chapon et al., the study utilized both MRI and FDG-PET to evaluate the localization and 
metabolic activity of the transplanted cells.187 FDG is a glucose analog with a fluorine-18 
radionuclide substituted for a hydroxyl group. Its uptake in cells is closely correlated to 
metabolic activity and viability. In a rat infarct model, bone marrow derived stem cells 
were labeled with SPION and injected directly into infarct zone. The stem cells could be 
detected for up to 6 weeks with MRI. With PET, an increase in FDG uptake was 
noticeable in the first week in infarct animals with the labeled stem cells as compared to 
infarct animals that did not receive stem cells. However, the increase in FDG did not 
persist the duration of the 6 weeks, potentially indicating death of the injected stem cells 
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providing valuable information about cell viability that could not be determined through 
MRI alone.  
   While PET can be used to assess function of the injected cells, a number of 
studies have sought to use radiolabeled tracers to track transplanted stem cells with 
PET/SPECT. Because of short half-lives of radionuclides, 111In is the most commonly 
explored agent (half-live 2.8 days) with most studies lasting one week.188-189 With 
SPECT, Mitchel et al. were able to observe 57% retention of 111In-tropolone labeled 
endothelial progenitor cells in the infarct border zone in a canine infarct model. The 
study observed that the cells could be detected after 15 days. Clinically, some studies 
have used PET to determine the engraftment of stem cells after delivery in short term 
cases of acute myocardial infarction.190-191 A study by Penicka et al. compared the 
engraftment of 99mTc labeled bone marrow derived mononuclear cells in acute (AMI) 
versus chronic myocardial infarction (CMI) patients. At 2 hours, myocardial activity from 
the transplanted cells could be seen in all five patients with AMI and 4 out of 5 CMI 
patients. However, after 20 hours, only 3 of the AMI patients had detection of the labeled 
cells. These results demonstrate that engraftment of cells for myocardial infarction may 
be limited to only acute cases. For cell tracking, PET/SPECT offers high sensitivity for 
cell detection but is limited by poor spatial resolution and short half-lives of agents.  
 There has been in interest in developing cell tracking agents for ultrasound (US) 
due to its low cost, non-invasiveness and real time imaging capabilities. Typical US 
agents are based on inert gases trapped inside a microparticle for detection. For cell 
labeling, long term stability of the agent within the cell remains a problem in addition to 
poor spatial resolution. Most studies for cell tracking with US have been limited to in vitro 
studies with polymer microbubbles as cell labels.192 A study by Toma et al. used lipid 
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microbubbles to label mesenchymal stem cells and deliver these cells via an intra-aortic 
injection to plaque rupture models in rabbits.193 After 24 hours, labeled cells could be 
detected on the lumen surface at the delivery site but did not show migration towards 
injury location.     
 Progress with CT cell tracking has been limited due to the low CT sensitivity 
towards contrast agents requiring relatively large payloads of agent for detection. 
Despite this limitation, researchers have developed cell tracking with CT, demonstrating 
feasibility in a number of applications.96, 194 Barnett et al. have demonstrated the use of 
perfluoroctylbromide (PFOB) nanoparticles (conjugated to rhodamine) to label and track 
exogenous cells non-invasively over time. The PFOB acted as a multimodal label 
allowing for CT and US imaging. Pancreatic islets were co-encapsulated with PFOB in 
alginate-based capsules, which allowed their visualization in vivo.195    
Several cell tracking applications with CT have found success in using AuNP to 
label cells. For instance, Betzer et al. utilized 20 nm AuNP surface functionalized with 
glucose to label mesenchymal stem cells.196 These gold labeled cells were injected 
directly into the left ventricle in the brain and monitored over 21 days. The authors were 
able to observe the migration of gold labeled cells over the 21 days to a specific region 
of injury. The authors were able to non-invasively quantify the number of AuNP labeled 
cells in particular regions, since x-ray attenuation is linearly proportional to the 
concentration of contrast agent, allowing for quantification of cell number from CT scans. 
This group has performed similar studies such as tracking the migration of AuNP labeled 
T-cells to xenograft tumors.197  
With AuNP and the use of synchrotron x-ray radiation sources, super high 
resolution of in vivo cells have been demonstrated.198 Astolfo et al. demonstrated the 
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feasibility of detecting engrafted rat F98 glioma cells in a mice model. The cells were 
labeled with 50 nm citrate coated spherical AuNP and 200,000 cells were injected into 
the striatum. The cells could be detected for the duration of the experiment, 7.5 days, 
using CT synchrotron radiation.198 While synchrotron radiation imaging remains 
experimental, researchers have been able to reach single cell resolution with AuNP 
labeled cells, opening new possibilities of future CT applications.199  
 
1.3 Conclusion 
 For medical imaging, contrast agents are able to provide additional anatomical 
and functional information that can help assess the health of the patient. The 
development of contrast agents continues to improve, further expanding their 
applications and capabilities. As discussed previously for CT, contrast agents have 
evolved from simple iodinated molecules to complex nanotechnologies with purposeful 
design. However, expanding the breadth of these nanotechnologies into specialized 
biomedical applications requires individual investigation to assess the effectiveness of 
the nanoparticles in that application.  
 Interest in cell tracking continues to grow with the advancement in cell-based 
therapies. While exploration of cell tracking contrast agents have been mostly limited to 
MRI (clinical) and optical (pre-clinical), CT’s spatial and temporal resolution make it a 
promising cell tracking modality for cardiovascular applications. Specifically, the 
development of atherosclerosis in the coronary arteries, subsequent rupture, and 
myocardial infarction present several stages where cell tracking technology is of high 
need. Monocytes are a cell type that plays a role in each stage, infiltrating developing 
plaques, promoting eventual plaque rupture, and participating in wound healing after an 
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infarct. The labeling and tracking of these monocytes can lead to more in-depth 
investigation of each stage, elucidating mechanisms in the disease. In the following 
chapters we present the development and assessment of nanotechnologies designed for 
labeling of monocytes for detection with CT. We investigate the parameters of the nano-
complexes that optimize the labeling and biocompatibility with monocytes. Lastly, we 
explore the use of the nanotechnologies in tracking monocytes during the progression of 
atherosclerosis in mice models. 
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Chapter 2: Design of polymer nanoparticle constructs as CT 
contrast agents 
 
2.1 Abstract 
Nanoparticles of complex architectures can have unique properties. Self-
assembly of spherical nanocrystals is a high yielding route to such systems. In this 
study, we report the self-assembly of a polymer and nanocrystals into aggregates, where 
the location of the nanocrystals can be controlled to be either at the surface or in the 
core. These nanospheres, when surface decorated with nanocrystals, resemble disco 
balls thus the term nano-disco balls. We studied the mechanism of this surface loading 
phenomenon and found it to be Ca2+ dependent. We also investigated whether excess 
phospholipids could prevent nanocrystal adherence. We found surface loading to occur 
with a variety of nanocrystal types including iron oxide nanoparticles, quantum dots, and 
nanophosphors, as well as sizes (10-30 nm) and shapes. Additionally, surface loading 
occurred over a range of polymer molecular weights (~30-3,000 kDa) and phospholipid 
carbon tail length. We also show that nanocrystals remain diagnostically active after 
loading onto the polymer nanospheres i.e. providing contrast in the case of magnetic 
resonance imaging for iron oxide nanoparticles and fluorescence for quantum dots. 
Hypothesizing that large, high payload nanoparticles would allow high cell loading, we 
investigated the labeling of monocytes with core loaded nanospheres for CT cell tracking 
applications.  
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2.2 Introduction 
Methods to create complex nanoparticle architectures such as stars, shells, 
cubes and frames have led to structures with unique properties.1-4 However, direct 
syntheses of such structures are frequently low yielding and difficult to scale up. An 
alternative approach is to form complex architectures from self-assembly of simpler, 
high-yielding components. One such route is incorporation of inorganic nanocrystals into 
polymeric nanoparticles. Such assemblies have a wide range of applications including 
uses in catalysis,5 energy,6 drug delivery,7-8 and medical imaging.9 Often the structural 
organization of these nanoparticles will dictate its function and behavior in a given 
application. For example, previous research has shown that gold nanoparticles are 
capable of quenching the emission of nearby fluorescent sources when closely 
arranged. Jennings et al showed that fluorescence could be recovered by separating the 
1.5 nm gold nanoparticles and fluorophore a distance as little as 15 nm.10 Hence, 
separate core and surface loading of gold cores and fluorophores could maintain 
fluorophore fluorescence. Therefore, the ability to control localization of nanocrystals via 
self-assembly would be a valuable tool in the synthesis of nanocrystal/polymer 
composite particles. Control over nanocrystal distribution within the core of polymer 
constructs has previously been demonstrated.11-17 For instance, Luo et al found that by 
modifying the surface ligands of gold nanoparticles, their incorporation could be focused 
to specific regions (i.e. the core center or at the edge of the core) within nanoparticles 
formed from amphiphilic co-polymers of polystyrene and poly(acrylic acid).18  
In this chapter, we report the serendipitous discovery of a system where 
nanocrystals can be selectively loaded onto the surface of polymer nanospheres, as 
opposed to the core. This forms a structure reminiscent of a disco ball, which we term a 
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nano-disco ball. We have found that phospholipid coated inorganic nanoparticles can be 
used to surface decorate a polymer nanosphere formed from poly(bis(4-
carboxyphenoxy)phosphazene), or PCPP, whereas carboxylic acid coated nanocrystals 
localize to the core. PCPP is a part of a larger class of phosphorous-nitrogen backbone 
based polymers called polyphosphazenes.19 These polymers have drawn interest for 
use in biomedical applications due to their tunable functionality and biocompatibility.20-22 
By modifying the polyphosphazene side chains and molecular weight, the 
biodegradation rate of polymers can be controlled, making this a promising platform for 
drug and contrast agent delivery.23-24 Specifically, PCPP has been used to form ionically 
cross-linked hydrogels,25-26 polymer films,27 and more recently microencapsulating 
spheres.23, 28-29 This is the first report of a system that integrates polyphosphazenes and 
nanocrystals. Furthermore, this is a rare instance of a system where nanocrystals can be 
preferentially loaded onto the surface of a particle as opposed to internal loading. We 
believe that this novel system has excellent potential as a contrast agent or theranostic 
delivery platform.  
Herein, we selectively incorporate nanocrystals into the core or surface of the 
nanospheres synthesized with PCPP. We investigate the conditions for surface 
localization of nanocrystals onto PCPP nanospheres (Figure 2.1). We report the 
synthesis of these nano-disco balls and their characterization via transmission electron 
microscopy, scanning electron microscopy and electron microscopy tomography. They 
can be loaded with separate core and surface payloads, maximizing contrast for two 
imaging methods. We have probed the synthetic process for the key steps in the 
formation of the nano-disco balls. We evaluated the effects of varying the physical and 
chemical properties of the nanocrystals used on surface loading. We also varied 
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phospholipid tail length for micelle formation and PCPP molecular weights for synthesis. 
In addition, we have investigated how competing micelles might affect the adherence of 
nanocrystals. Lastly, we assessed the biocompatibility and effectiveness of core loaded 
nanospheres and nano-disco balls as cell tracking contrast agents for monocyte 
labeling. Since CT is limited by low sensitivity, we hypothesized that large, ultra-high 
payload nanoparticles would be effective for creating high intra-cellular contrast agent 
loading. We therefore evaluated CT contrast generation, viability, and cytokine release 
for gold core loaded PCPP nanospheres. We also examined stability in serum and 
applications as a dual cell tracking and drug delivery agent for nano-disco balls.  
 
 
Figure 2.1 Schematic depictions of the PCPP nanosphere platform. 
(a) Versatility of PCPP platform for nanocrystal type and loading location. (b) Schematic 
of PCPP nanosphere synthesis.  
Table 2.1: Definitions for abbreviations in PCPP study 
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2.3 Materials and methods  
2.3.1 Materials 
 Poly(bis(4-carboxyphenoxy)phosphazene) disodium salt (PCPP, 1 MDa) was 
purchased from Sigma-Aldrich (St. Louis, MO). PCPP polymers of 3.8 MDa and 36.4 
kDa molecular weight were synthesized at The Pennsylvania State University. All 
phospholipids including 1-myristoyl-2-hydroxy-sn-glycero-3-phosphocholine (MHPC) and 
chain length variants were purchased from Avanti Polar Lipids (Alabaster, AL). Oleic 
acid capped cadmium sulfide quantum dots were purchased from NN-Labs, LLC 
(Fayettville, AR). Oleic acid capped iron oxide nanoparticles (IONP) of various sizes (10, 
15, 20, 25, 30 nm) were purchased from Ocean NanoTech (Springdale, AR) and some 
IONP were synthesized at University of Pennsylvania (vide infra). All other chemicals of 
analytical grade were purchased through Sigma Aldrich (St. Louis, MO) with the 
exceptions of sodium fluoride (Acros Organics, NJ), trifluoroacetic acid (Alfa Aesar, MA), 
Tetrahydrofuran (EMD, PA), dichloromethane (EMD, PA), and ethyl ether (EMD, PA).  
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Gadolinium or lanthanum trifluoroacetate precursors were prepared using a literature 
method by refluxing gadolinium or lanthanum oxide in trifluoroacetic acid/water mixture 
(50 vol%).30 A monocyte cell line, RAW 264.7, was purchased from ATCC. Cells were 
cultured in Dubecco’s Modified Eagle Medium supplemented with 10% fetal bovine 
serum and 1% penicillin/streptomycin (10,000 units/mL, 10,000 µg/mL) from Life 
Technologies Invitrogen (Grand Island, NY).   
 
2.3.2 Polyphosphazene synthesis 
For 35.6 kDa PCPP preparation, PCl5 (0.11 g) was dissolved in 50 mL anhydrous 
dicholormethane (DCM) for 10 min. Chlorophosphoranimine (6.00 g) prepared by a 
previous report,30 was added to the solution rapidly, and the mixture was stirred at room 
temperature for 4 hr. DCM was then removed under reduced pressure to give colorless 
viscous living oligo(dichlorophosphazene). The polymer was re-dissolved in anhydrous 
tetrahydrofuran (THF), and propyl 4-hydroxybenzoate (14.43 g) and CsCO3 (26.00 g) 
was added to the solution. The mixture was stirred at room temperature for 2 days. 
Afterwards, the reaction medium was concentrated and precipitated into water (300 
mL×3). The precipitate was isolated by centrifugation. Then, the crude product was re-
dissolved in DCM, and dialyzed versus methanol/DCM (1:4) for 3 days (Spectra/Por 
dialysis membrane, MWCO: 1,000). The solvent was removed under vacuum to give a 
white adhesive polymer. (Molecular weight: 35.6 g/mol; PDI: 1.07; repeat units: 82) For 
the deprotection reaction, the above 1.00 g of polymer was dissolved in 100 mL 
anhydrous THF. Potassium tert-butoxide (2.50 g) and water (0.45 g) were added to the 
polymer solution. The mixture was stirred at room temperature for 3 days. Then, the 
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reaction medium was dialyzed versus water for 1 day, water/methanol (1:1) for 2 days, 
and then methanol for 2 days (Spectra/Por dialysis membrane, MWCO: 1,000). 
Poly(bis(4-carboxylatophenoxy)phosphazene) dipotassium was obtained by the removal 
of all solvent under vacuum at 35 °C (overall yield: 46%). 31P NMR (D2O): δ -18.75 (s). 
1H NMR (D2O): δ 7.31 (d, 2H), 6.50 (d, 2H). 
A high molecular weight (MW) PCPP (3.8 MDa) was synthesized by first 
dissolving poly(dichlorophophazene) (2.00 g) in 200 mL of THF. 
Poly(dichlorophosphazene) was prepared by the thermal ring-opening polymerization of 
recrystallized and sublimed hexachlorocyclotriphosphazene (Fushimi Chemical Co., 
Japan) in evacuated Pyrex tubes at 250 °C. Propyl-4-hydroxy-benzoate (9.33 g) was 
dissolved in THF (100 mL) then added to the polymer solution. Solid cesium carbonate 
(16.9 g) was then immediately added to the reaction mixture. The reaction proceeded at 
room temperature for 3 days. Afterward, the solution was concentrated, and precipitated 
into water 3 times and hexane once. The solvent was removed under reduced pressure 
to yield a white solid that was obtained in an 80% yield (molecular weight: 3,882,000 
g/mol; PDI: 1.62; repeat units: 9,600). For the de-protection reaction, the polymer (3.00 
g) was re-dissolved in anhydrous THF (300 mL). Potassium tert-butoxide (7.51 g) and 
water (1.34 g) were added to the polymer solution. The reaction was stirred at room 
temperature for 3 days and was then concentrated. This was dialyzed versus water for 2 
days, (1:1) methanol/water for 2 days, and then (4:1) methanol/water for 1 day. The 
solvent was then removed under reduced pressure to yield the product with an 81% 
yield. 31P NMR (D2O): δ -18.53 (s). 1H NMR (D2O): 7.16 (s, 2H), 6.36 (s, 2H). 
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2.3.3 Iron oxide synthesis 
Iron oxide nanoparticles (IONP) were synthesized using oleic acid as the capping 
ligand following a modified literature method.31 Typically, 1.5 g of iron chloride and 5.2 g 
of sodium oleate were first added in a 100 mL flask. Subsequently, 20 mL of hexane, 
11.5 mL of ethanol, and 8.8 mL of distilled water were added to the flask and the mixture 
was sonicated. The two-phase mixture was heated to reflux (~70 °C) for four hours, 
which produced iron-oleate in the organic layer. The upper organic layer was washed 
three times with 30 mL of water and separated by centrifugation (5,000 rpm, 10 min). 
After washing, the hexane was evaporated from the dark brown organic layer and stored 
under vacuum. The synthesis of 15.6 nm iron oxide nanoparticles was carried out by 
reacting 5.5 g of iron-oleate and 1.5 g of oleic acid in 31 g of 1-octadecene in a 250 mL 
round-bottom flask. The reaction mixture was heated to 320 °C at a rate of 200 °C/hour, 
and kept at that temperature for 30 minutes. The color of the solution turned from dark 
brown to black upon the formation of nanoparticles. The resulting solution was cooled to 
room temperature and nanoparticles were precipitated by adding ethanol (35 mL). The 
precipitated nanoparticles were collected by centrifugation (5,000 rpm, 10 mins) and 
then redispersed in hexane (10 mL). The nanoparticles were further purified by 
precipitation with acetone (35 mL), centrifuging at 5,000 rpm for 10 min, and 
redispersing the collected nanoparticles in hexane (10 mL). This washing step was 
repeated two more times. After the final washing step, the IONP were redissolved in 
chloroform (10 mL) and centrifuged at low speed (3,000 rpm, 5 min) to remove 
aggregates. A sample of these IONP was rendered water soluble through encapsulation 
with dimercaptosuccinic acid (Figure 2.2) following previous literature methods (IO-
DMSA).32  
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Figure 2.2 Chemical structures. 
Chemical structures of iron oxide coatings (DMSA), and phospholipids used for micelle 
formation (MHPC, DMPC). 
 
2.3.4 Gold nanoparticle synthesis 
 Carboxylic-acid coated gold nanoparticles (AuNP) were synthesized using the 
Turkevich method with slight modifications.33 Briefly, 85 mg of chloroauric acid (HAuCl3) 
was dissolved in 250ml of Milli-Q water for a final concentration of 1 mM. After heating to 
a boil, a 38.8 mM solution of sodium citrate (285 mg in 25 ml Milli-Q water) was added, 
causing the color of the solution to become dark red. The solution was heated for 
another 15 minutes and then allowed to cool to room temperature. For carboxylic-acid 
ligand exchange, an 11.9 mM solution of 11-mercaptoundecanoic acid (11-MUA, 2.6 mg 
in 1 ml of EtOH) was added to the citrate AuNP as prepared above. The solution was 
stirred for 24 hours. Afterwards, the AuNP were purified and collected by centrifuging at 
12.5 krcf for 45 minutes. The pellet was resuspended with Milli-Q water and repeated 
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two times. The AuNP solution was finally resuspended in 1 ml of Milli-Q water and 
filtered through a 0.45 µm syringe filter.      
 
2.3.5 Nanophosphor synthesis 
Hexagonal phase sodium gadolinium tetrafluoride nanospheres (β-NaGdF4) were 
synthesized according to a previously reported procedure with slight modification.34 
Briefly, gadolinium trifluoroacetate (2 mmol) and sodium fluoride (5 mmol) were added 
into a 125 mL three-neck flask containing 60 mL of 1-octadecene/oleic acid solvent 
mixture (50% by volume). The solution was then degassed under vacuum at 125 oC for 
an hour to remove water. For nanocrystal growth, the solution was heated to 290 oC 
under N2 environment at a rate of 10 oC/min and maintained at this temperature for 5 
hours. Purification was performed twice by washing with ethanol and then centrifuging at 
6000 rpm for 2 min The nanocrystals were redissolved in hexane (10 mL) and residual 
sodium fluoride were removed by centrifugation at 3000 rpm for 2 min. β-NaGdF4 
nanorods were synthesized by using 2.5 mmol of sodium fluoride in the same method to 
synthesize nanospheres. Lanthanum trifluoride (LaF3) discs were synthesized using 
similar methods as β-NaGdF4 nanospheres while substituting lanthanum trifluoroacetate 
for gadolinium trifluoracetate The reaction were conducted at 290 oC for 5 hours under 
N2 environment. LaF3 nanoplates were redissolved in hexane and centrifuged at 3000 
rpm for 2 min to remove lithium fluoride salts. 
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2.3.6 Nanocrystal micelle synthesis 
 IONP, quantum dots, and nanophosphors were rendered water soluble through 
encapsulation in phospholipid micelles. In a typical preparation, 50 mg of MHPC (Figure 
2.2) was dissolved in a 1 mL chloroform/methanol mixture (4:1). Oleic acid coated IONP 
(5.00 mg in 0.5 mL chloroform) were added to the MHPC solution. This mixture was then 
added to heated Milli-Q water (10 mL) in a slow, drop-wise fashion. The resulting 
solution was heated for an additional 10 min to ensure organic solvent evaporation and 
then cooled to room temperature. Afterwards, the aqueous solution was centrifuged at 
800 g for 10 min to remove precipitates and multi-cored micelles. The supernatant was 
collected and centrifuged at 20,000 g for 90 min. The pellet was redispersed in Milli-Q 
water (~15 mL). These washes were performed three times to ensure purification. 
Finally, the sample was resuspended in approximately 1 mL of Mill-Q water yielding 
IONP encapsulated in MHPC micelles (IO-MHPC). Quantum dots and nanophosphors 
were encapsulated using similar methods as the IONP. Iron oxide encapsulation was 
also performed using the following additional lipids: 1-lauroyl-2-hydroxy-sn-glycero-3-
phosphocholine (IO-LHPC), 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine (IO-
PHPC), and 1-stearoyl-2-hydroxy-sn-glycero-3-phosphocholine (IO-SHPC). Additionally, 
MHPC micelles were formed in the absence of any nanocrystals to obtain samples of 
empty MHPC micelles. Mixed phospholipid micelles encapsulating IONP (10, 15, 20, 25, 
and 30 nm diameter) were formed with a 1:1 mixture of MHPC and dimyristoyl-2-
hydroxy-sn-glycero-3-phosphocholine (DMPC, Figure 2.2).  
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2.3.7 PCPP sphere synthesis 
Formation of polyphosphazene polymer nanospheres was performed using 
modified literature methods.28, 35 A typical synthesis was performed as follows, 40.0 mg 
of PCPP (1.0 MDa MW) was dissolved in 20 mL of Dulbecco’s phosphate buffered 
saline (DPBS, pH 7.4). IO-MHPC (0.15 mg, 200 µL) were added into 1 mL of this PCPP 
solution. Then 16.8 µL of a 70.0 mg/mL spermine solution (DPBS, pH 7.4) was added to 
the PCPP/IO-MHPC solution (0.98% spermine). The mixture was immediately added 
into a beaker of 88.0 mg/mL CaCl2 buffer (~100 mL) and incubated at room temperature 
for 30 minutes while stirring. This suspension was purified through centrifugation (800 g, 
10 min) and washed three times with Milli-Q water. The resulting IO-MHPC surface 
loaded nanospheres (IO-NB) were resuspended in 1 mL of Milli-Q water. This process is 
depicted schematically in Figure 1b. Synthesis of non-loaded PCPP nanospheres were 
formed similarly, except without the addition of IO-MHPC. PCPP nanospheres (AuIO-
NB) were formed, for example, by mixing IO-MHPC (0.15mg, 42 ul) and AuNP (1 mg, 32 
ul) together. Afterwards this solution was added to 1 mL of previously described PCPP 
solution. The synthesis followed as described above. Nanocrystal variants such as CdS 
quantum dots, nanophosphors (β-NaGdF4 spheres, rods, LaF3 discs), or iron oxides of 
varying cores sizes and coatings were substituted for IO-MHPC for inclusion in the 
PCPP nanosphere synthesis. PCPP of additional molecular weights (35.6 kDa and 3.88 
MDa) were also used to form surface loaded nanospheres. Additionally, FITC-BSA (0.1, 
0.25 mg) was core loaded into PCPP nanospheres using the standard synthesis method 
with and without the simultaneous surface loading of IO-MHPC (0.15 mg) to form FITC-
PCPP and FITC-IO, respectively.          
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2.3.8 Polymer and particle characterization 
1H and 31P NMR spectra were recorded on a Bruker WM–360 NMR spectrometer 
operated at 360 and 145 MHz, respectively. 1H NMR spectra were referenced to solvent 
signals while 31P NMR chemical shifts were relative to 85% phosphoric acid as an 
external reference, with positive shift values downfield from the reference. Molecular 
weights were estimated using a Hewlett–Packard HP 1090 gel permeation 
chromatograph (GPC) equipped with an HP-1047A refractive index detector, American 
Polymer Standards AM gel 10 mm and AM gel 10 mm 104 Å columns, and calibrated 
versus polystyrene standards. 
 Transmission electron microscopy images were acquired on a FEI Tecnai T12 
microscope at 120 kV. Scanning electron microscopy was performed with a Philips XL20 
at 10 kV. Fluorescent imaging for both the quantum dots and the FITC-BSA was 
performed with an IVIS Spectrum system using 465 nm excitation and 520 nm emission 
filters. Relaxivities were measured using a Bruker Minispec mq relaxometer at 1.41 T 
(60 MHz) and 40°C.  Freely suspended IO-MHPC were prepared in DPBS for 
measurements. PCPP samples were prepared in a 1% agar gel in DPBS to prevent 
sedimentation of nanospheres. Iron oxide concentrations were determined through 
inductively coupled plasma-optical emission spectroscopy (ICP-OES) on a Spectro 
Genesis system.  
  Magnetic hysteresis measurements were performed on a MicroMag 
Magnetometer (Westerville, OH) at in field range of 10 kOe. Samples (5 µl) were 
prepared on a coverglass for measurements. Magnetic resonance imaging (MRI) was 
used to evaluate IO-NB contrast generating properties. IO-NB were prepared in a 1% 
agar gel at concentrations of 0.05 mM and 0.16 mM of Fe. Additionally, control samples 
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of DPBS, non loaded PCPP, and 0.16 mM of Fe IO-MHPC in 1% agar gel were 
scanned. For MRI phantom preparation, samples were placed in a 2% agar gel doped 
with 0.35 mM manganese chloride. The samples were scanned using a head coil on a 
Siemens Magnetom Trio with a 3 T magnet. A 2D spin echo sequence was used. 
Relevant imaging parameters were: echo time (TE), 15 ms; repetition time (TR), 10 s; 1 
slice with thickness 3mm, 1 average, flip angle (FA), 90 degrees; acquisition matrix, 
184x256; in-plane spatial resolution 0.546 mm2, field of view (FOV) 140 mm2. The 
resulting images were processed using Osirix v.3.0.1 32-bit (Geneva, Switzerland; 
www.osirix-viewer.com). CT images were acquired with a Siemens Definition DS 64-
slice clinical CT scanner at 140 kV (245 mA) with a matrix size of 512x512, field of view 
37x37 cm, reconstruction kernel B30f and slice thickness of 0.6 cm. Images were 
analyzed using Osirix 64 bit (v3.7.1). 
 
2.3.9 In vitro incubations  
 RAW 264.7 cells were cultured on 6-well plates at a concentration of 2 million 
cells/mL at 37° C. After 24 hours, the cells were treated with IO-NB at a concentration of 
50 µg Fe/mL (0.89 mM) for 4 hours. The cells were washed 3 times with DPBS and then 
collected by gentle scraping. The cells were fixed in a solution of 2% glutaraldehyde and 
5% paraformaldehyde in DPBS. Fixed cells were embedded in resin and prepared for 
TEM using standard methods.36 Cell sections were imaged using a FEI Tecnai T12 
electron microscope. 
  For cytotoxicity, Au-PCPP5 (AuNP core loaded in PCPP nanospheres at 5:1 
mass ratio, 10 mg gold to 2 mg PCPP) was incubated with monocytes for 24 hours at 
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37˚C on 20 mm glass bottom dishes at 7.5 x 104 cells per dish. Afterwards, the media 
was washed with DPBS and LIVE/DEAD cocktail was added (2 mL DPBS, 2 µL stock 
Ethidium-1 homodimer, 0.5 µL stock Calcein AM, and 0.5 µL 3.2 mM Hoechst 33342). 
The cocktail was left on for 20 mins before imaging with Nikon Eclipse Ti-U fluorescent 
microscope. Filters for DAPI (Ex. 359, Em. 461 nm), FITC (Ex. 495, Em. 519 nm), and 
Texas Red (Ex. 595, Em. 613 nm) were used to visualize cell nuclei, living cells and 
dead cells respectively. Four fields were taken per dish and analyzed with a custom 
written MATLAB (MathWorks, Natick MA) program for cell counting. The values for each 
field were averaged for cytotoxicity results. Viability % is expressed as living cells/total 
cells *100.   
 To evaluate cytokine expression, ELISA was used to measure TNF-α from media 
collected following treatment of monocytes with Au-PCPP5. Monocytes were cultured in 
96 well plates at 1.0 x105 cells per well for 24 hours. Afterwards, cells were treated with 
increasing concentrations of Au-PCPP5 for 24 hours. Cells were washed twice with 
DPBS and the media was replaced with or without lipopolysaccharide (LPS) for 3 hours. 
The media was collected and ELISA was performed according to kit instructions (Life 
Technologies Invitrogen, Grand Island, NY).   
 For fluorescent microscopy, RAW 264.7 cells were cultured on glass-bottomed 
well dishes (20 mm diameter) at a concentration of 800k cells per well. After 24 hours, 
the cells were treated with 50 ug Fe/ml (0.89 mM) of FITC-NB or FITC-PCPP for 4 
hours. The cells were then washed with DPBS 3 times and stained with DAPI. Imaging 
was performed on a Nikon Eclipse fluorescence microscope (Nikon Eclipse Ti-U, 
Melville, NY). The DAPI stain was imaged using a 358 nm excitation filter and a 461 nm 
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emission filter. FITC was imaged using a 494 nm excitation filter and a 516 nm emission 
filter.  
 
2.4 Results  
2.4.1 Core loading of PCPP nanopsheres 
 Gold nanoparticles of 15 nm in diameter were synthesized and coated in small 
chain carboxylic acid (11-mercaptoundecanoic acid). Inclusion of these particles into the 
one pot synthesis with PCPP, formed AuNP core-loaded PCPP nanospheres (AuPCPP). 
The core loading of AuNP into the PCPP nanospheres increased with higher starting 
concentrations of gold (Figure 2.3). The internal loading of the AuNP was confirmed with 
3D tomographic reconstruction, showing aggregation of AuNP into clusters within the 
core of the nanosphere (Figure 2.3d). At the highest ratio examined (10 mg Au to 2 mg 
PCPP), the incorporation of AuNP into the core distorted the morphological sphere 
shape of the nanosphere.   
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Figure 2.3 AuNP loaded PCPP nanospheres. 
TEM of PCPP nanoparticles loaded with varying amounts of carboxylic acid coated gold 
nanoparticles. A) 1:5, B) 1:1 and C) 5:1 mass ratios. D) 3D reconstruction of sample in 
B). 
 
2.4.2 Surface decoration of PCPP nanospheres 
PCPP is a biocompatible polymer, which we have used to create a novel platform 
to exploit for nanocrystal delivery in biomedical applications. PCPP nanospheres were 
synthesized using a modified method that was previously developed to make 
microspheres.28 The polycarboxylate PCPP is cross-linked with the polycation spermine 
to form polymer spheres. The self-assembled nanospheres were dispersed in CaCl2, 
which we found necessary to halt nanoparticle growth.35 This process resulted in 
polymer nanoparticles of 508 ± 185 nm (Figure 2.4a). With loading of these polymer 
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nanoparticles, we added dimercaptosuccinic acid coated iron oxides (IO-DMSA) to the 
synthesis prior to adding the spermine cross-linker. We found that IO-DMSA were 
included in the core of the polymer spheres (Figure 2.4b) similar to our findings with 
AuNP. We then decided to explore the incorporation of iron oxide nanoparticles with 
alternative coatings.  
 
Figure 2.4 Surface loaded PCPP nanospheres.  
Electron microscopy images of PCPP nanospheres. TEM images of (a) non loaded 
PCPP nanospheres, (b) IO-DMSA core loaded into PCPP nanospheres, (c) IO-MHPC 
surface loaded PCPP nanospheres (IO-NB). (d) Image of disco ball. SEM images of (e) 
non loaded PCPP and (f) IO-NB. (g) z-slice of tomographic reconstruction of IO-NB. (h) 
Localization control of IO-MHPC and AuNP with PCPP nanospheres. 
 
Lipid coatings are a common method used to make nanocrystals 
biocompatible.37 Oleic acid coated nanocrystals were rendered water soluble through 
encapsulation in micelles formed by MHPC.38-39 We mixed these phospholipids coated 
nanocrystals with PCPP before the addition of spermine. In the final product, we found 
 
83 
 
that surprisingly, the nanocrystals were exclusively localized to the surface of the 
nanospheres, in a structure we found reminiscent of a disco ball (Figure 2.4c, d). 
Electron microscopy images of these IO-MHPC surface loaded PCPP nanoparticles, or 
iron oxide loaded nano-disco balls (IO-NB), can be seen in Figure 2.4c. The average 
diameter of IO-NB was found to be 384 ± 127 nm (from analysis of 100+ nanoparticles in 
TEM images). SEM images revealed IO-NB to be an average diameter of 473.7 ± 125.9 
nm and non loaded PCPP nanospheres to be 548.7 ± 200.8 nm. (Figure 2.4e,f). Three 
dimensional tomographic reconstructions were performed to confirm the localization of 
IO-MHPC within PCPP nanoparticles. The reconstructions proved exclusive loading of 
IO-MHPC on the surface of PCPP nanospheres (Figure 2.4g). The total surface area 
available for IO-MHPC binding was calculated using the average size of PCPP 
nanospheres and found to be 123.2 cm2/mg polymer. The total occupied binding space 
of IO-MHPC was found to be 96.96 cm2, i.e. 78.7%. This coverage corresponds to 609 
IO-MHPC particles per PCPP nanosphere. However, we found that the coating density 
could be tuned, depending on the amount of IO-MHPC added in the synthesis 
procedure. These calculations can be found in the Appendix.  
Next, we studied whether two types of nanocrystal could be loaded into the 
PCPP nanoparticles. We added both carboxylic acid coated gold nanoparticles and IO-
MHPC to the synthesis at the same time. As can be seen in Fig. 2.4h, the gold 
nanoparticles could be selectively localized to the core, while the IO-MHPC were 
localized to the particle surface. Gold nanoparticles produce computed tomography (CT) 
contrast in high concentrations, with no access to water needed,40-41 therefore core 
loading is best for gold nanoparticles. On the other hand, less iron oxide is needed to 
produce MRI contrast and access to water is needed, which surface loading provides. 
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This formulation demonstrates the benefits of selective nanocrystal localization via 
optimization of the contrast properties for each technique. 
Having made the surprising observation of surface loading of PCPP nanospheres 
with IO-MHPC, we probed the role of different steps in the synthesis, the flexibility of the 
process, examined the contrast generating potential of the nano-disco balls, evaluated 
whether the surface attachment of the IO-MHPC was robust to biological conditions in 
vitro and demonstrated the theranostic potential of the nanoparticles. 
 
2.4.3 Surface adhesion occurs during stabilization with CaCl2 
 The surface loading of PCPP nanospheres occurs via self-assembly during 
synthesis. To investigate the crucial step in the formation of surface loaded 
nanospheres, we added IO-MHPC at different points in the process. Initially, we formed 
IO-NB by mixing IO-MHPC with a PCPP solution and then immediately adding spermine 
as schematically outlined in Figure 1b. The mixture was quickly transferred to a CaCl2 
solution and incubated at room temperature for 30 minutes. Afterwards the solution was 
washed through centrifugation and resuspended in water. To determine if longer 
incubations of IO-MHPC and PCPP solution together would result in internal loading of 
IO-MHPC, the reagents were incubated together at room temperature for 30 minutes 
and 24 hours before the addition of spermine. Results in Figure 2.5a-c, show no visible 
differences between our standard synthesis, 30 minute pre-incubation, or 24 hour pre-
incubation, indicating that longer incubation times did not affect spatial distribution of IO-
MHPC in PCPP nanospheres (Fig. 2.5c). 
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Figure 2.5 Probing synthesis steps of IO-PCPP. 
TEM images of synthesis variations: (a) standard synthesis, (b) 30 minute and (c) 24 hr 
pre-incubation of PCPP and IO-MHPC before spermine addition. TEM of (d) PCPP 
spheres formed with spermine and then incubated with IO-MHPC, (e) PCPP spheres 
formed with spermine, stabilized in CaCl2 and then incubated with IO-MHPC, (f) purified 
non loaded nanospheres re-synthesized with surface loading 
 
 Next we examined the effect of mixing PCPP with spermine before the addition 
of IO-MHPC. As shown in Figure 2.5d, IO-MHPC surface adherence was unaffected 
when added after spermine addition, demonstrating that surface loading does not occur 
during the PCPP and spermine cross-linking process. To further explore the mechanism 
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of surface loading, non loaded spheres were completely formed before the addition of 
IO-MHPC. The PCPP solution and spermine were first mixed and then transferred to 
CaCl2 for 30 minutes at room temperature. Afterwards, IO-MHPC were added into the 
solution and stirred for an additional 30 minutes. The results seen in Figure 2.5e showed 
no surface loading of IO-MHPC in the sample. These data demonstrate that surface 
loading of MHPC lipid coated IONP (IO-MHPC) is achievable at any stage before CaCl2 
stabilization. We also found fully synthesized non loaded nanospheres (nanospheres 
formed in the absence IO-MHPC) could be surface loaded by incubating the non loaded 
spheres with IO-MHPC and then transferring to 0.88% CaCl2 solution for 30 minutes 
Figure 2.5f). This data suggests a calcium dependent mechanism for surface loading. 
Presumably there is some form of calcium-mediated binding between the PCPP and 
phospholipid head group (Ca2+ binding to phospholipids is well known).42 Other divalent 
cations could likely produce similar phenomenon as Ca2+.   
With our standard synthesis method, we studied the IO-NB stability over time 
when stored in Milli-q water at room temperature. After 24 hours, the IO-NB were found 
to loosely settle, but could easily be re-dispersed with gently mixing. The surface loading 
and structure of these nanospheres was unaffected over the observed time frame of 7 
months as determined by TEM (Figure 2.6). These data indicate that the particles are 
robustly stable when stored at room temperature for extended periods of time.   
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Figure 2.6 Shelf life of IO-PCPP.  
TEM of IO-NB stored at room temperature for (a) 1 day, (b) 3 days, (c) 1 week, (d) 2 
weeks, (e) 3 weeks, and (f) 7 months. 
 
2.4.4 Surface loading is independent of polymer size, lipid length, core size, and 
core type  
 Exclusive surface loading was found with the use of MHPC lipids encapsulating 
15.6 nm diameter iron nanoparticles. We examined the flexibility of the reaction by 
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varying parameters such as PCPP molecular weight, phospholipid length, and 
nanocrystal core size and type. Surface loaded nanospheres were synthesized using our 
standard method with PCPP in a range of molecular weights (35.6 kDa, 1.0 MDa, 3.8 
MDa MW). Surface loading of IO-MHPC was found with each PCPP MW, demonstrating 
that the process is independent of polymer size (Figure 2.7). The effect of phospholipid 
tail length was studied by encapsulating 15.6 nm diameter IONP with 12 (LHPC), 14 
(MHPC), 16 (PHPC), and 18 (SHPC) carbon tail chain length phospholipids. PCPP 
nanospheres were successfully synthesized and surface loaded with each micelle 
formation (Figure 2.8). Note that LHPC is a relatively poor amphiphile and therefore 
formed aggregates as opposed to individually dispersed nanocrystals). Additionally, 
oleate-coated IONP of increasing sizes (10, 15, 20, 25, 30 nm diameters) were 
encapsulated in micelles using MHPC/DMPC mixtures (IO-MHPC-DMPC). Micelles 
synthesized using only MHPC to encapsulate the larger 25 and 30 nm IONP were not 
stable, however, we found that they could be stably coated with a 1:1 mixture of 
MHPC/DMPC and that nanoparticles with such coatings adhered to PCPP nanospheres 
also. The PCPP nanospheres were synthesized using our standard method with the 
various IONP core sizes. TEM revealed surface loading occurred for each core size 
(Figure 2.9). 
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Figure 2.7 IO-PCPP molecular weight.  
Surface loading using increasing PCPP MW polymer: (a) 35.6 kDa PCPP, (b) 1.0 MDa 
PCPP, (c) 3.8 MDa PCPP 
 
 
Figure 2.8 Loading with varying micelle phospholipid length. 
Surface loading of IONPs with increasing carbon tail lengths. (a) IO-LHPCs (12 carbon 
tail length) (b) IO-MHPCs (14 carbon tail length), (c) IO-PHPC (16 carbon tail length), 
and (d) IO-SHPC (18 carbon tail length) loaded onto PCPP nanospheres.   
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Figure 2.9 Size variants of IONPs formed in phospholipid micelles. 
TEM images of PCPP nanosphere phospholipid mixture micelles: (a) 10 nm IO-MHPC-
DMPC, (b) 15 nm IO-MHPC-DMPC, (c) 20 nm IO-MHPC-DMPC, (d) 25 nm IO-MHPC-
DMPC, (e) 30 nm IO-MHPC-DMPC particles.     
 
 To further explore the breadth of applicability of this surface loading process, a 
variety of diagnostically active nanocrystals were investigated for adherence to PCPP 
nanospheres. Oleic acid coated quantum dots (CdS spheres) and nanophosphors (β-
NaGdF4 spheres, rods, LaF3 discs) were all found to incorporate into MHPC micelles 
using the same procedure as for IONP. Surface loading of each core variant was 
achieved through our standard method of PCPP nanosphere synthesis. TEM verified 
surface adsorption to be present in each sample (Figure 2.10). From these data, 
nanocrystals encapsulated into phosphocholine head group lipid micelles can be 
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successfully surface adsorbed onto PCPP nanospheres regardless of the core type, 
size, or shape.       
 
 
Figure 2.10 Surface loaded nanocrystals variants. 
TEM images of PCPP nanosphere surface loaded with various nanocrystals. (a) β-
NaGdF4 spheres, (b) β-NaGdF4 rods, (c) LaF3 discs, and (d) CdS quantum dots surface 
loaded onto PCPP nanospheres (QD-NB).  
 
2.4.5 Excess empty micelles disrupt nanosphere formation but not surface 
adherence 
 We examined whether an excess of empty micelles would reduce surface 
adsorption of IO-MHPC on PCPP nanospheres. Empty MHPC micelles were mixed 
together with IO-MHPC at increasing ratios (1:1, 5:1, 10:1, 25:1, based on phospholipid 
content). PCPP nanosphere synthesis was performed using our standard method with 
these empty micelles:IO-MHPC ratios. From TEM, lower ratio mixtures did not appear to 
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affect surface adsorption of IO-MHPC onto the PCPP nanospheres (Figure 2.11). 
However, at larger ratios of 10:1 and 25:1, disruption of nanosphere formation was 
observed. These particles appeared amorphous but the surface adsorption of the IO-
MHPC was still present. The increased concentration of empty micelles appeared to 
interfere with the spermine-PCPP cross-linking. We hypothesized that performing the 
cross linking before the addition of IO-MHPC and empty micelles would allow for the 
observation of competition without disrupting the PCPP nanosphere formation. We found 
that by adding the spermine before the IO-MHPC, we were able to surface load IO-
MHPC in the presence of high concentrations of empty micelles. Ratios of 10:1, 15:1, 
20:1, 25:1 were used in the synthesis, and surface loading of IO-MHPC appeared similar 
in all samples (Figure 2.12). This phenomenon could be due to the larger area of 
interaction for the IO-MHPC with the PCPP nanospheres creating stronger attachments, 
therefore preferentially binding IO-MHPC as compared to empty MHPC micelles.  
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Figure 2.11 Empty micelle inhibition of PCPP formation. 
TEM images of PCPP nanosphere standard synthesis with increasing ratios of empty 
MHPC-micelles to IO-MHPC: (a) 1:1 (b) 5:1 (c) 10:1 (d) 25:1 
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Figure 2.12 Competitive inhibition with cross-linking before surface loading. 
TEM images of PCPP nanospheres formed with increasing ratios of empty MHPC-
micelles to IO-MHPCs: (a) 10:1 (b) 15:1 (c) 20:1 (d) 25:1. Samples synthesized with 
spermine addition preceding addition of IO-MHPCs and empty MHPC-micelles mixture. 
 
2.4.6 Particles remain diagnostically active after surface loading 
 With the ability to load a variety of diagnostically active nanoparticles, we 
evaluated the contrast generating properties of nanocrystal loaded polymer particles. 
Magnetic moment curves measured for IO-MHPC and IO-NB did not indicate magnetic 
hysteresis (Figure 2.13). IO-MHPC and IO-NB had almost identical magnetization 
saturation values of 67.81 and 65.01 emu/g, respectively. The longitudinal and 
transverse relaxivity (measures of MRI contrast) of surface loaded IO-NB were 
examined (Table 2.2) at 1.41 T and 37 °C. Surface loaded particles, IO-NB were found 
to have a lower transverse (r2) relaxivity than free IO-MHPC, although still at a 
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substantial value of 68.2 mM-1s-1. The decreased relaxivity could be caused by some 
loss of interaction between the surrounding water due to the absorption of IO-MHPC to 
the PCPP nanospheres.43  
 
 
Figure 2.13 Magnetic hysteresis curves for IO-NB and IO-MHPC. 
Measured magnetic saturation values were IO-MHPC, 67.81 and IO-NB, 65.01 emu/g. 
 
However, the ratio of transverse to longitudinal relaxivity (r2/r1) was higher for IO-
NB indicating good properties for T2-weighted imaging. Additionally for further 
evaluation, contrast generation for IO-NB was evaluated with a MRI scan. Iron oxide 
increases the rate of transverse relaxation therefore leading to a decrease in signal 
intensity, or darkening in T2/T2*-weighted MR images. An MR image of a phantom 
containing IO-NB (0.05 and 0.16 mM Fe), DPBS, free IO-MHPC (0.16 mM Fe) and non 
loaded PCPP spheres are displayed in Figure 2.14a. The DPBS and non loaded PCPP 
nanospheres were of relatively similar signal intensity. As expected, the IO-NB were 
much darker, with a concentration dependent intensity. Although, the IO-NB and IO-
MHPC samples were at the same concentration, the IO-NB produced less signal. This 
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effect could be due to the increased relaxivity (r2/r1) ratio seen in the relaxation 
measurements, or perhaps is due to the different field strengths used for imaging and to 
determine relaxivities. Overall, IO-NB retained relaxation properties that allow for 
contrast generation in MRI. Moreover, PCPP nanospheres loaded with quantum dots 
(QD-NB) exhibit similar fluorescent properties as free quantum dots (QD-MHPC). The 
fluorescence of the quantum dots persisted after encapsulation in micelles and PCPP 
surface loading (Figure 2.14). The phantom image in Figure 2.14 indicates the strong CT 
contrast produced by gold loaded PCPP particles. 
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Figure 2.14 Applications of surface loaded PCPP nanospheres.  
(a) MRI phantom image. (b) fluorescence image of non loaded PCPP particles, QD-
MHPC micelles and QD-NB. Scale bar in units of radiant efficiency (*107 
(p/s/cm2/sr)/µW/cm2) (c) CT phantom image of gold loaded PCPP particles (17 mg/ml). 
 
Table 2.2: Relaxation measurements for free IO-MHPC and IO-NB at 1.41 T. 
 
 
2.4.7 In vitro evaluation of core loaded nanospheres for monocyte labeling 
 With confirmation of diagnostic activity of core and surface loaded PCPP 
nanospheres, their effectiveness in biomedical applications were assessed. PCPP 
nanospheres core-loaded with AuNP were investigated for cell viability and function. 
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Monocytes were incubated with Au-PCPP for 24 hours for all studies. Uptake of these 
particles (5:1 ratio of gold to PCPP by mass, Au-PCPP5) were assessed with CT scans 
demonstrating an increase in x-ray attenuation with increased incubation concentrations 
(Figure 2.15a). Cytotoxicity across different gold concentrations were assessed with both 
Au-PCPP1 (1:1 mass ratio) and Au-PCPP5 (5:1 mass ratio). Cytotoxicity was observed 
with increasing concentration for both formulations, but was more pronounced for the 
Au-PCPP1 formulation (Figure 2.15b). We also sought to investigate the release of TNF-
α, an inflammatory cytokine released during activation of the monocytes. Monocytes 
were incubated with Au-PCPP5 at increasing concentrations with and without 
lipopolysaccharides (LPS). LPS causes the activation of the monocytes and subsequent 
release of TNF-α. At the highest concentrations examined (0.25 and 0.5 mg/ml), the 
difference between LPS and non LPS groups were non-significant indicating that the Au-
PCPP5 at those concentrations were activating the monocytes (Figure 2.15c).   
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Figure 2.15 In vitro assessment of AuNP core loaded in PCPP nanospheres. 
PCPP nanospheres loaded with AuNP (5:1 ratio gold to PCPP) incubated with a 
monocyte cell line for 24 hours. (a) X-ray attenuation measured at different treatment 
concentrations of Au-PCPP5. (b) (1:1, Au-PCPP1 and 5:1, Au-PCPP5) viability 
assessed at increasing concentrations after 24 hour treatment. (c) TNF-α release of 
monocytes treated with Au-PCPP5 for 24 hours with and without LPS activation. Student 
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t-test used to compare significance between groups with and without LPS at identical 
concentrations (p<0.05 for significance). Non-significance represented by n/s.  
 
2.4.8 In vitro evaluation of surface loaded nanospheres 
The robustness of surface attachment of IO-MHPC to PCPP nanospheres was 
briefly evaluated for potential biological applications. We incubated nano-disco balls (IO-
NB) for 1, 4, 24 hr in cell culture media at 37 °C. IO-NB were then collected through 
centrifugation and iron oxide content was measured through ICP-OES (Figure 2.16a). 
The loss of iron content in the samples appeared similar at each time point suggesting 
that after some initial IO-MHPC release, the remainder was retained over the timeframe 
tested. TEM performed on these nanoparticles revealed that many IO-MHPC were still 
attached to the surface of PCPP nanospheres after 4 hr incubation (Figure 2.16b). Next 
we incubated IO-NB with RAW 264.7 monocytes for 4 hr. Remarkably, TEM performed 
on these cells revealed IO-MHPC organized in ring shapes located within endosomes 
(Figure 2.16c). We believe this demonstrates that the IO-MHPC still remain surface 
bound to PCPP nanospheres after undergoing cellular uptake.  
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Figure 2.16 IO-NB stability and uptake for cell studies. 
(a) Remaining iron oxide concentration after incubation in serum for 1, 4, and 24 hrs. (b) 
TEM image of IO-NB incubated for 4 hours in cell culture media. (c) TEM images of 
macrophages that have been incubated with IO-NB. Arrows indicate areas of IO-NB 
uptake.   
 
2.4.9 Delivery of protein loaded IO-NB 
 With exclusive surface loading of polymer nanospheres, the internal core of the 
nanospheres can be used for drug loading. We used bovine serum albumin conjugated 
with fluorescein isothiocyanate (FITC-BSA, 0.25 mg) as a model drug. This was loaded 
into PCPP nanospheres (FITC-PCPP). Additionally, FITC-BSA was loaded into the core 
of nanospheres with simultaneous surface loading of IO-MHPC (FITC-NB, 0.1, 0.25 mg). 
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TEM and fluorescence imaging were used to characterize FITC-PCPP and FITC-NB. 
Both particles demonstrated successful loading of FITC-BSA into the PCPP nanosphere 
as evident from the fluorescence of the purified material. TEM of FITC-NB revealed that 
IO-MHPC were surface loaded in the presence of the additional FITC-BSA payload, 
without alteration of the NB structure (Figure 2.17).  
 
 
Figure 2.17 FITC-BSA loaded PCPP. 
Characterization of PCPP nanospheres with core loaded FITC-BSA. TEM images of (a) 
FITC-PCPP particles and (b) FITC-NB particles. Image of fluorescent intensity of FITC-
PCPP, FITC-NB, IO-NB, and DPBS. Scale bar in units of radiant efficiency (*108 
(p/s/cm2/sr)/µW/cm2). 
 
 To evaluate the ability of these particles to deliver FITC-BSA to cells, they were 
incubated with monocytes for 4 hours. Afterwards the cells were stained with DAPI and 
imaged with fluorescence microscopy. Phase images of treated cells reveal areas of 
 
103 
 
particle uptake within the cells (Figure 2.18). Additionally, FITC can be seen within the 
cells as defined by DAPI (nuclei stain). The added surface loaded IO-MHPC did not 
prevent the delivery of FITC-BSA to the cells. These data demonstrate that “drug” (FITC-
BSA) loading can be achieved with additional exclusive surface loading. Furthermore, 
the loaded nanospheres remained stable for in vitro tracking of delivery into cells.    
 
 
Figure 2.18 Delivery of FITC-BSA in PCPP nanospheres. 
Fluorescence of monocytes treated with FITC-BSA encapsulated PCPP nanospheres. 
Images of phase, DAPI (blue), FITC (green), and the combination of DAPI and FITC for 
the conditions indicated after 4 hours. 
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2.5 Discussion 
 In this study, we have examined the PCPP nanosphere platform, investigating 
the ability to load nanocrystals both internally and externally. With polymer nano-carriers, 
drugs and/or nanocrystals are incorporated into the core of the complex and have been 
explored with several biomedical applications.44-45 Similarly in our study, inclusion of 11-
MUA AuNP aggregated into the core of the PCPP-nanospheres. These Au-PCPP 
particles were able to incorporate up to a 5:1 mass ratio between gold and PCPP, albeit 
with a morphological distortion (Figure 2.3). However, with the use of MHPC coated 
nanocrystals, we found selective loading onto the surface of the PCPP nanospheres. 
 The controlled localization of nanocrystals to the surface opens opportunities in 
various delivery and imaging applications. In the study, the robustness of the synthesis 
and its steps were probed, demonstrating that many parameters (lipid coating, PCPP 
MW, nanocrystals) can be varied and still achieve selective surface loading of those 
particles. As shown in Figure 2.6, the IO-NB remain stable for prolonged periods at room 
temperature, demonstrating an overall stability. Additionally, the ability to load many 
different types of nanocrystals regardless of size, shape, or elemental composition 
(Figure 2.10) opens a number of interesting avenues for the platform. In the single pot 
synthesis, particles can be controlled to localize on the surface or core allowing for 
multimodal applications carrying different agents. In Figure 2.18, FITC-BSA was core 
loaded into PCPP with IO-MHPC localized to the surface of the platform. We 
demonstrated that the FITC-NB could be internalized by monocytes with the structure 
remaining intact. Both agents could be delivered simultaneously while remaining 
separated.  
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 Gold nanoparticles loaded into the PCPP nanospheres can be used as CT 
contrast agents due to gold’s x-ray attenuation. We investigated this potential application 
by evaluating 5:1 mass ratio (Gold to PCPP) Au-PCPP5. The Au-PCPP were able to 
generate CT contrast, as demonstrated by the phantom images shown in Figure 2.14. 
Additionally, when incubated with monocytes, high uptake was observed in the cells by 
measuring the x-ray attenuation in cell pellets (Figure 2.15). For biocompatibility, Au-
PCPP5 incubated with monocytes showed some cytotoxicity at the highest concentration 
of 0.5 mg/ml. At the same concentration, Au-PCPP1 showed nearly 100% cytotoxicity. 
These results demonstrated, that at high concentrations, Au-PCPP may be affecting cell 
behavior. To further investigate, the release of TNF-α from monocytes after incubation 
with Au-PCPP5 was measured. In Figure 2.15, high treatment concentrations of Au-
PCPP5 resulted in comparable releases of TNF-α to LPS activated monocytes. LPS is 
an activator of monocytes, causing monocytes to release TNF-α and other inflammatory 
cytokines.46 Ideally, the uptake of Au-PCPP5 should not affect the normal function of 
monocytes for cell tracking applications. For CT applications, high concentrations of gold 
are required for imaging, however at high concentrations of Au-PCPP5, some cytotoxic 
and activation effects were seen. For these reasons, Au-PCPP is not ideal for monocyte 
labeling and we therefore examined alternative nanoparticles for this application, as 
described in subsequent chapters.  
 
2.6 Conclusion 
As we have described above, PCPP nanospheres can be loaded with 
nanocrystals in a controlled fashion to result in exclusive localization of the nanocrystals 
to the surface of the sphere rather than the typically observed core loading of polymer 
 
106 
 
nanoparticles. We found that simultaneous surface and core loading is possible. A range 
of diagnostically active nanocrystals could be surface loaded onto the PCPP 
nanospheres regardless of their individual core size, shape, or chemical composition. 
The nanocrystals loaded on the spheres retained their contrast generating properties, 
i.e. MR contrast in respect to relaxation for iron oxide particles and fluorescence for 
quantum dots. The point of nanocrystal attachment was also probed through the 
investigation of each synthesis step. We observed that surface loading was successful 
prior to CaCl2 addition. In addition, we found that surface loading was achievable using a 
variation of polymer sizes and phospholipid tail lengths, demonstrating multiple feasible 
approaches to surface loading. We showed the stability of the nano-disco balls in cell 
culture media and the potential for drug delivery and cell tracking. However, labeling of 
monocytes with AuNP core-loaded PCPP nanospheres showed adverse effects on 
viability and cytokine expression, despite the excellent x-ray attenuation results. For 
monocyte tracking, the contrast generation of gold nanoparticles is promising, but further 
refinement of nanoparticle parameters to improve biocompatibility is necessary. We 
explore the physical and chemical properties for gold nanoparticles as optimized 
monocyte labeling in the following chapters.    
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2.7 Appendix 
Determination of IO-MHPC coverage on PCPP particles 
 
PCPP Available Surface Area 
Average diameter of sphere (from TEM): 487 nm 
Surface area of one sphere: 4πr2 
4π*((4.87e-5)/2)2) = 7.45e-9 cm2 
Volume of one sphere: 4/3πr3 
(4/3) π*(4.87e-5)/2)3) = 6.04e-14 cm3 
Assume density of PCPP = 1000 mg/ml, 
PCPP mass in one sphere: Vol of one sphere*density 
(6.04e-14)*(1000) = 6.04e-11 mg 
Assume 50% PCPP use in batch, total mass = 1mg 
Total number of PCPP spheres in batch: Total mass/mass of one sphere 
1/(6.04e-11) = 1.65e10 spheres 
Total available surface area for binding in one batch: SA for one sphere *total spheres 
(7.45e-9)*(1.65e10) = 123.2 cm2 
 
Binding Space of Iron Oxide Nanoparticle 
Average diameter of IONP (from TEM): 15.6 nm 
Volume of one particle: 4/3πr3 
(4/3) π*(1.56e-5)/2)3) = 1.98e-18 cm3 
Density of IO = 5175 mg/ml 
IO mass of nanoparticle: Vol of IONP*density 
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(1.98e-18)*(5175) = 1.03e-14 mg 
Average iron content in one batch (from ICP) = 0.075mg 
% iron in IO particle (Fe3O4): 
(3*55.6)/((3*55.6)+(4*15.9))*100 = 72.34% 
Total IO mass in one batch: (ICP mass)/(% iron in IO)  
0.075/(72.34/100) = 0.104 mg 
Total number of IONP particles in batch: (total IO mass)/(mass IO sphere)  
0.104/(1.03e-14) = 1.00e13 particles 
Hydrodynamic diameter of IONP =35 nm 
Binding area of IONP (area of circle) = 2πr2  
2π((3.5e-6)/2)2 = 9.63e-12 cm2 
Total binding area occupied by IONP in one batch: Binding Area*total IONP particles 
(9.63e-12)*(1.00e13) = 96.96 cm2 
 
Coverage of PCPP nanosphere 
Total binding area of IONP/Total available surface area of PCPP: 
(96.96/123.2) = 78.7% 
 
# of IONPs per PCPP sphere 
SA of one PCPP sphere *Coverage / Binding area of one IONP 
(7.45e-9)*(78.7/100) / (9.63e-12) = 609.49 IONPs per PCPP sphere 
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Chapter 3: Effect of size and surface functionality of AuNP for 
monocyte labeling 
 
3.1 Abstract 
With advances in cell therapies, interest in cell tracking techniques to monitor the 
migration, localization and viability of these cells continues to grow. X-ray computed 
tomography (CT) is a cornerstone of medical imaging but has been limited in cell 
tracking applications due to its low sensitivity towards contrast media. In this study, we 
investigate the role of size and surface functionality of gold nanoparticles for monocyte 
uptake to optimize the labeling of these cells for tracking in CT. We synthesized gold 
nanoparticles (AuNP) that range from 15 to 150 nm in diameter and examined several 
capping ligands, generating 44 distinct AuNP formulations. In vitro cytotoxicity and 
uptake experiments were performed with the RAW 264.7 monocyte cell line. The 
majority of formulations at each size were found to be biocompatible, with only certain 
150 nm PEG functionalized particles reducing viability at high concentrations. High 
uptake of AuNP was found using small capping ligands with distal carboxylic acids (11-
MUA and 16-MHA). Similar uptake values were found with intermediate sizes (50 and 75 
nm) of AuNP when coated with 2000 MW poly(ethylene-glycol) carboxylic acid ligands 
(PCOOH). Low uptake values were observed with 15, 25, 100, and 150 nm PCOOH 
AuNP, revealing interplay between size and surface functionality. TEM and CT 
performed on cells revealed similar patterns of high gold uptake for 50 nm PCOOH and 
75 nm PCOOH AuNP. These results demonstrate that highly negatively charged 
carboxylic acid coatings for AuNP provide the greatest internalization of AuNP in 
monocytes, with a complex dependency on size.    
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3.2 Introduction 
The ability to track specific cells non-invasively in biological systems is of growing 
importance.1 With surging interest in adoptive cell therapies for cancer treatment and the 
promise of stem cell therapy, techniques to monitor the behavior of transferred cells are 
becoming increasingly valuable tools.2-4 Labeling and tracking of transferred cells can be 
uniquely informative, revealing insights about cell migration, differentiation and viability 
without invasive procedures.3, 5 A number of studies have explored the potential benefits 
of cell tracking for cellular therapies including applications for stem cell implantations, T-
cell immunotherapy, and myeloid cells for treatment of myocardial infarction.6-10  
Only a few groups have attempted to use the advantages of x-ray computed 
tomography (CT) for the purpose of cell tracking.11-13 CT is a whole body imaging 
technique that has high spatial and temporal resolution, which has led it to become one 
of the foremost clinical imaging methodologies, with more than 70 million scans 
performed annually in the USA alone.14-15 CT is therefore the first-in-line imaging 
modality for a number of conditions, such as cardiovascular disease, lung cancer and 
trauma.15-16 The development of cell tracking for CT is therefore of considerable interest. 
For CT, attenuation from contrast agents is linearly proportional to the concentration of 
the agent allowing for quantification opportunities in cell tracking. For instance, Betzer et 
al., were able to estimate the number of gold labeled cells in vivo in a region of the brain 
non-invasively using CT scans.17 Quantifying cell numbers can reveal vital information 
for cell tracking studies including cell migration and viability. Advances in emerging CT 
technology continue to open new possibilities for cell tracking; e.g., with the use of x-ray 
synchrotron beams, some groups were able to achieve single cell resolution for cell 
 
118 
 
tracking.18-19 Additionally, with the emergence of spectral CT for specific differentiation of 
contrast agents from tissue, opportunities for cell tracking with CT continue to grow.14, 20    
Cell tracking requires the labeling of specific cells of interest with a reporter for 
imaging. The challenge for CT is its low sensitivity towards contrast agents, which 
demands efficient methods for labeling cells with high payloads. Gold nanoparticles 
(AuNP) are an attractive platform upon which to base CT contrast agents due to being 
biologically inert, providing strong attenuation for CT and their high density, which allows 
efficient payload delivery.21-22 Moreover, developments in AuNP chemistry have allowed 
for control over their size, shape and chemical functionality allowing the nanoparticle 
properties to be tailored for specific biomedical applications.23-24 Previous investigations 
have shown that these nanoparticle properties can affect cytotoxicity, cell uptake and 
serum protein interactions in biological systems.25-27 However, the interaction of the 
nanoparticles appears to be dependent on the surrounding biological environment and 
system of interest, so the optimal nanoparticle properties for desired interactions (i.e. cell 
avoidance or uptake) must be determined for each specific case.28 
Monocytes play a critical role in the progression of plaques and other diseases, 
with monocyte recruitment being prominent in early stages of disease development.29-32 
Imaging recruitment of these monocytes can reveal information about the disease state 
and allow further investigation of factors that may affect this behavior. In this study, we 
sought to optimize the uptake of AuNP by monocytes via examining in depth, the effects 
of size and chemical functionality on AuNP uptake. We synthesized and characterized a 
library of particles ranging from 15 nm to 150 nm in diameter, each coated with several 
functionally distinct ligands, totaling 44 unique formulations. We sought to explore short 
carbon chain carboxylic acid and poly(ethylene) glycol ligands with carboxyl acid end 
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groups. Additionally, we explored poly(ethylene) glycol ligands with alternate end groups 
to explore how differences in surface properties affect interactions with monocytes. The 
interactions of these nanoparticles with monocytes were assessed via viability and 
uptake studies. Moreover, parameters of incubation time were explored to optimize cell 
uptake. CT contrast generation of AuNP labeled monocytes was examined with CT 
scans and intracellular localization studied with TEM.  
 
3.3 Materials and methods 
3.3.1 Materials 
Chemicals of analytical grade were purchased from Sigma-Aldrich (St. Louis, MI) 
unless specified elsewhere. The monocyte cell line used for cell studies, RAW 264.7, 
was purchased from ATCC (Manassas, VA). Cells were cultured with Dubecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 
1% penicillin/streptomycin (10000 units/MI, 10000 µg/mL), purchased from Cellgro, 
Corning (Manassas, VA).      
 
3.3.2 AuNP synthesis 
Spherical AuNP of 15 nm and 25 nm in diameter were synthesized using a 
modified Frens/Turkevich method.33-34 For 15 nm AuNP, 600 µl of 1% gold(III) chloride 
(HAuCl3) was dissolved in 60 mL of ultrapure water (Milli-Q, EMD Millipore, Billerica MA). 
The solution was brought to a boil before 1.8 mL of 1% sodium citrate dihydrate was 
added to the mixture. The solution was left to reflux for 15 min before cooling to room 
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temperature. Similarly, 25 nm AuNP were synthesized by adding 1 mL of 1% sodium 
citrate dihydrate to the boiling gold solution. 
AuNP ranging from 50 nm to 150 nm in diameter were synthesized using the 
seeded growth method described by Perrault et al.35 Briefly, 15 nm spherical AuNP were 
used as seeds in this method and were produced as outlined above. For the synthesis, 1 
mL of 1% HAuCl3 was added to 100 mL of ultrapure water at room temperature. A 
number of gold “seeds” were added to the solution to create nanoparticles 50, 75, 100 or 
150 nm in diameter. The number of seeds needed for each size was empirically 
determined (Figure 3.1). A typical solution of seeds contained 1.54 x1012 seeds/mL. For 
example, 50 nm AuNP were synthesized by adding 3 mL of seed solution (as made in 
the above method) to HAuCl3 solution. To initiate the AuNP growth reaction, 220 µL 
sodium citrate dihydrate (1% weight/volume) and 1 mL of 0.03 M hydroquinone solution 
were added quickly in succession to the seed/HAuCl3 solution. The solution was allowed 
to stir for an hour before performing ligand exchange.  
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Figure 3.1 Seed number vs gold size diameter. 
Effect of seed number (15 nm seeds) on gold nanoparticle diameter in the seeded 
growth method used in this study. 
 
After AuNP core synthesis, ligand exchange was performed with a library of 
ligands to stabilize the AuNP for biomedical applications and provide differing chemical 
functionalities to explore their effect on cell uptake. AuNP that did not undergo ligand 
exchange remained coated with citrate and were also used in the study. Short carbon 
chain carboxylic acid ligands 11-mercaptoundecanoic acid (11-MUA) and 16-
mercaptohexadecanoic acid (16-MHA) were examined. Additionally, 2000 MW 
poly(ethylene-gycol) with methoxy (MPEG), carboxylic acid (PCOOH), and amine 
functional groups were examined. AuNP synthesized with PEG-amine were found to 
aggregate during ligand exchange, however, amine containing coatings were achieved 
by using 1:4 ratio of PEG-amine to MPEG (2N8M) or PCOOH (2N8C). Each 
nanoparticle size was capped with a ligand amount that we estimated based on the total 
nanoparticle surface area for that size. A ratio of 1.35 x 106 mmol/cm2 was used to 
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determine the amount of ligand to use (Table 3.1). Each ligand was dissolved at 5 
mg/mL concentration before addition to the gold solutions. 11-MUA and 16-MHA ligands 
were dissolved in ethanol and all PEG functionalized ligands were dissolved in water. 
For example, for 100 nm PCOOH, 85 µL (0.421 mg) of 5 mg/mL PCOOH solution was 
added to a typical 100 nm seeded growth solution (100 mL) for exchange. Gold solutions 
were allowed to stir overnight for complete ligand exchange. Afterwards, the 
nanoparticles were washed twice by centrifugation and then purified through a 0.45 µm 
syringe filter (EMD Millipore, Billerica MA). The parameters for centrifugation were 
specific to each size and can be found in Table 3.2.  
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Table 3.1 Ligand determination for each size of AuNP. 
 
 
 
124 
 
Table 3.2 Centrifuge parameters for gold nanoparticles. 
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3.3.3 Particle characterization 
The AuNP concentration after purification was determined through inductively 
coupled plasma – optical emission spectroscopy (ICP-OES). Samples (typically around 
10 µL) were dissolved in 1 mL aqua regia (3 parts HCl:1 part HNO3) for 30 mins before 
making the final volume of the sample to 3 mL with ultrapure water. The resulting 
solutions were analyzed with a Spectro-Genesis ICP (Spectro Analytical Instruments 
GmbH, Kleve, Germany) for gold content. Transmission electron microscopy (TEM) was 
used to visualize the AuNP and evaluate core size and was performed on a JEOL 1010 
(JEOL USA Inc., Peabody MA) at 80 kV. Over 200 AuNP in the TEM images were 
measured with ImageJ (National Institutes of Health) to determine the average diameter 
for each core size. UV/Vis spectra were recorded using an Evolution 201 UV-Visible 
Spectrophotometer (Thermo Scientific, Waltham, MA) scanning from wavelengths of 700 
to 300 nm. Typically, 10 µL of sample was added to a cuvette and diluted to 1 mL with 
ultrapure water. The hydrodynamic diameters (dynamic light scattering) and zeta 
potentials of the AuNP were evaluated using a Nano ZS-90 Zetasizer (Malvern 
Instruments, Worcestershire, UK). AuNP samples were diluted to 1 mL with ultrapure 
water for analysis with these techniques.    
 
3.3.4 In vitro studies 
The effects of AuNP size and coating were studied using a monocyte cell line, 
RAW 264.7. The LIVE/DEAD assay (Life Technologies, Frederick, MD) was used to 
study cytotoxicity. Monocytes were cultured in 20 mm glass bottom dishes at 7.5 x 104 
cells per dish for 24 hours at 37˚C, 5% CO2 with DMEM (10% FBS, 1% 
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streptomycin/penicillin). After this time, the media was removed and fresh media 
containing AuNP at 0.1, 0.5, 1.0 mg/ml or without AuNP was added. The cells were 
incubated with the AuNP for 24 hours before performing analyses, unless specified 
otherwise. After incubation, cells were washed twice with DPBS before 400 µL of 
LIVE/DEAD cocktail (2 mL DPBS, 2 µL stock Ethidium-1 homodimer, 0.5 µL stock 
Calcein AM, 0.5 µL 3.2 mM Hoechst 33342) was gently added to the cells. The cells 
were incubated for 20 mins with the LIVE/DEAD cocktail. Afterwards, the cells were 
imaged with Nikon Eclipse Ti-U fluorescence microscope. Filters for DAPI (Ex. 359, Em. 
461 nm), FITC (Ex. 495, Em. 519 nm), and Texas Red (Ex. 595, Em. 613 nm) were used 
to visualize cell nuclei, living cells and dead cells respectively. Four separate fields were 
taken for each dish for each filter channel. The images were analyzed by a custom 
MATLAB (MathWorks, Natick MA) program to count the number of stained cells in each 
field. The viability percent is expressed as number of living cells divided by total number 
of cells present in each field of view. Viability experiments were repeated 3 times (n=3).         
  
3.3.5 Cell uptake studies 
For uptake studies, monocytes were cultured in 12 well plates, 8.0 x 105 cells per 
well for 24 hours at 37˚C, 5% CO2 with DMEM (10% FBS, 1% streptomycin/penicillin). At 
this point, the media was removed and replaced with fresh media containing AuNP. 
Various concentrations, formulations and timeframes were used, see results for details. 
After incubation with AuNP, the media was removed and the cells were washed twice 
with DPBS and then scraped for collection in 1 mL of DPBS. The cells were counted with 
a hemocytometer and centrifuged at 200 g for 5 mins to form a pellet. The supernatant 
was discarded and the cells were re-suspended in 200 µL of 4% paraformaldehyde 
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(PFA) until preparation for ICP-OES. Cells were dissolved in 1 mL of aqua regia (3 parts 
HCl:1 parts HNO3) for 30 mins and then centrifuged at 200 g for 5 mins to pellet and 
discard cell debris. The supernatant was collected and diluted to 3 mL with ultrapure 
water and analyzed with ICP-OES.  
Cells treated with AuNP for 24 hours were also collected and fixed in 2% 
PFA/2.5% glutaraldehyde, cut into 60 nm sections and prepared using standard 
techniques for examination with TEM.36 Sections were viewed with a JEOL 1010 
Electron Microscope at 80 kV. For CT scans, after treating cells with AuNP, monocytes 
were collected and fixed with 200 µL 4% PFA. The cells were allowed to loosely settle 
into pellets in 250 µl tubes before scanning with a small animal MicroCAT II scanner 
(Imtek Inc., Knoxville, TN). The parameters used for the scan were 100 µm slice 
thickness (100 x 100 µm in-plane spatial resolution), 51.2 mm x 76.8 mm field of view, 
80 kVp tube voltage, and tube current of 500 µA. The microCT contains a 1.0 mm 
aluminum beam filter. Image reconstruction was done using a Feldkamp cone beam 
correction and a Shepp-Logan filter, which produced images scaled in Hounsfield units 
(HU). Images were analyzed with OsiriX v3.7.1 64-bit software. Identical regions of 
interest (1.5 mm2) were drawn on 3 sequential slices in the cell pellets and the recorded 
attenuation values averaged. The ΔHU was defined as the difference in attenuation 
between non treated cell pellets and samples treated with AuNP.  
 
3.3.6 Statistical methods 
 All error bars shown on figures are standard errors of means. Statistical analysis 
was performed using Stata-14 (64-bit, College Station, Texas). For viability of 150 nm 
PCOOH, 2N8M, and 2N8C, a one-way ANOVA was used to determine significance 
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among concentrations. Post-hoc, Tukey pairwise mean comparison was used to 
compare the interactions between each concentration. For our time course experiment, 
a one-way ANOVA was used to analyze significance for cell numbers and AuNP uptake. 
Tukey pairwise mean comparison was used to compare interactions between each time 
point for both cell number and uptake. For uptake experiments, a two-way ANOVA was 
used to analyze significance differences caused by both size and coating on uptake. 
Afterwards, a post-hoc Tukey pairwise mean comparison was used to analyze 
differences between coatings at each size. For CT attenuation experiments, a one-way 
ANOVA was performed to determine significant differences at each concentration 
examined. A post-hoc Tukey pairwise comparison was used for the coatings at each 
concentration examined. 
 
3.4 Results 
3.4.1 AuNP synthesis 
Spherical AuNP of approximately 15, 25, 50, 75, 100, and 150 nm in diameter 
were synthesized to examine the effect of size on cellular uptake. AuNP of 15 and 25 nm 
were synthesized using the Turkevich method.33-34 Diameters of 50 nm and above were 
synthesized using a modified seeded growth method described by Perrault et al.35 This 
method utilized 15 nm AuNP synthesized via the Turkevich method as nucleation points 
to further “grow” gold around these “seeds.” We used the seeded growth method for 
these larger diameter nanoparticles, since we found that the Turkevich method resulted 
in highly heterogeneous sizes and shapes when forming nanoparticles 50 nm or above. 
The number of seeds added to the synthesis dictated the final size of the AuNP. We 
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empirically determined the number of seeds needed to form nanoparticles of a range of 
sizes with this synthesis (Figure 3.1). TEM images in Figure 3.2 were analyzed to 
determine core sizes of the AuNP. The distributions for each nanoparticle size can be 
seen in Figure 3.3. A Shapiro-Wilk test was used to test for normality. Each nanoparticle 
formulation was found to be normally distributed except the 15 nm particles (p<0.05).   
 
 
Figure 3.2 TEM of AuNP from 15 to 150 nm. 
TEM images of spherical gold nanoparticle of increasing size from 15 to 150 nm. 15 and 
25 nm AuNP were synthesized through the Turkevich method. 50, 75, 100, and 150 nm 
AuNP were synthesized through a seeded growth method. 
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Figure 3.3 AuNP synthesis size distributions. 
Histogram plots of size distributions for each AuNP size. Sizes are measured 
nanoparticle core diameters from TEM images (>200 particles surveyed). Shapiro-Wilk 
test was used to test for normality. Normality was rejected for only 15 nm size particles 
(p<0.5). 
 
In addition to forming nanoparticles of a range of sizes, several different coatings 
were used for each nanoparticle size. With the use of thiol ligands, the surface coating of 
AuNP was exchanged to produce particles with various chemical functionalities. We 
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examined seven different coatings for each size of AuNP (including citrate) and each 
formulation was characterized for UV/Vis absorption, hydrodynamic diameter (dynamic 
light scattering) and overall surface charge (zeta potential) (Table 3.3). The chemical 
structure for each ligand is shown in Figure 3.4. Straight-chain hydrocarbon ligands with 
distal carboxylic acid functional groups (11-MUA and 16-MHA) were used as they 
demonstrate high uptake in monocytes without affecting viability as shown in our 
previous work with 15 nm AuNP.13 In addition, a variety of thiol-poly(ethylene-glycol) 
(PEG) based coatings were examined. PEG with a distal methoxy group (MPEG) is 
widely used to coat nanoparticles, typically providing high stability and resulting in low 
cell uptake.37-38 We used this coating as a control.  
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Table 3.3 Surface characterization of AuNP formulations  
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Figure 3.4 Schematic of gold ligand exchange. 
Schematic depiction of the range of AuNP sizes used in this study and the chemical 
structures of the ligands used as coatings. PEG-amine coatings were mixed in 1:4 ratios 
with MPEG and PCOOH to provide particle stability. Ligands examined represent 
different functionalities and charges. 
 
For this study, we sought to improve AuNP uptake by monocytes, therefore we 
investigated PEG coatings with charged distal end groups such as carboxylic acid 
(PCOOH) and PEG-amine. The bulky PEG coating should help to provide AuNP 
stability, while we hypothesized that the charged surfaces may increase cell uptake.39 
We found that 100% PEG-amine coated AuNP aggregated after 24 hours (data not 
shown). However, we found that AuNP coated with PEG-amine mixed in a 1:4 ratio with 
MPEG (2N8M) or with PCOOH (2N8C) were stable, and therefore were used in this 
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study. Characterization data for each AuNP core size coated are shown in Table 3.3. As 
the core diameter of the AuNP increases, the UV/Vis absorbance maxima increase in 
wavelength, in agreement with previously published results.40 The surface potential of 
PCOOH coated particles for each size is highly negative as expected due to the 
carboxylic acid functional end group. Measurements of hydrodynamic diameters were 
larger than core diameters measured by TEM as expected due to the ligands attached to 
the nanoparticle surfaces. Large PDI values were seen for 25 nm formulations indicating 
some heterogeneity for these particles (Table 3.3). With the 11-MUA ligand, 50, 75, 100, 
and 150 nm particles were not stable and aggregated during ligand exchange (Figure 
3.5) and therefore were not used in the study.  
 
Figure 3.5 Stability of 50 nm AuNP after 24-hour incubation with various ligands. 
Aggregation seen for short carboxylic acid coated 50 nm AuNP as compared to other 
coatings 
 
3.4.2 Cytotoxicity 
 As an initial screen for suitability for cell labeling purposes, the effect on cell 
viability of each AuNP formulation was examined. The cells were treated with AuNP for 
24 hours at concentrations of 0.1, 0.5, and 1.0 mg Au/ml to examine the effect of each 
size and surface functionality over a large concentration range (Figure 3.6). The majority 
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of formulations studied in the 15-100 nm diameter range were found to be biocompatible 
for the concentrations tested. However, significant reductions in cell viability were 
observed for several 150 nm AuNP that had PEG-based coatings. For 150 nm PCOOH 
AuNP, significant (p<0.05) cytotoxicity was only observed at the highest concentration 
tested (1.0 mg Au/ml). In the case of 150 nm 2N8M AuNP, 0.5 and 1.0 mg Au/ml 
concentrations resulted in cell viability of approximately 60% but only 0.5 Au/ml was 
found to be statistically significant. Lastly, 150 nm 2N8C AuNP caused significant 
reductions in cell viability at all concentrations examined.  
Formulations that did not cause adverse effects on cell viability were studied for 
their uptake by monocytes, as detailed in the next section. However, we found that some 
formulations aggregated under the conditions used for cell culture (i.e. 50 nm 2N8C, 75 
nm 16-MHA, 75 nm 2N8C, 100 nm 16-MHA, 100 nm 2N8M, 100 nm 2N8C, 150 nm 16-
MHA, 150 nm 2N8M and 150 nm 2N8C) likely due to a combination of particle instability 
and sedimentation. Since co-injection of free nanoparticles with labeled cells would 
result in erroneous conclusions in cell tracking experiments, these formulations were 
excluded from cell uptake experiments. Notably, this effect was seen in all citrate 
formulations regardless of size. This effect was also more common for larger size AuNP 
formulations such as 100 nm and 150 nm, for which only MPEG and PCOOH were 
found to be stable. This is likely due to the higher van der Waals interactions for these 
larger AuNP overcoming the steric/charge-based repulsion of the ligands. Additionally, 
formulations that resulted in toxicity at 0.5 mg/ml were excluded from uptake studies.     
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Figure 3.6 Cell viability with AuNP formulations. 
Cell viability of monocytes incubated with AuNP of a range of diameters and coatings. 
Cells were incubated with AuNP for 24 hours at 0.1, 0.5, 1.0 mg Au/ml. Viability was 
assessed with the LIVE/DEAD assay. Values are normalized to those for untreated 
monocytes. Values represent the mean of 3 replicates (n=3) and error bars represent 
standard error of mean. Significance for 150 nm AuNP was examined with one-way 
 
137 
 
ANOVA and post hoc Tukey pairwise comparisons. * indicates significance of treated 
groups compared to non-treated group (p<0.05).      
 
3.4.3 AuNP uptake by monocytes 
 We first investigated the optimal incubation time to yield high AuNP uptake. 
Figure 3.7 shows the results of experiments where monocytes were incubated with 15 
nm 11-MUA AuNP (0.5 mg Au/ml) for several different durations, ranging from 2 to 48 
hours. From 2 to 24 hours, AuNP uptake in the cells increased with increasing time in 
addition to the number of cells rising. However, there was no significant difference 
(p>0.05) in gold uptake between 24 and 48-hour incubations suggesting that the 
maximum limit of AuNP uptake had been reached at 24 hours. Additionally, when the 
cells were incubated with these AuNP for 48 hours, fewer cells were present after culture 
than at 24 hours (p<0.05). From these data, we concluded that 24 hours was the best 
duration over which to incubate monocytes with AuNP for both maximum uptake and 
number of cells. We therefore used 24 hours incubation time in all subsequent 
experiments.  
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Figure 3.7 Optimization of AuNP incubation time. 
Evaluation of gold content in monocytes incubated with 15 nm 11-MUA AuNP (0.5 mg 
Au/ml) for up to 48 hours. In addition, the total number cells at each time point is 
displayed. Values represent mean of 3 replicates (n=3) and error bars are standard error 
of mean. A one-way ANOVA was used to determine significance for both uptake and 
number of cells. Post-hoc Tukey pairwise comparison was used to compare significance 
between time points (p<0.05). Results for statistical comparisons between 24 and 48 
hours shown only.  
 
 For the investigation of cell uptake, all sizes and formulations were incubated 
with monocytes at a concentration of 0.5 mg/ml for 24 hours. In Figure 3.8, a number of 
distinct relationships between size of nanoparticle and coating ligand on uptake can be 
observed. Particles coated with small molecule functionalized carboxylic acids (11-MUA 
and 16-MHA) show high uptake with smaller size particles between 15 nm and 50 nm. 
However, these ligands were increasingly unstable at larger sizes, preventing 
experimental measurements being acquired. MPEG AuNP exhibited low gold uptake in 
cells with slightly increasing values at larger sizes. We suspect this result was due to 
these larger AuNP settling in the cell culture media, resulting in increased cell contact 
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and uptake. Most notably, PCOOH AuNP exhibited a complex relationship between 
uptake and particle size. Minimal uptake was found at 15 and 25 nm while the highest 
uptake values were observed at 50 and 75 nm. Interestingly, cell uptake for 100 and 150 
nm PCOOH AuNP was significantly less than for 50 and 75 nm AuNP. The uptake for 
50, 75, and 100 nm PCOOH AuNP was found to be significantly different than all other 
coatings at that size (p<0.05). Similar uptake values for 150 nm PCOOH and MPEG 
AuNP suggests that for both these nanoparticles uptake may be largely due to particle 
settling (non-significant, p >0.05). Low uptake was observed for 15 and 25 nm 2N8C and 
were found to aggregate at 50 nm and above. 
 
 
Figure 3.8 Uptake of gold nanoparticles in monocytes. 
Gold uptake in monocytes incubated with AuNP of a variety of sizes and coatings. 
Formulations exhibiting particle instability (significant aggregation and sedimentation) or 
cytotoxicity were excluded from the study. The cells were treated for 24 hours at 0.5 mg 
Au/ml and evaluated for gold content with ICP-OES. Values represent mean of typically 
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six replicates (n=6) and error bars are standard error of mean. A two-way ANOVA was 
used to determine significance of AuNP uptake for size and coating. A Tukey pairwise 
mean comparison was used to determine significance between coatings at each size. * 
indicates significance of PCOOH compared to all other coatings at that size.    
 
 Monocytes incubated with selected AuNP formulations were additionally 
examined with TEM to observe the intra-cellular localization of AuNP. Cells were treated 
for 24 hours with 0.5 mg/ml of 15, 75, 100, and 150 nm PCOOH AuNP. The results in 
Figure 3.8 show AuNP aggregated into intercellular vesicles located in the cytoplasm of 
the monocytes. With monocytes, the uptake of AuNP is likely through phagocytosis with 
particles concentrated into lysosomes. Further investigation would be required to confirm 
the route of uptake, but other researchers have shown that the major route of uptake of 
nanoparticles in monocytes and macrophages is phagocytosis.41-42 More AuNP were 
seen more frequently in 75 nm PCOOH AuNP treated monocytes as compared to other 
sizes, in agreement with the results observed from ICP-OES measurements (Figure 
3.9).      
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Figure 3.9 TEM of cells after treatment with AuNP. 
TEM of monocytes treated with 15, 75, 100, and 150 nm PCOOH AuNP. Cells were 
treated at 0.5 mg/ml for 24 hours before being harvested and fixed for TEM.  
 
3.4.4 CT imaging 
To demonstrate the contrast generating properties of the AuNP taken up in 
monocytes, cells were scanned with a microCT scanner at 80 kVp. Monocytes were 
treated with 50, 75, 100 and 150 nm PCOOH AuNP for 24 hours at 0, 0.1, 0.25, and 0.5 
mg/ml. Afterwards, cells were collected in 4% PFA and allowed to settle into loose 
pellets before scanning (Figure 3.10). Figure 3.10A shows CT scans of cells treated at 
increasing concentrations for 75 and 150 nm AuNP. The contrast generated from the 
AuNP increases as treatment concentration increases for these formulations. 
Quantitative analysis of the attenuation of these cell pellets is shown in Figure 3.10B, 
and revealed that the highest contrast enhancement arose for 50 and 75 nm AuNP. This 
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size dependent attenuation for the PCOOH AuNP closely matches the AuNP uptake 
results in Figure 3.8, signifying that the observed attenuation is due to the internalized 
AuNP. The change in attenuation was measured by normalizing to values obtained from 
untreated monocytes. A one-way ANOVA and post-hoc tukey pairwise mean 
comparison was used to determine significance between sizes at each concentration 
group. At each treatment concentration, the quantified attenuation was found to be 
significant between all sizes for PCOOH (p<0.05). To explore the relationship between 
gold uptake and CT attenuation, the attenuation of cell pellets (HU) was plotted against 
gold uptake (pg/cell). Figure 3.11 shows that there is a linear relationship (R2 = 0.89) 
between attenuation and gold uptake.             
 
 
Figure 3.10 CT attenuation of monocytes labeled with AuNP of each size. 
A) CT scans of monocytes settled into pellets after treatment with 75 and 150 nm 
PCOOH AuNP for 24 hours at 0, 0.1, 0.25 and 0.5 mg/ml. Cells were collected in 4% 
PFA solution after treatment. Scans performed on small animal microCT scanner with 
100 µm spatial resolution at 80 kVP and 500 µA. (B) Quantification of attenuation in 
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Figure 3.10A of monocytes incubated with PCOOH AuNP of various sizes. Values 
normalized to untreated cells. Error bars are standard error of the mean with (n=3 for 
each data point). A one-way ANOVA and post-hoc Tukey pairwise mean comparison 
used to compare different sizes at each concentration group. * indicates significance 
between all sizes at that concentration (p<0.05).  
 
 
Figure 3.11 Correlation of uptake and attenuation for PCOOH AuNP. 
Attenuation of cell pellets plotted against cell uptake for PCOOH coatings. Attenuation of 
untreated cell pellets used for zero uptake. The dotted line is the line of best fit for this 
data, assuming linearity. 
 
3.5 Discussion 
We studied a total of 44 AuNP formulations with a range of diameters and 
diverse capping ligands as potential labels for monocyte cell tracking. While the majority 
of the formulations studied did not affect cell viability, we observed that 150 nm AuNP 
with PEG-amine as part of the coating (2N8M, 2N8C) resulted in significant reductions in 
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cell viability (Figure 3.6). This toxicity is likely due to the presence of the positively 
charged amine groups in combination with increased AuNP-cell interactions due to these 
large nanoparticles settling in the cell culture media. Researchers have hypothesized 
that cytotoxicity from cationic surface coatings could be due to increased diffusion of 
nanoparticles through the cell membrane, disrupting the lipid bilayer.43 Formation of 
protein coronas adsorbed onto the AuNP from the serum in the cell culture media during 
the incubation is also likely to play a role in their monocyte interactions.44 The protein 
corona formed would be unique to each AuNP formulation and some speculate these 
adsorbed proteins are highly influential in the interactions between cells and 
nanoparticles.45 
The small animal microCT scanner used in the study was limited to 80 kVp as 
the maximum x-ray tube voltage. At 80 kVp the photons produced are below the k-edge 
(80.7 keV) of Au. However, at 80 kVp, the attenuation difference between Au and tissue 
remains substantial, allowing for strong contrast in our study. With the higher voltages 
typically available on clinical scanners (100-140 kVp), we would likely see greater 
contrast between Au and controls than seen in this study.         
 In the uptake experiments, high uptake of AuNP was found with short carbon 
chain carboxylic acid ligands, consistent with those of others.7, 46 It may be the case that 
upon incubation in serum, formation of protein coronas or aggregation of these AuNP 
with proteins cause changes in size. The resulting nanoparticles may be highly taken up 
by monocytes due to their size or due to settling. Future experiments will probe the 
structure of these nanoparticles in serum to answer these questions. For AuNP coated 
with these short carboxylic acid ligands, uptake was greater for 15 nm particles than 25 
nm particles, however a size trend could not be discerned due to a lack of stability of 
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larger diameter AuNP with these coatings. 11-MUA particles were unstable during ligand 
exchange for particles larger than 25 nm, while 16-MHA coated were stable during 
synthesis but produced significant aggregation artifacts in uptake studies with particles 
larger than 50 nm (Figure 3.8). These results indicate that larger AuNP may require 
larger ligands for robust stability. For increased stability at larger AuNP diameters, we 
explored a variety of PEG-2000 ligands. PEG-2000 is well known to provide nanoparticle 
stability in serum as well as ‘stealth’ properties.47 As expected, MPEG coated AuNP 
were taken up at low levels for all particle sizes, although slightly increased uptake was 
seen at the largest sizes, i.e. 100 and 150 nm (Figure 3.8). This uptake is likely a 
function of the increased settling rates for larger nanoparticles rather than due to the 
particle’s surface properties. Due to the lack of uptake with methoxy-PEG coating, we 
explored PEG coating ligands that possessed carboxyl and amine functional groups at 
their distal ends. 
  PEG functionalized carboxylic acids coated particles (PCOOH) were stable for 
each diameter of AuNP studied. The monocyte uptake of AuNP coated with this ligand 
demonstrated a complex relationship with size (Figure 3.8). The highest gold uptake 
values were seen with 50 and 75 nm PCOOH AuNP. Other researchers have suggested 
50 nm as optimal uptake size for AuNP in other cell lines.48 For instance, Chithrani et al., 
observed the highest accumulation for 50 nm citrate coated AuNP in HeLa cells after 24 
hours.49 While the data for PCOOH AuNP from our experiments are in agreement with 
these prior studies, maximal uptake for 50 nm AuNP was not common to all coatings, 
demonstrating that uptake is dependent on both size and surface functionality. The 
PCOOH ligand and citrate both expose carboxylic acid groups to the surrounding milieu 
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and may therefore form similar protein coronas around them, which may explain the 
similarity between our results and those of Chithrani et al.   
Several studies have reported favorable nanoparticle uptake with amine based 
coatings.50-51 Therefore for this study, we incorporated PEG-amine ligands into MPEG 
(2N8M) and PCOOH (2N8C) at a 1:4 ratio (AuNP coated with 100% PEG-amine were 
not stable). Low uptake values with both coatings at 15 and 25 nm suggest similar 
properties to MPEG and PCOOH coated AuNP. However, for larger core sizes only 50 
and 75 nm 2N8M AuNP were found to be without stability issues, limiting the extent to 
which these coatings could be explored. The gold uptake values of 50 and 75 nm 2N8M 
AuNP are similar to those of MPEG of the same sizes, suggesting the observed 
behavior is dominated by the presence of MPEG and that the availability of the amine 
groups was limited. A higher ratio of PEG-amine to MPEG may be necessary to fully 
explore the effect of size with PEG-amine coated AuNP.  
In CT imaging of cell pellets, the uptake of PCOOH coated AuNP resulted in 
large attenuation values, <2000 HU for the formulations with the highest uptake. These 
values are dependent on the amount of gold present in the volume of the cell pellet. For 
75 nm PCOOH, we calculated the total mass of gold in the cell pellet from the cell 
uptake value (174.68 pg/cell) and the number of cells in the pellet (2.5 million) to be 0.44 
mg. Since the volume of the pellet was 10 µL, we calculated the concentration of gold in 
the pellet to be 221.7 mM. The attenuation change relative to the concentration of gold 
was therefore approximately 9.65 HU/mM of Au. This attenuation per concentration of 
gold value is close to those reported previously in the literature when using similar CT 
scanners.52             
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 For the purpose of labeling monocytes, similar values of gold uptake were seen 
with 15 nm 11-MUA, 50 nm PCOOH, and 75 nm PCOOH AuNP. Both types of coatings 
have functional carboxylic acid end groups with strong negative surface charge. 
Previous research has shown that anionic surface charges may lead to favorable protein 
corona formation for uptake by preferential binding of Apolipoprotein H (ApoH) 
compared to positively charged particles.53 The increased presence of ApoH on 
nanoparticles showed increased uptake in human mesenchymal stem cells compared to 
other highly abundant proteins composing the corona. Considering synthetic efficiency, 
15 nm AuNP are easier to produce on a large scale (performing seeded growth to form 
50-75 nm AuNP adds another synthetic step which we have found challenging to scale 
up). The scalability of a synthesis is important feature for future translation, an issue that 
few studies have sought to address.54 Additionally, the low cost of the 11-MUA ligand 
($13.14/g, Sigma-Aldrich, St. Louis, MO) compared to the ligand PCOOH ($1400/g, 
Creative PEGworks, Chapel Hill, NC) reinforces the justification for use of 15 nm 11-
MUA coated AuNP for future monocyte labeling studies.    
 
3.6 Conclusion 
 In this study, we explored the effect of size and surface coating on AuNP 
biocompatibility and uptake in monocytes. We synthesized AuNP ranging in diameter 
from 15 to 150 nm and examined both short carbon chain ligands and PEG-2000 
functionalized ligands. The majority of these formulations had no adverse effect on cell 
viability except 150 nm AuNP coated with charged PEG ligands. We found that small 
AuNP coated with short carboxylic acid ligands were taken up extensively. We also 
observed a complex effect of diameter for PCOOH coated AuNP, with high uptake 
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values at the intermediate sizes of 50 and 75 nm but lower uptake for smaller and larger 
diameters. Additionally, TEM and CT scans of monocytes incubated with these 
formulations showed similar patterns of high uptake for 50 and 75 nm PCOOH AuNP. 
Gold uptake values at 50 and 75 nm for PCOOH AuNP were similar to values seen for 
15 nm 11-MUA particles. Therefore in the following chapter, we evaluate 15 nm gold 
nanoparticles as an effective monocyte label and track these labeled cells in a mouse 
model of atherosclerosis. 
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Chapter 4: Labeling of monocytes for CT cell tracking to 
atherosclerotic plaques 
 
4.1 Abstract  
Monocytes are actively recruited from the circulation into developing 
atherosclerotic plaques. In the plaque, monocytes differentiate into macrophages and 
eventually form foam cells. Continued accumulation of foam cells can lead to plaque 
rupture and subsequent myocardial infarction. X-ray computed tomography (CT) is the 
best modality to image the coronary arteries non-invasively, therefore we have sought to 
track the accumulation of monocytes into atherosclerotic plaques using CT. Gold 
nanoparticles were synthesized and stabilized with a variety of ligands. Selected 
formulations were incubated with an immortalized monocyte cell line in vitro and 
evaluated for cytotoxicity, effects on cytokine release, and cell uptake. These data 
identified a lead formulation, 11-MUA capped gold nanoparticles, to test for labeling 
primary monocytes. The formulation did not the affect the viability or cytokine release of 
primary monocytes and was highly taken up by these cells. Gold labeled primary 
monocytes were injected into apolipoprotein E deficient mice kept on Western diet for 10 
weeks. Imaging was done with a microCT scanner. A significant increase in attenuation 
was measured in the aorta of mice receiving the gold labeled cells as compared to 
control animals. Following the experiment, the biodistribution of gold was evaluated in 
major organs. Additionally, plaques were sectioned and examined with electron 
microscopy. The results showed that gold nanoparticles were present inside monocytes 
located within plaques. This study demonstrates the feasibility of using gold 
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nanoparticles as effective cell labeling contrast agents for non-invasive imaging of 
monocyte accumulation within plaques with CT.       
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4.2 Introduction 
Cardiovascular disease is the leading cause of death in the United States, 
accounting for 1 in every 3 deaths.1 The majority of these deaths arise from the 
development of atherosclerosis in the coronary arteries, where rupture of vulnerable 
plaques can potentially lead to thrombus formation and myocardial infarction. Over the 
last decade, the role of inflammation in atherosclerosis has become a prominent point of 
study in progression of the disease.2 
After the initial development of inflammation in the arterial wall, monocytes are 
actively recruited from the circulation into the arterial wall. In the intima, monocytes 
differentiate into macrophages and eventually foam cells after engulfing low density 
lipoproteins (LDL).3 These foam cells release cytokines and enzymes that lead to growth 
and destabilization of the plaque over time.4 Continued recruitment of monocytes and 
subsequent accumulation of foam cells increase the likelihood of plaque rupture and 
clinical manifestations of atherosclerosis. Monocyte recruitment is a possible drug target 
for atherosclerosis regulation.5 Studies have found that targeting the chemokine 
receptors on monocytes reduces overall plaque progression.6-8 The accumulation of 
monocytes has been found to correlate to the progression and severity of 
atherosclerosis.9 These studies typically involve destructive processes to analyze 
monocyte population in plaques preventing the study of multiple time points in the same 
animal. With non-invasive detection, monocyte accumulation can be rapidly assessed, 
informing the direction of the study before its end. This information can be revealing in 
clinical trials, where imaging may demonstrate the effectiveness or lack of effectiveness 
of drug therapies without invasive measures or waiting for patient mortality outcomes.10  
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CT is one of the best and most frequently used modalities to image the coronary 
arteries non-invasively in patients.11 Modern CT scanners allow for fast, high resolution 
image acquisition, reducing common cardiac and respiratory motion artifacts when 
imaging the coronary arteries.12 With increasing interest in cell imaging, the use of x-ray 
CT is an emerging modality in cell tracking applications. Astolfo et al. and Menk et al. 
performed detailed analysis of gold nanoparticle uptake in cells, as well in vivo detection 
and proliferation of gold labeled tumor cells in rat brain tumor models.13-14 Moreover, 
recent studies utilizing synchrotron radiation sources for x-rays, have been able image 
gold nanoparticle labeled cells with single cell resolution in ex vivo and in vitro 
samples.15-16 Of the few studies regarding monocyte tracking, SPECT and MRI 
modalities were used.17-18 SPECT and MRI face challenges due to chest and heart 
motion when imaging the coronary arteries.19 Therefore, we sought to develop a 
technique to monitor the monocyte accumulation in atherosclerotic plaques non-
invasively through computed tomography. 
Gold nanoparticles (AuNP) have been explored for biomedical applications due 
to the synthetic control over size, shape and coating, their high biocompatibility and their 
unique physical properties.20 This allows the development of AuNP that have specific 
properties tailored for given biomedical applications. For instance, the addition of 
poly(ethylene glycol) (PEG) coatings to particles can be used to increase in vivo 
circulation time by avoiding uptake by cells of the reticuloendothelial system.21 AuNP are 
popular as experimental CT contrast agents, as they attenuate x-rays strongly, as well 
as the afore-mentioned characteristics of biocompatibility and control over size and 
surface functionality.22-24 AuNP have been shown to be effective as both blood pool and 
targeted contrast agents for CT.25-28  
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In this study, we demonstrate the use of AuNP to label monocytes and track their 
migration into atherosclerotic plaques non-invasively using CT. We synthesized AuNP 
15 nm in diameter and performed ligand exchange with a variety of ligands to create a 
library of AuNP. These particles were characterized with dynamic light scattering (DLS), 
zeta potential, and transmission electron microscopy (TEM). After characterization, 
AuNP were evaluated in vitro for the effects on cytotoxicity, cytokine production, and cell 
uptake with monocytes. A lead formulation was then evaluated in vitro with primary 
monocytes isolated from spleens. Lastly, atherosclerotic mice were injected with AuNP 
labeled monocytes and scanned with CT before injection and days 3, 4, and 5 post 
injection. The CT scans were analyzed for intensity. Aortic plaques were excised and 
examined with TEM for the presence of gold labeled monocytes.   
 
4.3 Materials and methods 
4.3.1 Materials 
All chemicals were of analytical grade and were purchased from Sigma Aldrich 
(St. Louis, MO). A monocyte cell line, RAW 264.7, was purchased from ATCC 
(Manassas, VA). Dubecco’s Modified Eagle Medium (DMEM) and RPMI-1640 
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (10000 
units/Ml, 10000 µg/mL) were purchased from Cellgro, Corning (Manassas, VA). 
LIVE/DEAD assay and ELISA kits were purchased from Life Technologies Invitrogen 
(Grand Island, NY). All mice were acquired from Jackson Laboratory, Bar Harbor, ME.  
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4.3.2 Gold synthesis 
Citrate capped gold nanoparticles were synthesized using the Turkevich 
method.29 Briefly, 85 mg of gold(III) chloride hydrate was dissolved in 250 mL of 
ultrapure water (Milli-Q, EMD Millipore, Billerica MA). The gold solution was heated to a 
boil. 25 mL of a 38.8 mM sodium citrate solution was then added, producing citrate 
coated gold nanoparticles. The solution was refluxed for 15 minutes and allowed to cool 
to room temperature. For ligand exchange, capping ligands were added to the solution 
for a final concentration of 0.047 mM in the gold solution. For instance, 2.6 mg of 11-
mercaptoundecanoic acid (MW 218.36) was dissolved in 1 ml of ethanol and added into 
the gold solution to stir overnight. The full library of ligands examined can be found in 
Figure 4.1. After exchange, the particles were spun at 8.5 krcf for 3 hours to pellet the 
particles. The pellets were collected into 1.5 ml micro-centrifuge tubes and washed twice 
with ultrapure water by centrifuging at 8.5 krcf for 45 minutes. The AuNP were then 
filtered through a 0.45 µm syringe filter (EMD Millipore, Billerica MA) in a biosafety 
cabinet for sterilization. 
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Figure 4.1 Library of capping ligands. 
Ligand library explored for AuNP stability. Chemical structures and stability 
determination shown for each ligand.  
 
4.3.3 Particle characterization 
For electron microscopy, AuNP samples were drop casted onto Formvar carbon 
copper grids with 200 mesh (Electron Microscopy Sciences, Hatfield, PA). Samples were 
exposed to air for 30 mins and excess solution was blotted away with filter paper. The 
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grids were viewed with an FEI Tecnai T12 electron microscope at 120 kV. Dynamic light 
scattering and zeta potential analysis was performed with a Nano ZS-90 Zetasizer. 
Stability was tested by diluting 10 µL sample of AuNP into 1 mL of DPBS and 1 mL of 
cell media.     
 
4.3.4 In vitro viability assessment 
The interaction of stable AuNP formulations with monocytes was evaluated using 
RAW 264.7 and isolated primary monocytes. The LIVE/DEAD assay was used to assess 
cytotoxicity. Briefly, RAW 264.7 cells were cultured in 20 mm diameter glass bottom 
dishes at 7.0 x 105 cells per well with DMEM supplemented with 10% FBS and 1% 
penicillin/streptomycin (PS). After 24 hours of incubation, monocytes were treated with 
AuNP formulations for an additional 24 hours. After treatment, cells were washed 2x with 
DPBS and incubated with 400 µL of LIVE/DEAD cocktail (2 ml DPBS, 2 µL stock 
Ethidium-1 homodimer, 0.5 µL stock Calcein AM and 0.5 µL 3.2 mM Hoechst 33342). 
Primary isolated monocytes were prepared similarly but cultured using RPMI-1640 
supplemented with 10% FBS and 1% PS. Cells were imaged with Nikon Eclipse Ti-U 
fluorescence microscope using DAPI (Ex: 359, Em: 461 nm), FITC (Ex: 495, Em: 519 
nm), and Texas Red (Ex: 595, Em: 613 nm) filters. Four images were taken per well for 
each channel. A custom MATLAB (MathWorks, Natick, MA) program was used to count 
the number of cells for the Hoechst, Ethidium-1 homodimer, and Calcein AM stain for 
each sample. The ratio of living cells to total number of cells was used to determine the 
viability percentage. 
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4.3.5 In vitro cytokine expression 
Monocyte cytokine expression of TNF-α and IL-6 was evaluated using an ELISA 
kit from Life Technologies, (Frederick, MD). First, monocytes were cultured in 96 well 
plates at 1.0 x 105 cells per well for 24 hours. Immortalized monocytes were then treated 
with 0.5 mg/ml of various AuNP formulations for 24 hours (note: all nanoparticle 
concentrations are given as mg/ml of gold). Primary monocytes were treated with 
concentrations of 0.1, 0.25, and 0.5 mg/ml of 11-MUA AuNP. The cells were then 
washed twice with DPBS to remove remaining free AuNP. Afterwards cell media in each 
well was replaced with 100 µL of cell media containing 100 ng/mL of lipopolysaccharides 
(LPS) for 3 hours or replaced with new media for non-activated samples. The media was 
then collected for use in the ELISA, which was performed according to kit instructions. 
 
4.3.6 Cell uptake evaluation   
The uptake of AuNP was measured using both a direct method (analytical 
determination of gold content) and an indirect method (CT imaging of cell pellets). For 
both methods, cells were cultured onto 6-well plates at 2.0 x 106 cells per well for 24 
hours. The cells were treated with varying concentrations of AuNP formulations for 24 
hours. The cells were then washed twice with DPBS and collected. For direct 
measurements, the cells were dissolved in aqua regia (3 parts hydrochloric acid, 1 part 
nitric acid) for 15 mins. The gold content of these samples were measured using 
inductively coupled plasma-optical emission spectroscopy (ICP-OES) on a Spectro 
Genesis ICP (SPECTRO Analytical Instruments GmbH, Boschstr, Germany). Gold 
content was normalized by the number of cells in each sample to express the value as 
gold per cell.   
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For CT measurements, after AuNP treatment, the cells were collected and fixed 
in 4% paraformaldehyde. The cells were allowed to loosely settle and then scanned 
using a clinical CT scanner (Siemens Definition DS 64-slice) at 100 kVp, 440 mA, 
512x512 matrix, 37x37 cm FoV, a slice thickness of 0.6 cm and reconstructed using 
kernel B30f. Intensities in the scan were measured in 3 sequential sections using ROI 
measurements and averaged for an intensity measurement using OsiriX v.3.7.1 64-bit 
software. 
 
4.3.7 Primary monocyte cell dispersion scans 
Primary monocytes were cultured for 24 hours after isolation and then 
subsequently treated with 0.5 mg/ml of 11-MUA AuNP. After 24 hours, the cells were 
washed x2 with DPBS and resuspended into increasing concentrations of 0, 100 k, 250 
k, 500 k, 1.0 M, 2.5 M, and 5.0 M cells/ml in 100 µl of DPBS and then 100 µl of 1% 
agarose. The agarose was heated prior to addition and then cooled on ice for 15 
minutes. The suspensions were then scanned with microCT scanner (Imtek Inc, 80 kVP, 
500 µA). The scans were quantified using OsiriX v3.7.1 with 64-bit software.        
 
4.3.8 Transmission electron microscopy of tissue 
RAW 264.7 cells and aorta samples from treated ApoE-/- mice were prepared for 
TEM imaging using standard preparation techniques.30 Cells and tissue were fixed in 2% 
PFA and 2.5% glutaraldehyde before staining and embedding. Samples were cut into 60 
nm thick sections and mounted onto grids before viewing with a JEOL 1010 Electron 
Microscope at 80 kV.  
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4.3.9 Primary monocyte isolation 
Spleens from C57BL/6 donor mice were used as the source for primary 
monocytes. Mice were anesthetized with isoflurane and then euthanized. The chest 
cavity was opened and mice were perfused through the left ventricle with 10 mL of 
DPBS before removal of the spleen. After excision, the spleen was mechanically 
homogenized using the plunger of a 1 mL syringe in 1 mL of Hank’s balanced salt 
solution (HBSS). The resulting cell slurry was filtered through a 70 µm filter and spun at 
250 rcf for 5 mins to pellet the cells. The pellet was then re-suspended in 250 µL of RBC 
lysis buffer for 1 min on ice. Afterwards, HBSS supplemented with 0.6% bovine serum 
albumin (BSA) and 0.3 mM EDTA was added to the cells for a total volume of 10 mL. 
The cell solution was centrifuged at 250 rcf for 5 mins and re-suspended with HBSS+ 
BSA. This step was repeated twice. The cell suspension was then incubated with anti-
CD11b magnetic microbeads (Mitlenyi Biotech, 140-049-601) for 30 mins at 4°C. After 
incubation, the suspension was washed with eluting buffer (DPBS, 0.5% BSA, 2mM 
EDTA). The cell suspension was then passed through a LS separation column (Miltenyi 
Biotech, 130-042-401) in the presence of a strong magnet to retain only CD11b+ cells in 
the column. Afterwards, the column is removed from the magnet and 5 mL of eluting 
buffer is used to remove the cells from the column. The cells were eluted through two 
sequential LS columns for increased purity. The resulting solution was spun at 250 rcf 
for 5 mins and re-suspended with RPMI medium 1640 supplemented with 10% FBS and 
1% penicillin/streptomycin for cell culture.      
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4.3.10 Flow cytometry 
The purity of the resulting cell suspension was analyzed using flow cytometry. Cells 
were incubated with Fc blocking agent for 15 minutes. After blocking, cells were 
incubated with markers for CD11b-PE Cy7, Ter119-PE, CD3-APCeF780, CD19-PerCP 
Cy5.5 for 30 mins on ice. Flow cytometry were performed on a BD FACSCanto System 
(BD Sciences, San Jose, CA). Fluorescence minus one solutions and compensation 
beads for each fluorophore were used for controls. 
 
4.3.11 Animals 
Six week old male apolipoprotein E (ApoE) deficient mice (B6.129P2-ApoEtm1UnC/J) were 
fed western chow diet (Research Diets Inc, New Brunswick, NJ) for 10 weeks to 
establish early atherosclerosis before use. Age-matched male C57BL/6 were kept on 
regular chow diet for the duration of the experiment as controls. All experimental 
protocols were approved by University Laboratory Animal Resources in conjunction with 
the Institutional Animal Care and Use Committee at University of Pennsylvania. 
 
4.3.12 In vivo monocyte imaging 
The treated group (AtT, n=8) received AuNP labeled monocytes following the 
procedure below. Briefly, primary monocytes isolated through magnetic sorting as 
described above were cultured for 24 hours before gold labeling. The cells were then 
treated with 0.5 mg/ml of 11-MUA AuNP for an additional 24 hours. The cells were 
washed twice with DPBS and collected. After resuspension in 250 µl of DPBS, 1.0 x 106 
cells were injected intravenously into the ApoE deficient mouse model. The animals 
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were scanned with a microCT II scanner (Imtek Inc, 80 kVp, 500 µA, 512x512 matrix, 
100 µm slice thickness) pre-injection and on day 3, 4, and 5 post-injection. Wild type 
mice receiving gold labeled monocytes following a similar procedure were used as 
controls (WdT, n=9). Additionally, atherosclerotic mice receiving non labeled monocytes 
were also used as a control group (AtN, n=8). CT scans were analyzed using OsiriX 
software. For aorta measurements, 3 sequential ROI were measured in the ascending 
aorta and averaged for a final attenuation value. The location of the aorta was identified 
by comparing the CT images with scans from a separate mouse experiment using a CT 
blood pool contrast agent. Identical ROI were used for each day for each mouse. The 
image sets from different days were matched for each animal using the spine and 
ribcage as markers. 
 
4.3.13 Ex-vivo and biodistribution 
After the final scan, mice were euthanized and dissected for biodistribution. 
Tissue including the heart, lungs, spleen, kidney, and liver were fixed in 4% PFA after 
excision. For biodistribution, tissue was dissolved in 500 µL of HNO3 for 18 hours at 
60°C. Afterwards, 300 µL of HCl was added and incubated at 60°C for an additional 
hour. The resulting solution was spun at 300 rcf for 10 mins for remove cell debris. The 
samples were analyzed using ICP-OES for measurement of gold content.     
4.3.14 Statistics 
Statistical analysis was performed with guidance from the Center for Clinical 
Epidemiology and Biostatistics at the University of Pennsylvania. A linear mixed effect 
model was used to analyze intensities from in vivo scans. Each mouse was assumed to 
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have a unique intercept and inputted into the model as a random effect to control for 
baseline differences between mice. Attenuation measurements were used as the 
dependent variable and each day as the independent variable in the model. Analysis 
was performed using Stata 13.1 (64-bit, College Station TX). 
 
4.4 Results 
4.4.1 Gold nanoparticle synthesis and characterization 
The Turkevich method of synthesizing gold nanoparticles was used to produce 
citrate coated gold nanospheres (Figure 4.2a).29 For additional stability in biological 
media, a library of thiol-ligands was used to displace the citrate ligands of the AuNP 
(Figure 4.1). Stability for each AuNP formulation was evaluated with Dulbecco’s 
Phosphate Buffered Saline (DPBS). When suspended in a salt based solution, stable 
gold nanoparticles of this size appear as a deep red solution while non-stable gold 
particles aggregate causing the solution to change to a blue-black color. We identified 
the following 5 stable coatings which we tested further: 11-mercaptoundecanoic acid 
(11-MUA), 16-mecaptohexadecanoic acid (16-MHA), poly(ethyleneimine) (PEI), 4-
mercapto-1-butanol (4-MB), and 11-mercaptoundecyl-tetra(ethylene gycol) (MTEG). 
These ligands give the nanoparticles several different surface functionalities, which 
could influence cellular interactions including cell uptake and cytotoxicity.  
TEM was used to observe the particle size and shape (Figure 4.2b). TEM 
revealed monodispersed spheres of 14.6 ± 1.5 nm in average diameter. DLS and zeta 
potential were performed to characterize hydrodynamic diameters and surface charges 
(Table 4.1). The hydrodynamic diameter of the particles seemed to relate to the size of 
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the ligand used to stabilize the particle, i.e the shortest ligand 4-MB displayed the 
smallest hydrodynamic diameter, although it seems likely that for the PEI and MTEG 
coated AuNP that there is some degree of aggregation of cores. The zeta potential 
results showed that carboxylic acid ligands (11-MUA, 16-MHA) and alcohol ligands (4-
MB) had negative surface potentials, as expected. Additionally, AuNP coated with PEI, 
which has many amine groups, had a positive surface potential. AuNP that were coated 
with MTEG, which has a methoxy group at the distal end, had a nearly neutral charge.      
 
 
Figure 4.2 AuNP synthesis, coating and characterization. 
(a) Schematic of ligand exchange for citrate capped gold nanoparticles. (b) Chemical 
structures of 5 formulations further used in experiments. (c) TEM image of 11-MUA 
capped AuNP.   
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Table 4.1 Characterization of selected AuNP formulations. 
 
 
4.4.2 In vitro evaluation of selected AuNP formulations 
Following selection of AuNP formulations, we examined the interaction of these 
particles with a monocyte cell line, RAW 264.7. The viability of the cells after the 
treatment with AuNP formulations was examined using the LIVE/DEAD assay. Each 
formulation was assessed at several concentrations (0.025, 0.05, 0.1, 0.5, and 1.0 
mg/ml of Au) for 24 hours. The ratio of living cells to total cells was determined via 
automatic counting by a custom MATLAB program. The results shown in Figure 4.3a 
demonstrate high biocompatibility for each formulation at the concentrations examined 
except for PEI. Due to being a polycation, PEI has been widely used as a transfection 
agent in gene therapy applications, but it is known that PEI can cause toxicity.31   
We next assessed if the uptake of AuNP would affect monocyte function in an 
inflammatory role. Circulating monocytes produce pro-inflammatory cytokines such as 
TNF-α, and IL-6 after activation.32 We therefore evaluated the cytokine release of TNF-α 
and IL-6 from monocytes after 0.5 mg/ml treatment of each AuNP formulation and 
activation with lipopolysaccharides (LPS). The AuNP formulations did not appear to 
disrupt cytokine release for 11-MUA, 16-MHA, and MTEG. However, the 4-MB 
formulation was found to decrease the cytokine release of TNF-α, but not IL-6. PEI 
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coated AuNP, on the other hand, were found to decrease the release of IL-6, but not 
TNF-α. Expression of TNF-α and IL-6 for AuNP treated monocytes was relatively similar 
to non-treated cells.    
 
Figure 4.3 Effects of AuNP on the viability and cytokine release of monocytes. 
(a) Viability of monocytes after treatment with different AuNP formulations at increasing 
concentrations. Viability % expressed as the ratio of living cells to total cells in the well. 
(b) Results from ELISA for TNF-α and IL-6 release after treatment (0.5 mg/ml) with 
different AuNP formulations. LPS groups were treated with LPS for 3 hours after gold 
treatment. * P<0.05 compared to samples not treated with AuNP. (Student’s t-test)  
 
Previous studies have demonstrated that size, shape, and surface functionality of 
the AuNP can significantly affect the amount of uptake into the cells.33-34 While each of 
our formulations are spherical in shape, the different surface ligands resulted in altered 
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hydrodynamic sizes and surface properties of the particle. After treating with AuNP, 
monocytes were found to take up the AuNP into vesicles, likely to be lysosomes. Figure 
4.4a shows TEM images of sections of monocytes that had been incubated with 11-
MUA. The uptake of these gold particles may be via phagocytosis as found in other gold 
cell labeling studies.35 
We studied the amount of AuNP uptake by monocytes for each formulation by 
examining CT contrast generation. Each formulation was incubated at three 
concentrations (0.1, 0.25, 0.5 mg/ml) for 24 hours. After treatment, cells were collected 
and scanned using a clinical CT scanner. The scans show an observable increase in CT 
attenuation dependent on the treatment concentration for our formulations (Figure 4.4b). 
The attenuation was quantified by measuring the intensity of the pellets. The attenuation 
of 11-MUA, 16-MHA, and 4-MB increased proportionally with treatment concentration of 
AuNP. It is important to note that the images seen in Figure 4.4b are not saturated, but 
some pixels are very bright due to the CT windowing scale used. All attenuation values 
in these experiments were well below the maximum CT attenuation values handled by 
this clinical system (3000 HU).22 The attenuation for the PEI formulation was not 
dependent on the concentration of gold, likely due to the toxicity seen in Figure 4.3a. 
Interestingly, 11-MUA displayed significantly higher attenuation than 16-MHA despite 
both ligands having carboxylic acid functional groups. The size difference in 
hydrodynamic diameter (Table 4.1) may account for the difference in gold uptake 
between the formulations. The MTEG formulation was found to have the lowest uptake, 
which was not surprising since ethylene glycol based ligands are known to reduce 
nanoparticle uptake by the mononuclear phagocytosis system.36 The results show that 
formulations of 11-MUA and 4-MB displayed the highest CT attenuation and therefore 
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AuNP uptake (Figure 4.4c). From the DLS and zeta potential results, both formulations 
4-MB and 11-MUA have relatively low hydrodynamic diameters and strong negative 
surface charge suggesting that these particle properties may encourage high AuNP 
uptake.37 Taking together all the results from these in vitro experiments, we chose to 
move forward with 11-MUA as our lead formulation as it displayed low cytotoxicity, no 
disruption of cytokine release, and high uptake in monocytes.            
 
176 
 
 
Figure 4.4 Uptake of AuNP in monocytes. 
(a) TEM image of a RAW 264.7 monocyte cell after 24 hr incubation with 11-MUA AuNP. 
(b) CT images of pellets of 11-MUA and 4-MB AuNP treated monocytes at increasing 
concentrations. (c) Quantification of intensities from CT scans for each formulation.  
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4.4.3 In vitro evaluation of 11-MUA coated AuNP with primary monocytes 
We first isolated primary monocytes from donor C57BL/6 mice. Others have 
shown the spleen to be a large reservoir of monocytes that are nearly identical in 
subtype and behavior to circulating blood monocytes.38 Purified monocytes isolated from 
the spleen of donor mice were examined with flow cytometry. Cells were incubated with 
cocktail of antibodies consisting of CD11b-PE Cy7, Ter119-PE, CD3-APCeF780, and 
CD19-PerCP Cy5.5. The enriched monocyte population contained 99.3% of CD11b+ 
(monocyte marker), CD19- (B-cell marker), CD3- (T-cell marker) cells in the suspension 
(Figure 4.5). 
 
Figure 4.5 Flow cytometry for primary monocytes. 
Flow cytometry of cell suspension from spleen. Purity determined by population of 
CD11b+, CD3-, and CD19- cells. (a) Original population of cell suspension. (b) Depleted 
cell population from magnetic cell sorting. (c) Enriched population from magnetic cell 
sorting.  
 
We examined these primary monocytes in a method similar to the immortalized 
monocyte cell line. The primary monocytes were treated with 11-MUA AuNP and 
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evaluated for cytotoxicity and cytokine release of TNF-α. Additionally, the uptake of 
AuNP was directly quantified using ICP-OES and compared to the uptake of the 
immortalized cell line. The results show that 11-MUA AuNP treatments up to 1.0 mg/ml 
did not decrease cell viability of cultured primary monocytes (Figure 4.6a). Similarly, the 
uptake of 11-MUA AuNP did not significantly alter the release of TNF-α after activation 
with LPS as seen in Figure 4.6b. In much the same way, the uptake of 11-MUA AuNP 
did not significantly alter the release of TNF-α after activation with LPS as seen in Figure 
4.6b. The TNF-α release for monocytes without LPS activation was found to be at similar 
low levels for non-treated and 11-MUA treated cells. These results confirm that the 
primary monocytes were not activated during the isolation, culturing, and gold labeling 
procedures. Comparable results were found with the monocyte cell line, RAW 264.7. 
The quantified cell uptake of AuNP was comparable between the primary monocytes 
and the cell line. The uptake of AuNP in primary monocytes after 24 hours of 0.5 mg/ml 
11-MUA AuNP incubation was found to be 127 pg/cell (Figure 4.6c). These data 
demonstrated that the uptake of 11-MUA AuNP did not impact the behavior of the 
primary monocytes during the ex-vivo labeling process.   
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Figure 4.6 Effects of 11-MUA coated AuNP on primary monocytes. 
Mouse monocytes from the spleen were cultured and evaluated in vitro for (a) viability 
using LIVE/DEAD assay, (b) TNF-α release using ELISA, and (c) AuNP cell uptake 
using ICP-OES for primary monocytes compared to the cell line.  
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4.4.4 In vivo detection of gold labeled monocytes 
Having established a method for labeling monocytes with AuNP without affecting 
cell viability or cytokine production, we proceeded to track the recruitment of these 
labeled monocytes in a mouse model of atherosclerosis via CT imaging. ApoE deficient 
mice were kept on a Western diet for 10 weeks to promote the development of aortic 
plaques. To track the recruitment of monocytes, primary monocytes were cultured and 
labeled ex-vivo with 11-MUA AuNP a day before intravenous injection of these cells. The 
timeline of the experiment is shown in Figure 4.7. The mice were scanned with CT 
(Imtek, Inc, 80kVp, 500 µA) before I.V. injection and on days 3, 4, and 5 post-injection. 
The groups consisted of atherosclerotic mice receiving gold labeled monocytes (AtT), 
atherosclerotic mice receiving non-labeled monocytes (AtN) and wild-type mice receiving 
gold labeled monocytes (WdT). 
 
 
Figure 4.7 In vivo experiment timeline. 
Experimental timeline for CT scanning of ex-vivo labeled monocytes injected I.V. into 
atherosclerotic mice.        
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Figure 4.8 shows images of an atherosclerotic mouse that received AuNP labeled 
monocytes for day 0 and day 5 scans; attenuation was seen to increase in the aorta over 
time as compared to the day 0 scan. The AtT group (atherosclerotic mice receiving 
AuNP labeled monocytes) showed a continual increase in attenuation over time resulting 
in a final 15.3 HU difference on day 5 as compared to the pre-injection scan (Figure 
4.8c). The increase for the AtN group (atherosclerotic mice receiving non-labeled 
monocytes) animals was much less. The WdT group (wild type mice receiving gold 
AuNP monocytes) attenuation values varied across acquisitions with no significant 
increase. Due to the heterogeneity of developing atherosclerosis, a linear mixed effects 
statistical model was used to account for disease variation among animals over time. 
Accounting for the attenuation values obtained each day (day 1 through 5) and random 
effects, we found a statistically significant increase in attenuation for the AtT group 
(p=0.002) of 15.3 HU. In comparison, the WdT (p=0.305) and the AtN (p=0.251) models 
showed no significant change in attenuation over time. This increase in attenuation in 
our AtT animals suggests that the recruitment of AuNP labeled monocytes can be 
detected by CT imaging. While the change in attenuation in the AtN group was not 
statistically significant, there may be small increases in the attenuation of the plaque 
during the 5 days of the experiment due to disease progression. 
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Figure 4.8 In vivo attenuation of gold labeled monocytes. 
CT scans of an atherosclerotic mouse injected with gold labeled monocytes (AtT) for (a) 
day 0 and (b) day 5. White boxes indicated aortic region of interest. Attenuation 
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increases in the aorta over 5 days as compared to the pre-injection scan. (c) Graph 
plotting the average intensities in the aorta of mice in CT scans over time. 
 
For an estimation of the number of gold labeled cells in the plaque, a standard 
curve of attenuation versus gold labeled cells per unit volume was generated. Primary 
monocytes were treated with 0.5 mg/ml of 11-MUA AuNP for 24 hours and resuspended 
in an agarose gel at increasing concentrations. The cell concentrations were scanned 
with microCT scanner (Imtek Inc., 80 kVp, 500 µA) and quantified (Figure 4.9). Using 
this standard curve, the change in attenuation of 15.3 HU in the AtT treated group 
correlated to be approximately 15 gold labeled cells/voxel in the plaque. The true 
number of gold labeled cells in the plaque would vary depending on plaque size but we 
believe this to be a reasonable estimation. 
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Figure 4.9 Quantification of gold labeled cells. 
Standard curve of attenuation versus cells per voxel (isotropic voxel size 0.1 mm).  
Quantification of attenuation for gold labeled primary monocyte, values normalized to 
attenuation at 0 cells/voxel.  
 
4.4.5 Biodistribution of AuNP 
At the end of the experiment, animals were sacrificed and organs excised for 
biodistribution. The gold content in the tissue was analyzed using ICP-OES to measure 
the distribution after 5 days post injection. Figure 4.10 shows high gold uptake in the 
spleen and liver, which are organs that typically host large numbers of monocytes and 
monocyte derived cells. Swirski et al., showed similarly high uptake of labeled 
monocytes in the spleen 5 days after intravenous injection.9  
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Figure 4.10 Biodistribution of gold from in vivo experiments. 
Gold content of tissue analyzed by ICP-OES at 5 days post injection of the 
atherosclerotic and wild type mice receiving AuNP labeled monocytes.   
 
4.4.6 Ex-vivo analysis of atherosclerotic plaques 
The aortas of AtT mice (received AuNP labeled monocytes) were sectioned 
through the atherosclerotic plaque and examined with TEM. AuNP were found in 
monocytes that were located in the atherosclerotic plaque (Figure 4.11). This indicates 
that the attenuation increase seen in the in vivo CT scans is due to recruitment of the 
AuNP labeled monocytes into the plaques. 
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Figure 4.11 AuNP labeled cells in aortic sections. 
Excised aortas from atherosclerotic mice receiving AuNP labeled monocytes were 
sectioned through the plaque and examined with TEM for localization of gold 
nanoparticles.    
 
4.5 Discussion 
In this study, we demonstrate the successful labeling of monocytes with AuNP of 
varying formulations. Each ligand conferred a distinct combination of particle parameters 
including hydrodynamic diameter, surface potential and chemical functionality (Table 
4.1). Formulations of 4-MB and 11-MUA, which have similar diameters and negative 
surface potential, were found to have low cytotoxicity and the highest monocyte 
uptake.37 Previous reports have shown that anionic AuNP exhibit less toxicity as 
compared to cationic nanoparticles.39 The authors suggest that positively charged 
particles may directly diffuse through the plasma membrane, disrupting the lipid bilayer 
causing cytotoxicity. Additionally, our incubation of monocytes with AuNP occurs in 
media with serum. Studies have shown that the makeup of the protein corona 
surrounding the particle could be responsible for differences in cellular uptake.40-41 It is 
likely that 4-MB and 11-MUA AuNP formulations form a protein corona preferential for 
cell uptake as compared to other our examined ligands. We found uptake of 127 pg 
Au/cell in our in vitro incubations performed with 0.5 mg Au/ml in the cell culture media. 
This is comparable to previous work since Menk et al. reported uptake of 33-36 pg 
Au/cell for incubations performed with 0.052 mg Au/ml, a ten-fold lower concentration 
than in our experiments, over a similar timeframe.14 Furthermore, others have loaded 
cells with iron oxide nanoparticles up to a weight of 39 pg Fe/cell. Adjusting for the 
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differing densities of gold and iron oxide, this would be equivalent to 209.9 pg Au/cell.42-
43 
We found that the migration of these labeled monocytes to atherosclerotic 
plaques could be observed and measured with CT. We believe this is the first study to 
non-invasively track monocyte recruitment into atherosclerotic plaques using computed 
tomography. For plaque imaging, a number of targets have been previously studied with 
MRI, PET, SPECT, and NIRF. Researchers have successfully imaged cell-adhesion 
molecules, lipoproteins, ECM, proteases, and angiogenesis in plaques.44 Studies looking 
to image inflammatory cells primarily focus on macrophage presence in the plaque.45-47 
Due to the insensitivity of contrast agents in CT, few imaging studies of plaque use x-ray 
computed tomography as the sole means of imaging. Researchers have previously 
demonstrated the in vivo detection of macrophages in atherosclerotic plaques with CT 
by using an iodinated agent,48 PEGylated nanoparticles49 and gold core lipoproteins.27-28 
High macrophage content atherosclerotic plaque is a potential indicator of imminent risk 
of plaque rupture.50 In the present study, we sought to track the process of monocyte 
recruitment, which has been found to be informative of disease progression. A study by 
Robbins et al. found that monocyte recruitment is a significant source of the macrophage 
population in early plaques while the macrophage populations in established are due to 
in-situ proliferation.51 Therefore, the detection of monocyte recruitment into the plaque 
could be an early marker for patients at risk of development of cardiovascular disease. 
Our study presented here looks at the important process of monocyte recruitment 
in early stage atherosclerosis utilizing CT. This technique can improve the study of 
monocyte recruitment and help elucidate monocyte role in atherosclerosis progression 
and/or regression. Additionally, this technique may help assess new atherosclerotic 
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interventions that target monocytes and plaque inflammation. However, CT sensitivity to 
contrast agents has been a significant obstacle in the further development of this 
method.  The present study demonstrated increased intensity in the aorta (Δ 15.3 HU) 
as compared to pre-scan values. This attenuation change is on par with similar studies 
in the field. For instance, Hyafil et al. reported a change of 13.3 HU in the atherosclerotic 
plaques of rabbits intravenously injected with iodinated nanoparticles designed to target 
macrophages.48 Similarly, Eck et al., injected anti-CD4 gold nanoparticles intravenously 
to target lymph in-vivo and found an attenuation change of 20 HU at 1 hr and 25 HU at 
48 hrs for 28 nm gold nanoparticles.52 However, for our study, an increase in sensitivity 
and overall attenuation change would be required to discern small reductions of 
monocyte uptake (e.g. <30%). A recent study by Betzer et al., presented the use of a 
“CT ruler” to approximate the number of gold labeled cells in a tissue non-invasively.53 
However, the high attenuation required for this method was achieved by directly injecting 
the gold labeled cells at the site of interest. In our study, increasing the signal from our 
cells may be achieved by further optimizing the method. By increasing the number of 
injected gold label monocytes, we hypothesize a higher intensity in our scans is 
possible; however in this approach, injecting more monocytes than are physiologically 
present in the circulation may significantly alter the response of the animal to these cells. 
Instead, increasing the amount of gold per cell may be the ideal strategy to increase CT 
contrast in the images without increasing the number of injected cells. Translation of 
nanoparticle-facilitated cell tracking to clinical scanners would be beneficial, due to the 
lower image noise in clinical scanners as compared with preclinical scanners.54 Lower 
image noise improves signal-to-noise ratios and hence improves sensitivity.   
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An alternative solution to achieve higher intensities may be to purify the 
monocyte subtype further. In the current study, monocytes are isolated by the 
expression of CD11b marker, a conserved monocytes marker across many subtypes.55 
In mice, the “inflammatory” Ly6CHi monocyte subtype has been described as the 
dominant subtype for migration in early atherosclerotic plaques as compared to the 
“resident” monocyte, Ly6CLo.56-57 Hence, we may improve the overall recruitment of our 
gold labeled monocytes by further purifying our isolated monocytes for CD11b+, Ly6CHi 
subtype in future studies. 
In this cell tracking study, isolated monocytes are labeled ex-vivo before injection 
as opposed to labeling in-situ. The emergence of adoptive cell therapies as successful 
clinical therapies reinforces the need for methods of cell tracking ex-vivo cultured cells.58 
Cell tracking using ex-vivo labeled cells with CT has been demonstrated with a number 
of applications including T-cell labeling for cancer, C6 glioma cells for brain tumor 
models, olfactory ensheathing cells for spinal compression injury models and pancreatic 
islets labeling for diabetes.14, 59-63 In-situ labeling, where nanoparticles are injected into 
animals and cells take up the nanoparticles in vivo, is more straightforward and simpler 
to implement clinically.64-65 However, in-situ labeling may result in labeling a variety of 
cells, such as macrophages and monocytes resident within the plaque, as well as 
circulating monocytes, confounding results from imaging. In the future, we will explore 
ways to adapt our current approach for in-situ labeling and compare the results.  
 
4.6 Conclusion 
In this study, we screened AuNP formulations for effective uptake in monocytes 
without disruption of viability or inflammatory function. We identified a lead formulation 
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with these characteristics, which was confirmed with primary monocytes. These labeled 
monocytes were intravenously injected and monitored for recruitment into atherosclerotic 
plaques using x-ray computed tomography. We found an increase in the attenuation in 
the aorta, post injection of these labeled cells. We confirmed the presence of these 
labeled monocytes in the plaque through the use of TEM. This study demonstrates the 
feasibility of tracking labeled monocytes with CT. Further studies are required to 
optimize the detection of these cells for quantification of monocyte accumulation in the 
plaque. Increased sensitivity will allow for examination of monocyte recruitment in the 
presence of emerging atherosclerosis therapies. 
While we demonstrated that detection of gold labeled monocytes recruited to 
atherosclerosis is achievable, further experimental refinement is needed to be utilized as 
research tool. However, we believe this study continues to expand the use of CT as a 
cell tracking modality. The use of gold nanoparticles to track monocytes and other cells 
in other disease applications is possible. In the following chapter, we indicate future 
directions for the work and discuss expanded biomedical applications for gold labeling of 
cells for cell tracking.          
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Chapter 5: Discussion and future directions 
 
5.1 Overall discussion 
5.1.1 Overview 
 In the work presented herein, we hypothesized that we could track monocyte 
migration with x-ray computed tomography (CT) through the use of gold nanoparticle 
constructs as labels. Cell tracking tools have become increasingly desired due to the 
ability to track cells that have been delivered from an external source. These tools are 
able to provide near real time information about cell location, migration, and viability. We 
sought to develop gold nanoparticles (AuNP) agents that could label monocytes and 
monitor their recruitment into atherosclerotic plaques.  
We first explored using polyphosphazene polymers to create nanospheres with 
AuNP loaded into the core as discussed in Chapter 2. We also assessed the controlled 
localization of nanoparticles onto the surface of the nanospheres. We found substantial 
uptake of these nanospheres both for core-loaded and surface-loaded variants allowing 
for CT imaging of gold labeled monocytes in addition to drug delivery with surface-
loaded particles. However, we found that high levels of uptake of core-loaded 
nanospheres negatively affected monocyte viability and cytokine release. Because CT 
requires high payloads of gold for contrast production, we explored alternative AuNP 
formulations for improved biocompatibility with high monocyte uptake. 
In chapter 3, we examined a range of AuNP sizes (15 to 150 nm) and various 
surface ligands, totaling 44 distinct AuNP formulations. We sought to explore the 
relationship between size and surface ligand in the application of monocyte labeling. 
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AuNP formulations were examined for cytotoxicity and uptake by monocytes. Only the 
largest size, 150 nm AuNP, with polyethylene glycol (PEG) surface ligands were 
cytotoxic. We found the relationship between size and uptake to be specific for each 
surface ligand. High uptake in monocytes was seen with small (15, 25 nm) particles 
coated in short chain carboxylic acids. We also found a complex relationship between 
size and uptake for PEG-carboxylic acid coated (PEG-COOH) AuNP. High uptake in 
monocytes was found for intermediate sizes (50, 75 nm), but relatively low uptake at 
smaller and larger sizes. With synthetic efficiency and cost advantages for 15 nm 
particles, we choose to further proceed with this size to evaluate monocyte labeling for 
CT cell tracking in atherosclerosis.  
With a focus on 15 nm diameter AuNP, we examined their potential as cell 
tracking agents for labeling monocytes. We examined an expanded library of surface 
ligands for stability and selected five ligands to evaluate with monocytes. Of these 
ligands, AuNP coated with 11-mercaptoundecanoic acid (11-MUA) did not affect 
monocyte viability or cytokine release, and were highly taken up by these cells (in both a 
monocyte cell line and primary monocytes). Therefore, we used this formulation to label 
primary monocytes and deliver the cells to mice with early atherosclerotic lesions. Using 
CT, we were able to detect a significant increase in x-ray attenuation in aortic plaques 
after 5 days. Sections through the aortic plaque showed the presence of gold labeled 
cells, reaffirming the migration to gold labeled monocytes to the plaque. 
While this work demonstrated the feasibility of using AuNP constructs to track 
monocyte recruitment in atherosclerosis, further development is needed to improve this 
tool for expanded applications in monocyte tracking. Here, we discuss factors involved in 
the uptake and cytotoxicity seen with some AuNP formulations. We also discuss 
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strategies for improving monocyte detection in the atherosclerosis model and expanded 
uses for monocyte cell tracking. Last, we explain the barriers that need to be overcome 
to translate such a technology into the clinic.     
 
5.1.2 Uptake and toxicity 
 One of the key features of the work presented here is the interaction between 
nanoparticles and cells. Specifically, the interaction between monocytes and each gold 
nanostructure investigated led to differing uptake and/or effects on monocyte 
viability/function. The work explored different structures (i.e. free and polymer 
nanosphere encapsulated AuNP), AuNP of differing sizes (15 to 150 nm) and a variety 
of gold nanoparticle surface chemistries. 
 In the work presented in Chapter 3, the highest uptake values in the monocyte 
cell line were seen with short chain carboxylic coated (11-mercaptoundecanoic acid, 11-
MUA; 16-mercaptohexadecanoic acid, 16-MHA) 15 nm AuNP and intermediate sized 
AuNP (50, 75 nm) coated with a PEG carboxylic acid. Both the coating and size play a 
role in the gold uptake of the monocytes. Chithrani et al. also reported a size 
dependency of cellular AuNP uptake, with 50 nm particles being taken up to the greatest 
extent. In that study, the AuNP were citrate coated and uptake was examined in HeLa 
cells.1-2 Other studies have also shown intermediate sized (~50 nm) AuNP to have 
highest cellular uptake.3 A number of studies have sought to explain this observation. 
Jiang et al. and Chithrani et al. hypothesized that there is an optimal size for receptor 
mediated uptake of nanoparticles.3-4 Receptor mediated uptake relies on binding of 
surface receptors on the cell and then “wrapping” around the bound material through 
invagination.5-6 These works hypothesized that, with receptor mediated endocytosis as 
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the uptake route, particles (with surface adsorbed proteins) interact with surface 
receptors of the cell. With activation of those surface receptors, the cells “wrap” around 
the nanoparticle through invagination and internalize the particle. In this mechanism, 
smaller nanoparticles (less than 40 nm), due to low surface ligand density, do not bind to 
the cell surface for a long enough duration for this process to occur frequently. 
Conversely, larger nanoparticles (less than 70 nm) bind efficiently, but their large size 
presents challenges for the cell to wrap around the nanoparticle and therefore are not 
taken up extensively. However, intermediate sized nanoparticles (i.e. around 50 nm) 
have strong enough binding kinetics and their size allows for successful internalization. 
 This mechanism may explain the uptake profile seen with our differently sized 
nanoparticles. Phagocytosis, the likely uptake route of AuNP in our study, operates in a 
similar manner to receptor-mediated endocytosis, with binding of surface receptors and 
invagination for internalization of the nanoparticle. Monocytes have a family of toll-like 
receptors (TLR4, TLR2, TLR8) used to recognize foreign materials for phagocytosis.7 In 
Chapter 3, AuNP above 25 nm in size and coated with 11-MUA aggregated severely in 
serum-containing media. It is likely that 15 nm 11-MUA AuNP also aggregate in serum-
containing media to a certain extent, forming aggregates of an intermediate size that 
allow for very high uptake. This may explain why coatings that minimize aggregation 
such as the PEG-COOH coating result in high uptake at intermediate AuNP sizes, but 
low uptake at small sizes.  
 In addition to the size of the nanoparticles, surface ligands also play a large role 
in defining the biological interaction between nanoparticles and cells. Surface ligands 
provide stability and a surface charge (neutral, positive, negative) to the particle 
depending on the chemical groups of the ligand. Mammalian cells, due to the 
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phospholipid bi-layer, are typically negative in charge. Hence for cellular uptake, 
research has focused on the use of positively charged coating for preferential 
electrostatic interaction.8 However, some researchers have shown cellular uptake with 
anionic nanoparticles to be greater than cationic nanoparticles in the same system.9-11 
This effect has been noted in greater frequency with phagocytic cells than non-
phagocytic mammalian cells.12-13 While intuitively, negatively charged nanoparticles 
should be repulsed by negatively charged cell membranes, researchers have shown that 
the adsorption of serum proteins onto the surface of the membrane drastically affects the 
interaction between the cell and nanoparticle.14 In the 2006 study by Chithrani et al., 
after incubation in serum, negatively charged AuNP were found to contain amine groups 
through Fourier transform infrared spectroscopy.2 The authors attribute this finding to the 
amine groups contained in amino acids. Ritz el al. took a further step by identifying the 
serum proteins that adhered to polystyrene (PS) nanoparticles functionalized with 
different chemical groups.15 The study evaluated a variety of surface coatings including 
carboxylic acids (PS-COOH), amine (PS-NH2), or sulfates (PS-SO3), with each 
nanoparticle approximately 100 nm in diameter. Apolipoproteins were found to adsorb 
onto all of these nanoparticles, however some proteins were found to significantly 
adsorb to specific formulations. For PS-COOH nanoparticles (carboxylic functional 
group), a significant increase in the presence of apolipoprotein-H was shown to increase 
the uptake of these particles with human mesenchymal stem cells. Our work presented 
here found highest uptake with carboxylic acid coated AuNP. Adsorption of serum 
proteins that aid in uptake in combination with the optimal size for uptake may explain 
why the highest uptake in monocytes were seen with those specific formulations. 
Examination of the composition of the protein corona of these nanoparticles and 
 
205 
 
consequent determination of their mechanism of uptake could be the topic of future 
work. 
 In the work presented here, some AuNP formulations exhibited cytotoxic effects 
at high concentrations. A number of studies have sought to elucidate the mechanisms 
behind the toxicities of various AuNP formulations since gold is typically described as 
bio-inert. The generation of reactive oxygen species (ROS) has previously been shown 
to be responsible for the observed cytotoxicity with nanoparticles.16-17 A study by Chuang 
et al., investigated the cytotoxicity of citrate capped gold nanorods (10 x 39 nm, 10 x 41 
nm, 10 x 45 nm) at different concentrations in multiple mammalian cell lines.18 The group 
found different mechanisms of cytotoxicity based on the cell type. For instance, these 
gold nanorods delayed the cell cycle for lung epithelial (A549) cells but induced 
apoptosis in gastric adenocarcinoma cells (AGS). These gold nanorods also increased 
the generation of ROS in AGS cells. However, the authors suggested that the observed 
increase in ROS did not induce apoptosis due to low response of anti-oxidative proteins. 
Another study utilizing 20 nm carboxyl-polysytrene particles demonstrated that negative 
nanoparticles were able to induce apoptosis and necrosis in the absence of reactive 
oxygen species.19 A study by Chueh et al. also demonstrated that cytotoxicity of AuNP 
(citrate capped nanorods, 10 x 40 nm) may be dependent on the cell type.20 After 
incubation with AuNP, kidney epithelial cells were found to undergo apoptosis mediated 
through inhibition of enzyme activity. In lung fibroblasts, arrestment of cell cycle and 
damage to DNA mechanisms were likely causes of cytotoxicity. Embryonic fibroblasts 
were found to undergo autophagy, a form of programmed cell death. Other studies have 
reported different mechanisms of cytotoxicity in the presence of AuNP in other cell 
systems.21-23 
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 In this thesis, monocyte toxicity was observed with AuNP into loaded PCPP 
nanospheres (Chapter 2), large AuNP (Chapter 3), and PEI coated AuNP (Chapter 4). 
Taking into account the studies mentioned above, toxicity in instances of high uptake of 
AuNP may be due to arrest of cell cycle leading to apoptosis. Therefore, the toxicity we 
observed with AuNP loaded PCPP nanospheres and large AuNP may be due to this 
reason. More studies evaluating apoptosis with those formulations would be necessary 
to confirm this hypothesis. However, toxicity with PEI coated AuNP are likely due to the 
positively charged amine groups on the PEI coating. Previous reports have indicated 
that the high positive charge of PEI can cause toxicity at even low concentrations.24-25       
 
5.1.3 Increasing sensitivity of monocyte detection 
 In this thesis, we systemically delivered gold labeled monocytes and after 5 days 
were able to detect a significant increase in CT attenuation in the region of the aorta. 
This increase was attributed to the migration of gold labeled monocytes from circulation 
to the plaque. Ex-vivo sectioning and transmission electron microscopy of the plaque 
revealed the presence of gold labeled cells. The change in attenuation over 5 days was 
15.3 HU on average. This value is comparable to in vivo detection with CT contrast 
agents seen in other studies.26-27 However, to be able to detect the effects of genes or 
drugs on modulating monocyte recruitment would likely necessitate higher changes in 
attenuation. 
 In Chapter 4, in vivo experiments were carried out using 1 x 106 labeled primary 
monocytes that were injected intravenously. Increasing the number of gold labeled cells 
for delivery may be an avenue to increase the amount of monocytes recruited to the 
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plaques. In preliminary studies, we trialed a 5-fold (5 x 106) delivery of gold labeled 
monocytes to apolipoprotein deficient (ApoE -/-) mice on a western diet for 10 weeks 
(AtT). The control groups were wild type mice injected with gold labeled monocytes 
(WdT) and atherosclerotic mice injected with non-labeled monocytes (AtN). Similar to 
the experiment in Chapter 4, the mice were CT scanned at 3, 4, and 5 days post 
injection. The results in Figure 5.1a show an attenuation change of 33.6 HU for the AtT 
group which was found to be significant (p <.002). Therefore, a significant increase in CT 
attenuation was achievable with an increase in the number of delivered gold labeled 
monocytes. The CT attenuation for atherosclerotic mice receiving 5 x 106 compared to 
receiving 1 x106 gold labeled monoyctes were also found to be significant. The 
biodistribution of this dose of gold labeled monocytes was similar 1 x 106 monocytes, 
with high accumulation of gold per tissue weight in the spleen (Figure 5.1b). However, 
mice have approximately 1 x 106 monocytes in blood circulation and the delivery of 5 x 
106 monocytes may have unintended biological consequences that would require further 
evaluation. 
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Figure 5.1 Changes in aorta attenuation and biodistribution arising from injections of 5 x 
106 AuNP labeled monocytes. 
Atherosclerotic mice defined as ApoE-/- mice kept on western diet for 10 weeks. (a) 
Atherosclerotic mice receiving gold labeled monocytes (AtT, n=4) show higher 
attenuation in aortic plaques after 5 days as compared to wild-type mice receiving gold 
labeled monocytes (WdT, n=3) and atherosclerotic mice receiving non-labeled 
monocytes (AtN, n=3). (b) Biodistribution of gold labeled monocytes in organs. 
 
 Another approach to increase the CT attenuation in the scans is to increase the 
number of recruited gold labeled monocytes to the plaques. In the current study, primary 
monocytes were isolated based on the surface marker CD11b, a conserved monocyte 
marker for all monocyte subtypes.28 As mentioned in Chapter 1, there are two distinct 
monocyte populations conserved across species. In humans, classical “inflammatory” 
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monocytes are described by the presence of CD14+ CD16- CCR2+ CX3CR1- surface 
markers.29 These monocytes have phagocytic properties and known to migrate from the 
circulation to inflamed tissue. The other “resident” monocyte is identified by CD14- 
CD16+ CCR2- CX3CR1+ surface markers and participate more frequently in wound 
healing.30 In mice, inflammatory monocytes can be identified by Ly6C+ and resident 
monocytes by Ly6C- markers.31 In our studies, primary monocytes were isolated from 
spleens of donor mice. Swirski et al. analyzed the population of monocytes in the spleen, 
indicating that nearly 50% of the monocytes in the spleen were Ly6C+.32 By further 
purifying primary monocytes for the Ly6C+ marker, we could isolate inflammatory 
monocytes for gold labeling. Injecting only inflammatory monocytes may increase the 
amount of gold labeled monocytes recruited to atherosclerotic plaques.  
 In addition to experimental changes, advances in CT technology are likely to 
improve the detection of gold labeled monocytes for atherosclerosis. Photon-counting 
CT presents the opportunity to use the k-edge of gold to improve detection of gold 
labeled cells.33 This may also allow for better delineation between surrounding soft 
tissue and gold labeled cells in CT scans.34-35 Advances in reconstruction methods are 
also likely to improve detection of gold labeled cells with improved signal to noise (SNR) 
in CT images. The development of iterative reconstruction methods have shown 
improved SNR as compared to traditional back filtered projection algorithms.36 Iterative 
reconstruction may also improve detection of contrast agents in CT scans.37 Together, 
the advances in CT technology are likely to improve the technology of cell tracking with 
CT. 
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5.1.4 Modulation of monocyte recruitment 
 With improvement to the detection of monocytes in vivo, we hypothesize that the 
technique can be used to both further assess mechanisms behind monocyte recruitment 
and therapies aimed at decreasing monocyte recruitment. As described in Chapter 1, 
monocytes play a crucial role in the progression of atherosclerosis through continued 
recruitment to developing plaques. Monocyte recruitment involves a number of 
processes including increased expression of adhesion molecules on endothelial cells 
and chemokine gradients for transmigration. In the intima, monocytes differentiate in 
macrophages and then foam cells, leading to the production of enzymes and cytokines 
that promote plaque rupture. Due to the pivotal roles of monocytes and macrophages in 
plaque progression, there has been significant interest in developing therapies that 
target their recruitment and atherogenic functions.  
 In mice, a number of studies have sought to examine the impact of plaque 
burden after the knocking down or therapeutically reducing the expression of key cell 
adhesion molecules (VCAM, ICAM, P-selectin).38-41 For instance, Cybulsky et al. 
generated an VCAM-1 knockdown mice model to evaluate plaque formation.42 The 
group observed a significant decrease in plaque formation in the whole aorta and arch 
(lesion area decreased by 31% and 45%, respectively) as compared mice expressing 
VCAM-1. The group also noted an increase in overall circulating leukocytes, including 
increased levels of circulating blood monocytes as compared to controls. Taken 
together, the authors suggested that increased blood monocytes indicate less lesional 
migration and therefore less plaque progression. With the development of cell tracking 
for monocytes, the study may have been able to confirm and quantify the reduction of 
monocyte recruitment in VCAM-1 knockdown mice. Interestingly in the study, the 
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authors show that knock down of both ICAM-1 and VCAM-1 produced similar reductions 
of plaque size to VCAM-1 knockdown alone. With comparing the significance of ICAM-1 
versus VCAM-1 in plaque formation, the ability to quantify monocyte recruitment to 
plaques in each case could help elucidate the importance of each.  
 With the success of VCAM-1 inhibition seen in mice, researchers have explored 
VCAM inhibitors as possible therapeutics for coronary artery disease.43-44 Specifically, 
groups have shown that natural antioxidants are able to inhibit VCAM-1 expression.43 
The anti-oxidant Succinobucol (AGI-1067) was investigated in a double-blind placebo 
trial for patients with acute coronary syndrome.45 In the study, 6144 patients with either a 
recent myocardial infarction or unstable angina were split into Succinobucol receiving 
and placebo groups. However, no significant improvements were identified in the 
primary endpoints of severe cardiovascular events including death over 2 years. We 
believe that cell tracking techniques such as those demonstrated in this thesis could 
quickly determine the effectiveness of proposed drugs. In this study, monitoring 
monocyte migration over time in vivo may have demonstrated the drug’s effectiveness or 
non-effectiveness on monocyte recruitment to plaques as a VCAM-1 inhibitor before 
launching a lengthy and costly primary outcome study.  
 Researchers continue to probe stages of monocyte recruitment to plaques as a 
possible therapeutic target for atherosclerosis. A number of pre-clinical studies have 
demonstrated the reduction of plaque formation in decreased expression of chemokine 
receptors responsible for monocyte migration through plaques (CCR2, CX3CR1, 
CCR5).46-49 Similarly, clinical trials have explored inhibitors of these chemokine receptors 
as potential targets for plaque development. In a study with 243 patients, groups 
received either MLN1202 (monoclonal anti-body inhibitor of CCR2 binding to MCP-1) or 
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placebo.50 The study showed reduced concentrations of serum C-reactive protein in the 
serum for treatment groups. C-reactive protein is a marker of inflammation and is 
positively correlated to the progression of atherosclerosis. The study also found a 
decrease in circulating monocytes with administration of MLN1202. The authors suggest 
reduced emigration of monocytes from the bone marrow as the cause of this result but 
no confirmatory data is shown. However, with real time monocyte tracking, the authors 
would be able to confirm their hypothesis and possibility determine if MLN1202 reduces 
monocyte recruitment to plaques. 
 In the monocyte recruitment pathway, additional potential targets continue to 
emerge as areas of interest. Studies have explored the effects of inhibiting 
transmigration targets such as junctional adhesion molecules (JAM-A) and connexins.51-
53 Monocyte-platelet interactions and macrophage migration inhibitory factor have also 
been explored as possible drug targets.54-57 These studies aim to interfere with the 
monocyte recruitment process, but not directly observe or quantify monocyte 
recruitment. The monocyte cell tracking tool demonstrated in this thesis could enhance 
similar studies in the future via observation of monocyte localization and migration. 
   
5.1.5 Barriers to translation 
 Cell tracking presents an opportunity to observe cell migration in a variety of cell 
based therapies. Currently, the state of cell tracking tools remains investigative with the 
technology under development in a breadth of applications.58 While our technology of 
monocyte cell tracking with CT is in the early stages of preclinical examination, the 
capacity of translation into a clinical tool stands as a possibility. As mentioned in this 
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chapter, monocyte cell tracking could be used to assess mechanisms of monocyte 
recruitment or evaluate novel therapeutics targeting the recruitment pathway. In the work 
presented, we demonstrated the feasibility of isolating monocytes with high purity from 
donor animals. The cells were labeled with AuNP ex-vivo and delivered intravenously to 
atherosclerotic mice. The mice were then scanned with a preclinical CT scanner and 
monocytes localized to the plaques in the aorta were visualized. With the advances in 
clinical CT scanners and clinical cell transfer technologies, adapting our work with 
monocyte cell tracking to a clinical setting is a possibility. 
 In our studies, murine atherosclerotic plaques were visualized within the aorta 
using a pre-clinical scanner at 80 kVp and reconstructed at 100 µm spatial resolution 
(isotropic voxel). Modern clinical scanners are capable of spatial resolutions between 
350 and 500 µm.59 For translation of our technology, monocyte recruitment would likely 
be observed for plaque burden in the human coronary arteries. Current CT scanners are 
capable of resolving the coronary arteries and assessing plaque burden, therefore 
spatial detection of gold labeled cells in the human coronary arteries appears feasible. 
Additionally, clinical CT scanners are capable operating at higher energies (100 kV, 120 
kV, 140 kV), which would result in greater contrast since gold’s k-edge (80 keV) is within 
those spectra, and likely improving detection of gold labeled cells with clinical CT 
scanners.60      
 In a study by Dey et al., the plaque burden in the human coronary arteries were 
quantified in patients with stable plaques and acute coronary syndrome.45 Plaque 
volume was similar in both groups, 332.8 vs 334.3 mm3, respectively. For comparison, 
the average volume of plaques measured in mouse aortas was 107.1 mm3 based on 
estimations from our CT scans. In our mice, the average change in attenuation in the 
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plaque was 15.3 HU. From our in vitro cell dispersions from Chapter 4, we correlated 
this attenuation to approximately 15 cells/voxel (0.1 mm isotropic voxel). With 
approximation of plaque size in the mice (107.1 mm3), we estimate that a change of 15.3 
HU correlates to 1.07 x 103 gold labeled monocytes in the plaque. Theoretically for 
human coronary plaques, a similar change in attenuation measurement would require 
recruitment of 3.32 x 103 gold labeled monocytes based on coronary plaque volume 
(332.8 mm3).  
 A significant barrier in the translation of this technology would be the isolation of 
monocytes from the patient for labeling. In our study, 1.0 x 106 gold labeled monocytes 
were delivered intravenously and localized to aortic plaques in mice. In mice, 
approximately 1.0 x 106 monocytes are present in circulation.61 In humans, the number of 
circulating monocytes range from 1.0 to 5.0 x 109 cells.62 For similar ratios as our mice 
experiments, a cell delivery of 1.0 x 109 gold labeled monocytes may prove challenging. 
However, with recent advancements in cell therapeutics, isolating and purifying this 
magnitude of cells (109) has been demonstrated.63-64 Currently, dendritic cells are being 
explored as clinical cell treatments for a number of diseases including cancer.65-67 The 
process of acquiring dendritic cells for cell therapy begins with the isolation of monocytes 
from patients through a process of leukapheresis.68-69 This process involves collecting 
blood continuously, filtering out desired cells, and returning the remaining constituents to 
the patient. Recent technology developments utilizing elutriation for purification have 
yielded 109 monocytes in highly purified populations.70 The technologies show that 
acquiring monocytes from patients for ex-vivo labeling is achievable. 
 After acquiring cells from the patient, the process of ex-vivo labeling with AuNP 
could face challenges involving the cost of gold and scaled up manufacturing. For our 
 
215 
 
current labeling experiments, we used a ratio of 0.5 mg of AuNP for 1 x 106 cells (0.5 
mg:1 million cells). To label 1.0 x 109 cells under the same conditions, 500 mg of AuNP 
would be required. Previously in our lab, we have synthesized large batches of AuNP 
through the Turkevich method (1280 mg gold chloride trihydrate, HAuCl4). With 20% 
efficiency from HAuCl4 to purified and capped AuNP, we can achieve approximately 250 
mg of AuNP in a single batch. However, each batch requires 3 days to complete. As of 
this writing, the cost of HAuCl4 is $1600 USD for 25 g (Gold(III) chloride trihydrate, 
G4022-25G, Sigma-Aldrich, St. Louis, MO). Therefore, synthesis of AuNP for labeling of 
1 x 109 cells, would require HAuCl4 costing approximately $160 and 6 days to complete. 
These estimations are with the current procedures that would likely be refined for large 
scale manufacturing as a clinical tool. The process of ex-vivo labeling with AuNP for 
translation into the clinic appears feasible with these estimations.    
 With the current state of the CT scanners and technologies involved with 
adoptive cell therapies, our technology appears to be translatable into clinical tool. 
However, currently the cost and technical difficulty of the clinical procedures list above 
constrain the realistic translational of our technology into a clinical tool. These 
procedures continue to be reserved for experimental adoptive cell treatments and 
determining their efficacy i.e. T-CAR cell immuno-therapy and dendritic cell vaccines. 
With continued research and advancement, there may be a time where utility of 
monocyte cell tracking to investigate the efficacy of atherosclerotic drugs outweigh the 
challenges of these clinical procedures. 
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5.2 Future directions 
5.2.1 Overview 
The ability to track the location and migration of cells in vivo is an emerging tool 
of need, providing valuable information in the study of disease mechanisms and 
assessment of treatment effectiveness. In our work, the successful tracking of 
monocytes with CT opens a number of opportunities to not only study monocyte 
behavior, but the possibility of additional cells in different applications. Here I discuss 
future directions of the work and potential avenues for future projects. I will describe the 
potential use of monocyte tracking to study their role in myocardial infarction wound 
healing. I will examine alternative labeling strategies for monocytes and the potential 
applications for these approaches. Additionally, I discuss other cell types that would be 
interesting to track in atherosclerosis. Finally, I discuss the potential use of AuNP to 
track other cell types in other disease applications.    
 
5.2.2 Myocardial infarction 
Monocytes have several functional roles in the progression of coronary artery 
disease. In this thesis, we explored tracking the recruitment of monocytes to developing 
plaques. In addition, monocytes play a large role in wound healing after a myocardial 
infarct. Immediately following the infarct, monocytes are recruited from the circulation to 
the injured tissue. Evidence has shown that this recruitment period for wound healing 
consists of two overlapping phases.71 The first phase is dominated by the recruitment of 
an inflammatory monocyte subset for phagocytosis and clearing of necrotic tissue, 
lasting for 1-4 days post infarction. From day 4 onwards, the anti-inflammatory monocyte 
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subset or “residential” monocytes are most present in the infarct. These monocytes are 
necessary for wound healing and tissue repair. This phenomenon was demonstrated in 
mice by Nahrendorf et al. with Ly-6c+ and Ly-6c- monocyte subsets.72 The authors 
suggest that this bi-phasic recruitment of monocytes is due to shifts in chemokine 
expression in the infarct tissue that favor each monocyte subtype at different times. The 
release of MCP-1 (CCR ligand) promotes Ly-6c+ monocyte recruitment initially and a 
subsequent shift to fractalkine (CX3CR1 ligand) release promotes Ly-6c- monocyte 
recruitment. This bi-phasic monocyte recruitment has also been studied in human 
myocardial infarcts with CD14++CD16- (inflammatory) and CD14+CD16+ (anti-
inflammatory) monocytes subsets. The recruitment of monocytes in both phases are 
critical to proper wound healing as studies with increased inflammatory monocyte 
recruitment have shown poorer outcomes in left ventricular remodeling.73-75 In our work, 
the development of monocyte cell tracking can be directly applied to studying monocyte 
recruitment after a myocardial infarction. There has been continued interest in 
developing cell tracking methods for cell therapy for myocardial infarction.76     
In preliminary studies, we labeled primary monocytes with AuNP via ex-vivo 
incubation for 24 hours. Afterwards these cells were directly injected into the infarct 
region of mice post myocardial infarction. After 5 days, the hearts were excised and 
scanned with a microCT scanner. The results in Figure 5.2 show localized high CT 
attenuation areas in the infarct region indicating the persistence of gold labeled 
monocytes in the region. Further experiments could demonstrate the migratory process 
of gold labeled monocytes to infarct regions after intravenous delivery. With this 
development, monocyte tracking could potentially be used to study therapies that 
modulate monocyte recruitment and may alter wound healing outcomes in the infarct. 
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Figure 5.2 Gold labeled monocytes in myocardial infarct.  
Monocytes were labeled with AuNP and directly injected into infarct region. Heart was 
excised 5 days post-injection and scanned with CT. 
 
5.2.3 In-situ spleen labeling 
 In our studies, cells are isolated from the spleens of donor mice and labeled with 
AuNP ex-vivo. As mentioned, ex-vivo labeling remains a strategy that may procedurally 
translate clinically for adoptive cell therapies. However, this procedure requires the 
isolation of cells before labeling which can be technically challenging. A cell tracking 
agent that could label specific cells in-situ would be advantageous. 
 For monocyte labeling, we observed the high trafficking of AuNP to the spleen 
after intravenous delivery. The spleen has been shown as a major reservoir for 
monocytes containing as much as 50% of the total monocyte population.32, 77 The 
monocytes are held in the red pulp with arterial access in the spleen. Studies have 
demonstrated that upon significant injury, monocytes in the spleen are deployed into 
circulation to address the wound.78-79 A study by van der Laan et al., studied the 
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recruitment of monocytes after myocardial infarction in humans.80 The group found an 
abundance of CD14+CD16- cells (markers for inflammatory monocytes) in the border 
zone during the inflammatory recruitment phase. During this inflammatory phase (>3 day 
post infarct), the authors also found a decrease in CD14+ cells in the spleen and an 
increase in the blood circulation. Taken together, the results suggest that early after a 
myocardial infarction, monocytes are released into circulation and are recruited into the 
surrounding infarct region for repair.  
 We hypothesis a cell tracking method could be developed to label monocytes in 
the spleen before deployment to sites of inflammation. In preliminary studies, we 
intravenously injected AuNP coated with methoxy-poly(ethylene glycol)  (AuNP-MPEG, 
250 mg/kg) into wild type mice. The mice were scanned with CT over 48 hours after 
which they were dissected for biodistribution afterwards. The spleen was excised and 
monocytes were purified through magnetic labeling for CD11b similar to methods in 
Chapter 4. The monocytes were collected and ICP-OES was run to determine if AuNP 
were present in the isolated monocyte fraction.  
  In Figure 5.3a, CT images are shown of the abdomen and thorax acquired over a 
48 hour period pre- and post-injection of AuNP. There is a significant increase in 
attenuation in the spleen over this time period. The scans also show initial increases in 
attenuation in the vasculature and heart, reflection the presence of the AuNP in the 
circulation. After 48 hours, the attenuation in the spleen remained high, indicating AuNP 
accumulation. This organ was excised and monocytes were isolated. We found higher 
gold uptake in the enriched monocyte population, as compared to the discarded cell 
fraction (Figure 5.3b). This indicates that AuNP from intravenous injection were taken up 
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by monocytes in the spleen. Figure 5.3c shows the biodistribution after 48 hours with 
AuNP taken up to the greatest extent by the liver. 
 The uptake of AuNP in our purified monocyte population indicates that labeling of 
monocytes in the spleen may be achievable. However, the uptake of approximately 4 
pg/cell is considerably less than our ex-vivo labeling uptake values of 126 pg/cell. 
Further experiments on different AuNP formulations may be explored to improve uptake 
for the monocytes in the spleen. In this study, mPEG was used to provide long 
circulation for the AuNP; however mPEG is well known to minimize cell uptake, which 
may have contributed to low monocyte uptake values. Eventually, with adequate uptake 
in monocytes for detection, we envision pre-labeling monocytes in the spleen. 
Afterwards, we expect a significant injury leading to a strong inflammatory response will 
allow for detection of monocytes migrating from the spleen to the site of injury, as in the 
case of myocardial infarction. This cell tracking approach would open opportunities in 
studying monocyte response to various inflammation reactions, including the timing and 
magnitude of monocyte responses.  
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Figure 5.3 In-situ labeling of monocytes in the spleen. 
Wild-type mice received intravenous injections of AuNP-mPEG (250 mg/kg). (a) CT 
scans of mice pre-injection, 5 minutes, 60 minutes, 4 hours, 24 hours, and 48 hours post 
injection. Red arrows indicate the location of spleen. (b) ICP-OES quantification of gold 
uptake in monocyte enriched populations versus discarded cell populations. (c) 
Biodistribution of AuNP-mPEG after 48 hours. 
 
5.2.4 Alternative cell tracking for atherosclerosis 
 In our work, we focused on the role of monocytes in the progression of 
atherosclerosis. While monocyte recruitment contributes significantly to plaque 
progression, it is only one part of the inflammation story in atherosclerosis. A number of 
different cells, especially other leukocytes including neutrophils, dendritic cells, platelets 
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and T-cells, have been found contribute to plaque progression due to their association 
with inflammation.81-82 Similar to monocytes, the increase in expression of cellular 
adhesion molecules on endothelial cells promotes the adherence and extravasation of 
leukocytes into the vessel wall. The work with monocyte tracking with CT could be 
expanded to other cells playing a role in atherosclerosis.  
     Neutrophils are essential to the innate immune system and typically are the 
“first responders” to acute injury sites. More recently, the role of neutrophils in chronic 
diseases have attracted attention due their ability to release a number of different cell 
modulators including various cytokines.83-84 In atherosclerosis, neutrophil adherence and 
rolling relies on several chemokine receptors on their surface including CCR2, CXCR2 
and CCR5.85-86 Recent studies have shown that neutrophils play a role in recruiting 
monocytes to atherosclerotic lesions. In Cramp (neutrophil secreted protein) deficient 
mice, a reduction of early plaque formation was observed due to reduced monocytes 
recruitment.87 Other neutrophil secreted factors including cathepsin G and α-defensins 
also have shown to play role in driving monocyte recruitment into plaques.88-90 
Neutrophils have also demonstrated compounding effects to atherosclerosis progression 
including increasing endothelial dysfunction at plaque prone sites and promoting foam 
cell formation of lesional macrophages.91-92 Neutrophils represent a possible candidate 
for CT cell tracking to allow further elucidation of their role in plaque progression. 
  Along with monocytes, T-cells undergo recruitment to developing plaques 
through adherence to VCAM-1 and migration through CX3CR1 cell surface marker.81 In 
the plaque, with exposure to abundant low density lipids, T-cells differentiate into T-1 
helper cells (TH1).93 TH1 cells have been shown to be atherogenic with release of pro-
inflammatory cytokines including interferon-γ (IFN-γ), interleukin-12, and interleukin-
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18.94-96 Particularly, the release of IFN-γ can exacerbate plaque instability by further 
amplifying macrophage/foam cell release of degradation enzymes and proteases.97-98 
Also found in lesions were the presence of T-2 helper cells (TH2) and T-17 helper cells 
(TH17). However, the atherogenic or atheroprotective roles of these cells remain 
unclear.99 More recently, the role of T-regulatory (Treg) cells have become a point of 
investigation in atherosclerosis due to their auto-immunity protective properties. Treg cells 
have been found to have several functions in atherosclerosis including inhibiting foam 
cell formation, inhibiting macrophage activation, and inhibiting atherogenic properties of 
TH1 cells.100-103 The effects of Treg cells are mostly accomplished through the release of 
anti-inflammatory cytokines, interleukin-10 and transforming growth factor-β.104-105 
Inhibition of these cytokines has shown accelerated plaque progression.106-107 
Interestingly, Treg cells are found in low concentrations in plaques as compared to other 
inflammatory diseases, implying a suppression of their presence under atherosclerotic 
disease conditions.108-109 Therefore, there is considerable interest in utilizing Treg cells as 
a potential cell therapy for atherosclerosis.110-111 Studies enhancing migration of Treg cells 
to atherosclerosis may greatly benefit from similar cell tracking tools developed in our 
work. Cell tracking may also help further elucidate the effects of T-helper cells by altering 
their plaque migratory properties.        
  
5.2.5 Alternative CT cell tracking applications  
 X-ray computed tomography with high spatial and temporal resolution allows for 
imaging of the human coronary arteries and is therefore a preferred choice in developing 
cell tracking tools for the study of atherosclerosis. However, with advances in photon 
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counting CT, especially in material decomposition, the utility of cell tracking can be 
further expanded.  
 In a collaboration with Marlène Wiart from the Center for National Research 
(Lyon, France), we are exploring the use of our AuNP to track macrophages in the 
treatment of stroke. The work entails utilizing a gadolinium labeled scaffold to deliver 
AuNP labeled macrophages to the site of injury. The use of photon-counting CT allows 
for the discrimination between gold labeled macrophages and the gadolinium scaffold. 
This could provide information on cell migration from the scaffold to injured areas. While 
studies are still preliminary, the successful labeling of macrophages and their detection 
with photon-counting CT have been demonstrated (Figure 5.4).       
 
 
Figure 5.4 Gold labeling of macrophages for stroke cell therapies. 
(a) Labeling of primary macrophages with AuNP. (b) Detection of gold labeling 
macrophages using single photon counting CT. 3D overlay of gold specific image 
(yellow) on a conventional CT image (greyscale) with an injection of AuNP labeled 
macrophages in the brain 
 
5.3 Concluding remarks 
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 The work of monocyte cell tracking for CT, the improvement of labeling 
techniques has the opportunity for this tool to be utilized to study atherosclerotic 
mechanisms and therapies. The work reported in this thesis is the initial steps in using 
CT cell tracking to study monocyte recruitment. Overall, I think this work is a significant 
development in the use of CT as a cell tracking method, which has been relatively 
unexplored compared to MRI and PET. Few studies have reported the use of CT for cell 
tracking, but with rapidly improving CT technology, I believe that this field will grow, 
especially with the use of photon counting CT and material decomposition. With further 
research, I envisage that cell tracking will emerge as a valuable tool for the development 
and implementation of clinical cell therapies. 
 
 
226 
 
5.4 References  
1. Chithrani, D. B., Intracellular uptake, transport, and processing of gold 
nanostructures. Mol Membr Biol 2010, 27 (7), 299-311. 
2. Chithrani, B. D.; Ghazani, A. A.; Chan, W. C., Determining the size and shape 
dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 2006, 6 (4), 
662-668. 
3. Chithrani, B. D.; Chan, W. C., Elucidating the mechanism of cellular uptake and 
removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett 
2007, 7 (6), 1542-1550. 
4. Jiang, W.; Kim, B. Y.; Rutka, J. T.; Chan, W. C., Nanoparticle-mediated cellular 
response is size-dependent. Nat Nanotechnol 2008, 3 (3), 145-150. 
5. Gao, H.; Shi, W.; Freund, L. B., Mechanics of receptor-mediated endocytosis. 
Proc Natl Acad Sci U S A 2005, 102 (27), 9469-9474. 
6. Shi, W.; Wang, J.; Fan, X.; Gao, H., Size and shape effects on diffusion and 
absorption of colloidal particles near a partially absorbing sphere: implications for uptake 
of nanoparticles in animal cells. Phys Rev E Stat Nonlin Soft Matter Phys 2008, 78 (6 Pt 
1), 061914. 
7. Dale, D. C.; Boxer, L.; Liles, W. C., The phagocytes: neutrophils and monocytes. 
Blood 2008, 112 (4), 935-945. 
8. Lee, K. D.; Nir, S.; Papahadjopoulos, D., Quantitative analysis of liposome-cell 
interactions in vitro: rate constants of binding and endocytosis with suspension and 
adherent J774 cells and human monocytes. Biochemistry 1993, 32 (3), 889-899. 
 
227 
 
9. Jiang, X.; Musyanovych, A.; Rocker, C.; Landfester, K.; Mailander, V.; Nienhaus, 
G. U., Specific effects of surface carboxyl groups on anionic polystyrene particles in their 
interactions with mesenchymal stem cells. Nanoscale 2011, 3 (5), 2028-2035. 
10. Frohlich, E., The role of surface charge in cellular uptake and cytotoxicity of 
medical nanoparticles. Int J Nanomedicine 2012, 7, 5577-5591. 
11. Jiang, X.; Dausend, J.; Hafner, M.; Musyanovych, A.; Rocker, C.; Landfester, K.; 
Mailander, V.; Nienhaus, G. U., Specific effects of surface amines on polystyrene 
nanoparticles in their interactions with mesenchymal stem cells. Biomacromolecules 
2010, 11 (3), 748-753. 
12. Champion, J. A.; Walker, A.; Mitragotri, S., Role of particle size in phagocytosis 
of polymeric microspheres. Pharm Res 2008, 25 (8), 1815-1821. 
13. Lunov, O.; Syrovets, T.; Loos, C.; Beil, J.; Delacher, M.; Tron, K.; Nienhaus, G. 
U.; Musyanovych, A.; Mailander, V.; Landfester, K., et al., Differential uptake of 
functionalized polystyrene nanoparticles by human macrophages and a monocytic cell 
line. ACS Nano 2011, 5 (3), 1657-1669. 
14. Cai, H.; Yao, P., Gold nanoparticles with different amino acid surfaces: Serum 
albumin adsorption, intracellular uptake and cytotoxicity. Colloids Surf B Biointerfaces 
2014, 123, 900-906. 
15. Ritz, S.; Schottler, S.; Kotman, N.; Baier, G.; Musyanovych, A.; Kuharev, J.; 
Landfester, K.; Schild, H.; Jahn, O.; Tenzer, S., et al., Protein corona of nanoparticles: 
distinct proteins regulate the cellular uptake. Biomacromolecules 2015, 16 (4), 1311-
1321. 
16. Ahmad, J.; Ahamed, M.; Akhtar, M. J.; Alrokayan, S. A.; Siddiqui, M. A.; 
Musarrat, J.; Al-Khedhairy, A. A., Apoptosis induction by silica nanoparticles mediated 
 
228 
 
through reactive oxygen species in human liver cell line HepG2. Toxicol Appl Pharmacol 
2012, 259 (2), 160-168. 
17. Passagne, I.; Morille, M.; Rousset, M.; Pujalte, I.; L'Azou, B., Implication of 
oxidative stress in size-dependent toxicity of silica nanoparticles in kidney cells. 
Toxicology 2012, 299 (2-3), 112-124. 
18. Chuang, S. M.; Lee, Y. H.; Liang, R. Y.; Roam, G. D.; Zeng, Z. M.; Tu, H. F.; 
Wang, S. K.; Chueh, P. J., Extensive evaluations of the cytotoxic effects of gold 
nanoparticles. Biochim Biophys Acta 2013, 1830 (10), 4960-4973. 
19. Frohlich, E.; Samberger, C.; Kueznik, T.; Absenger, M.; Roblegg, E.; Zimmer, A.; 
Pieber, T. R., Cytotoxicity of nanoparticles independent from oxidative stress. J Toxicol 
Sci 2009, 34 (4), 363-375. 
20. Chueh, P. J.; Liang, R. Y.; Lee, Y. H.; Zeng, Z. M.; Chuang, S. M., Differential 
cytotoxic effects of gold nanoparticles in different mammalian cell lines. J Hazard Mater 
2014, 264, 303-312. 
21. Coradeghini, R.; Gioria, S.; Garcia, C. P.; Nativo, P.; Franchini, F.; Gilliland, D.; 
Ponti, J.; Rossi, F., Size-dependent toxicity and cell interaction mechanisms of gold 
nanoparticles on mouse fibroblasts. Toxicol Lett 2013, 217 (3), 205-216. 
22. Cui, W.; Li, J.; Zhang, Y.; Rong, H.; Lu, W.; Jiang, L., Effects of aggregation and 
the surface properties of gold nanoparticles on cytotoxicity and cell growth. 
Nanomedicine 2012, 8 (1), 46-53. 
23. Pan, Y.; Neuss, S.; Leifert, A.; Fischler, M.; Wen, F.; Simon, U.; Schmid, G.; 
Brandau, W.; Jahnen-Dechent, W., Size-dependent cytotoxicity of gold nanoparticles. 
Small 2007, 3 (11), 1941-1949. 
 
229 
 
24. Moghimi, S. M.; Symonds, P.; Murray, J. C.; Hunter, A. C.; Debska, G.; 
Szewczyk, A., A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for 
gene transfer/therapy. Mol Ther 2005, 11 (6), 990-995. 
25. Fischer, D.; Li, Y.; Ahlemeyer, B.; Krieglstein, J.; Kissel, T., In vitro cytotoxicity 
testing of polycations: influence of polymer structure on cell viability and hemolysis. 
Biomaterials 2003, 24 (7), 1121-1131. 
26. Hyafil, F.; Cornily, J. C.; Feig, J. E.; Gordon, R.; Vucic, E.; Amirbekian, V.; Fisher, 
E. A.; Fuster, V.; Feldman, L. J.; Fayad, Z. A., Noninvasive detection of macrophages 
using a nanoparticulate contrast agent for computed tomography. Nat Med 2007, 13 (5), 
636-641. 
27. Eck, W.; Nicholson, A. I.; Zentgraf, H.; Semmler, W.; Bartling, S., Anti-CD4-
targeted gold nanoparticles induce specific contrast enhancement of peripheral lymph 
nodes in X-ray computed tomography of live mice. Nano Lett 2010, 10 (7), 2318-2322. 
28. Gordon, S.; Taylor, P. R., Monocyte and macrophage heterogeneity. Nat Rev 
Immunol 2005, 5 (12), 953-964. 
29. Geissmann, F.; Jung, S.; Littman, D. R., Blood monocytes consist of two principal 
subsets with distinct migratory properties. Immunity 2003, 19 (1), 71-82. 
30. Passlick, B.; Flieger, D.; Ziegler-Heitbrock, H. W., Identification and 
characterization of a novel monocyte subpopulation in human peripheral blood. Blood 
1989, 74 (7), 2527-2534. 
31. Yang, J.; Zhang, L.; Yu, C.; Yang, X. F.; Wang, H., Monocyte and macrophage 
differentiation: circulation inflammatory monocyte as biomarker for inflammatory 
diseases. Biomark Res 2014, 2 (1), 1. 
 
230 
 
32. Swirski, F. K.; Nahrendorf, M.; Etzrodt, M.; Wildgruber, M.; Cortez-Retamozo, V.; 
Panizzi, P.; Figueiredo, J. L.; Kohler, R. H.; Chudnovskiy, A.; Waterman, P., et al., 
Identification of splenic reservoir monocytes and their deployment to inflammatory sites. 
Science 2009, 325 (5940), 612-616. 
33. Schirra, C. O.; Brendel, B.; Anastasio, M. A.; Roessl, E., Spectral CT: a 
technology primer for contrast agent development. Contrast Media Mol Imaging 2014, 9 
(1), 62-70. 
34. Roessl, E.; Brendel, B.; Engel, K. J.; Schlomka, J. P.; Thran, A.; Proksa, R., 
Sensitivity of photon-counting based K-edge imaging in X-ray computed tomography. 
IEEE Trans Med Imaging 2011, 30 (9), 1678-1690. 
35. Cormode, D. P.; Roessl, E.; Thran, A.; Skajaa, T.; Gordon, R. E.; Schlomka, J. 
P.; Fuster, V.; Fisher, E. A.; Mulder, W. J.; Proksa, R., et al., Atherosclerotic plaque 
composition: analysis with multicolor CT and targeted gold nanoparticles. Radiology 
2010, 256 (3), 774-782. 
36. Singh, S.; Khawaja, R. D.; Pourjabbar, S.; Padole, A.; Lira, D.; Kalra, M. K., 
Iterative image reconstruction and its role in cardiothoracic computed tomography. J 
Thorac Imaging 2013, 28 (6), 355-367. 
37. Bernstein, A. L.; Dhanantwari, A.; Jurcova, M.; Cheheltani, R.; Naha, P. C.; 
Ivanc, T.; Shefer, E.; Cormode, D. P., Improved sensitivity of computed tomography 
towards iodine and gold nanoparticle contrast agents via iterative reconstruction 
methods. Sci Rep 2016, 6, 26177. 
38. Dansky, H. M.; Barlow, C. B.; Lominska, C.; Sikes, J. L.; Kao, C.; Weinsaft, J.; 
Cybulsky, M. I.; Smith, J. D., Adhesion of monocytes to arterial endothelium and 
 
231 
 
initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 
gene dosage. Arterioscler Thromb Vasc Biol 2001, 21 (10), 1662-1667. 
39. Kumar, A.; Hoover, J. L.; Simmons, C. A.; Lindner, V.; Shebuski, R. J., 
Remodeling and neointimal formation in the carotid artery of normal and P-selectin-
deficient mice. Circulation 1997, 96 (12), 4333-4342. 
40. Nageh, M. F.; Sandberg, E. T.; Marotti, K. R.; Lin, A. H.; Melchior, E. P.; Bullard, 
D. C.; Beaudet, A. L., Deficiency of inflammatory cell adhesion molecules protects 
against atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1997, 17 (8), 1517-1520. 
41. Patel, S. S.; Thiagarajan, R.; Willerson, J. T.; Yeh, E. T., Inhibition of alpha4 
integrin and ICAM-1 markedly attenuate macrophage homing to atherosclerotic plaques 
in ApoE-deficient mice. Circulation 1998, 97 (1), 75-81. 
42. Cybulsky, M. I.; Iiyama, K.; Li, H.; Zhu, S.; Chen, M.; Iiyama, M.; Davis, V.; 
Gutierrez-Ramos, J. C.; Connelly, P. W.; Milstone, D. S., A major role for VCAM-1, but 
not ICAM-1, in early atherosclerosis. J Clin Invest 2001, 107 (10), 1255-1262. 
43. Schreiner, E. P.; Kern, M.; Steck, A.; Foster, C. A., Synthesis of ether analogues 
derived from HUN-7293 and evaluation as inhibitors of VCAM-1 expression. Bioorg Med 
Chem Lett 2004, 14 (19), 5003-5006. 
44. Besemer, J.; Harant, H.; Wang, S.; Oberhauser, B.; Marquardt, K.; Foster, C. A.; 
Schreiner, E. P.; de Vries, J. E.; Dascher-Nadel, C.; Lindley, I. J., Selective inhibition of 
cotranslational translocation of vascular cell adhesion molecule 1. Nature 2005, 436 
(7048), 290-293. 
45. Dey, D.; Achenbach, S.; Schuhbaeck, A.; Pflederer, T.; Nakazato, R.; Slomka, P. 
J.; Berman, D. S.; Marwan, M., Comparison of quantitative atherosclerotic plaque 
 
232 
 
burden from coronary CT angiography in patients with first acute coronary syndrome and 
stable coronary artery disease. J Cardiovasc Comput Tomogr 2014, 8 (5), 368-374. 
46. Boring, L.; Gosling, J.; Cleary, M.; Charo, I. F., Decreased lesion formation in 
CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 
1998, 394 (6696), 894-897. 
47. Combadiere, C.; Potteaux, S.; Gao, J. L.; Esposito, B.; Casanova, S.; Lee, E. J.; 
Debre, P.; Tedgui, A.; Murphy, P. M.; Mallat, Z., Decreased atherosclerotic lesion 
formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 2003, 107 (7), 
1009-1016. 
48. Combadiere, C.; Potteaux, S.; Rodero, M.; Simon, T.; Pezard, A.; Esposito, B.; 
Merval, R.; Proudfoot, A.; Tedgui, A.; Mallat, Z., Combined inhibition of CCL2, CX3CR1, 
and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes 
atherosclerosis in hypercholesterolemic mice. Circulation 2008, 117 (13), 1649-1657. 
49. Tacke, F.; Alvarez, D.; Kaplan, T. J.; Jakubzick, C.; Spanbroek, R.; Llodra, J.; 
Garin, A.; Liu, J.; Mack, M.; van Rooijen, N., et al., Monocyte subsets differentially 
employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin 
Invest 2007, 117 (1), 185-194. 
50. Gilbert, J.; Lekstrom-Himes, J.; Donaldson, D.; Lee, Y.; Hu, M.; Xu, J.; Wyant, T.; 
Davidson, M.; Group, M. L. N. S., Effect of CC chemokine receptor 2 CCR2 blockade on 
serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide 
polymorphism of the monocyte chemoattractant protein-1 promoter region. Am J Cardiol 
2011, 107 (6), 906-911. 
 
233 
 
51. Kwak, B. R.; Veillard, N.; Pelli, G.; Mulhaupt, F.; James, R. W.; Chanson, M.; 
Mach, F., Reduced connexin43 expression inhibits atherosclerotic lesion formation in 
low-density lipoprotein receptor-deficient mice. Circulation 2003, 107 (7), 1033-1039. 
52. Ostermann, G.; Fraemohs, L.; Baltus, T.; Schober, A.; Lietz, M.; Zernecke, A.; 
Liehn, E. A.; Weber, C., Involvement of JAM-A in mononuclear cell recruitment on 
inflamed or atherosclerotic endothelium: inhibition by soluble JAM-A. Arterioscler 
Thromb Vasc Biol 2005, 25 (4), 729-735. 
53. Zernecke, A.; Liehn, E. A.; Fraemohs, L.; von Hundelshausen, P.; Koenen, R. R.; 
Corada, M.; Dejana, E.; Weber, C., Importance of junctional adhesion molecule-A for 
neointimal lesion formation and infiltration in atherosclerosis-prone mice. Arterioscler 
Thromb Vasc Biol 2006, 26 (2), e10-13. 
54. Afek, A.; Kogan, E.; Maysel-Auslender, S.; Mor, A.; Regev, E.; Rubinstein, A.; 
Keren, G.; George, J., Clopidogrel attenuates atheroma formation and induces a stable 
plaque phenotype in apolipoprotein E knockout mice. Microvasc Res 2009, 77 (3), 364-
369. 
55. da Costa Martins, P.; van den Berk, N.; Ulfman, L. H.; Koenderman, L.; Hordijk, 
P. L.; Zwaginga, J. J., Platelet-monocyte complexes support monocyte adhesion to 
endothelium by enhancing secondary tethering and cluster formation. Arterioscler 
Thromb Vasc Biol 2004, 24 (1), 193-199. 
56. Pan, J. H.; Sukhova, G. K.; Yang, J. T.; Wang, B.; Xie, T.; Fu, H.; Zhang, Y.; 
Satoskar, A. R.; David, J. R.; Metz, C. N., et al., Macrophage migration inhibitory factor 
deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. 
Circulation 2004, 109 (25), 3149-3153. 
 
234 
 
57. Schober, A.; Bernhagen, J.; Thiele, M.; Zeiffer, U.; Knarren, S.; Roller, M.; 
Bucala, R.; Weber, C., Stabilization of atherosclerotic plaques by blockade of 
macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient 
mice. Circulation 2004, 109 (3), 380-385. 
58. Ngen, E. J.; Artemov, D., Advances in Monitoring Cell-Based Therapies with 
Magnetic Resonance Imaging: Future Perspectives. Int J Mol Sci 2017, 18 (1). 
59. Otero, H. J.; Steigner, M. L.; Rybicki, F. J., The "post-64" era of coronary CT 
angiography: understanding new technology from physical principles. Radiol Clin North 
Am 2009, 47 (1), 79-90. 
60. Galper, M. W.; Saung, M. T.; Fuster, V.; Roessl, E.; Thran, A.; Proksa, R.; Fayad, 
Z. A.; Cormode, D. P., Effect of computed tomography scanning parameters on gold 
nanoparticle and iodine contrast. Invest Radiol 2012, 47 (8), 475-481. 
61. Nemzek, J. A.; Bolgos, G. L.; Williams, B. A.; Remick, D. G., Differences in 
normal values for murine white blood cell counts and other hematological parameters 
based on sampling site. Inflamm Res 2001, 50 (10), 523-527. 
62. Johnson, W. D., Jr.; Mei, B.; Cohn, Z. A., The separation, long-term cultivation, 
and maturation of the human monocyte. J Exp Med 1977, 146 (6), 1613-1626. 
63. Fesnak, A.; Lin, C.; Siegel, D. L.; Maus, M. V., CAR-T Cell Therapies From the 
Transfusion Medicine Perspective. Transfus Med Rev 2016, 30 (3), 139-145. 
64. Krug, C.; Wiesinger, M.; Abken, H.; Schuler-Thurner, B.; Schuler, G.; Dorrie, J.; 
Schaft, N., A GMP-compliant protocol to expand and transfect cancer patient T cells with 
mRNA encoding a tumor-specific chimeric antigen receptor. Cancer Immunol 
Immunother 2014, 63 (10), 999-1008. 
 
235 
 
65. Coelho, A. V.; de Moura, R. R.; Kamada, A. J.; da Silva, R. C.; Guimaraes, R. L.; 
Brandao, L. A.; de Alencar, L. C.; Crovella, S., Dendritic Cell-Based Immunotherapies to 
Fight HIV: How Far from a Success Story? A Systematic Review and Meta-Analysis. Int 
J Mol Sci 2016, 17 (12). 
66. Fujii, S.; Takayama, T.; Asakura, M.; Aki, K.; Fujimoto, K.; Shimizu, K., Dendritic 
cell-based cancer immunotherapies. Arch Immunol Ther Exp (Warsz) 2009, 57 (3), 189-
198. 
67. Matsue, H.; Morita, A.; Matsue, K.; Takashima, A., New technologies toward 
dendritic cell-based cancer immunotherapies. J Dermatol 1999, 26 (11), 757-763. 
68. Cao, H.; Verge, V.; Baron, C.; Martinache, C.; Leon, A.; Scholl, S.; Gorin, N. C.; 
Salamero, J.; Assari, S.; Bernard, J., et al., In vitro generation of dendritic cells from 
human blood monocytes in experimental conditions compatible for in vivo cell therapy. J 
Hematother Stem Cell Res 2000, 9 (2), 183-194. 
69. Pullarkat, V.; Lau, R.; Lee, S. M.; Bender, J. G.; Weber, J. S., Large-scale 
monocyte enrichment coupled with a closed culture system for the generation of human 
dendritic cells. J Immunol Methods 2002, 267 (2), 173-183. 
70. Perseghin, P.; D'Amico, G.; Dander, E.; Gaipa, G.; Dassi, M.; Biagi, E.; Biondi, 
A., Isolation of monocytes from leukapheretic products for large-scale GMP-grade 
generation of cytomegalovirus-specific T-cell lines by means of an automated elutriation 
device. Transfusion 2008, 48 (8), 1644-1649. 
71. Nahrendorf, M.; Pittet, M. J.; Swirski, F. K., Monocytes: protagonists of infarct 
inflammation and repair after myocardial infarction. Circulation 2010, 121 (22), 2437-
2445. 
 
236 
 
72. Nahrendorf, M.; Swirski, F. K.; Aikawa, E.; Stangenberg, L.; Wurdinger, T.; 
Figueiredo, J. L.; Libby, P.; Weissleder, R.; Pittet, M. J., The healing myocardium 
sequentially mobilizes two monocyte subsets with divergent and complementary 
functions. J Exp Med 2007, 204 (12), 3037-3047. 
73. Bouchentouf, M.; Paradis, P.; Forner, K. A.; Cuerquis, J.; Boivin, M. N.; Zheng, 
J.; Boulassel, M. R.; Routy, J. P.; Schiffrin, E. L.; Galipeau, J., Monocyte derivatives 
promote angiogenesis and myocyte survival in a model of myocardial infarction. Cell 
Transplant 2010, 19 (4), 369-386. 
74. Panizzi, P.; Swirski, F. K.; Figueiredo, J. L.; Waterman, P.; Sosnovik, D. E.; 
Aikawa, E.; Libby, P.; Pittet, M.; Weissleder, R.; Nahrendorf, M., Impaired infarct healing 
in atherosclerotic mice with Ly-6C(hi) monocytosis. J Am Coll Cardiol 2010, 55 (15), 
1629-1638. 
75. van Amerongen, M. J.; Harmsen, M. C.; van Rooijen, N.; Petersen, A. H.; van 
Luyn, M. J., Macrophage depletion impairs wound healing and increases left ventricular 
remodeling after myocardial injury in mice. Am J Pathol 2007, 170 (3), 818-829. 
76. Wei, H.; Ooi, T. H.; Tan, G.; Lim, S. Y.; Qian, L.; Wong, P.; Shim, W., Cell 
delivery and tracking in post-myocardial infarction cardiac stem cell therapy: an 
introduction for clinical researchers. Heart Fail Rev 2010, 15 (1), 1-14. 
77. Hey, Y. Y.; Tan, J. K.; O'Neill, H. C., Redefining Myeloid Cell Subsets in Murine 
Spleen. Front Immunol 2015, 6, 652. 
78. Seifert, H. A.; Hall, A. A.; Chapman, C. B.; Collier, L. A.; Willing, A. E.; 
Pennypacker, K. R., A transient decrease in spleen size following stroke corresponds to 
splenocyte release into systemic circulation. J Neuroimmune Pharmacol 2012, 7 (4), 
1017-1024. 
 
237 
 
79. Wu, W.; Zhang, J.; Yang, W.; Hu, B.; Fallon, M. B., Role of splenic reservoir 
monocytes in pulmonary vascular monocyte accumulation in experimental 
hepatopulmonary syndrome. J Gastroenterol Hepatol 2016, 31 (11), 1888-1894. 
80. van der Laan, A. M.; Ter Horst, E. N.; Delewi, R.; Begieneman, M. P.; Krijnen, P. 
A.; Hirsch, A.; Lavaei, M.; Nahrendorf, M.; Horrevoets, A. J.; Niessen, H. W., et al., 
Monocyte subset accumulation in the human heart following acute myocardial infarction 
and the role of the spleen as monocyte reservoir. Eur Heart J 2014, 35 (6), 376-385. 
81. Libby, P., Inflammation in atherosclerosis. Nature 2002, 420 (6917), 868-874. 
82. Libby, P.; Lichtman, A. H.; Hansson, G. K., Immune effector mechanisms 
implicated in atherosclerosis: from mice to humans. Immunity 2013, 38 (6), 1092-1104. 
83. Drechsler, M.; Doring, Y.; Megens, R. T.; Soehnlein, O., Neutrophilic 
granulocytes - promiscuous accelerators of atherosclerosis. Thromb Haemost 2011, 106 
(5), 839-848. 
84. Mocsai, A., Diverse novel functions of neutrophils in immunity, inflammation, and 
beyond. J Exp Med 2013, 210 (7), 1283-1299. 
85. de Jager, S. C.; Bongaerts, B. W.; Weber, M.; Kraaijeveld, A. O.; Rousch, M.; 
Dimmeler, S.; van Dieijen-Visser, M. P.; Cleutjens, K. B.; Nelemans, P. J.; van Berkel, T. 
J., et al., Chemokines CCL3/MIP1alpha, CCL5/RANTES and CCL18/PARC are 
independent risk predictors of short-term mortality in patients with acute coronary 
syndromes. PLoS One 2012, 7 (9), e45804. 
86. Nencioni, A.; da Silva, R. F.; Fraga-Silva, R. A.; Steffens, S.; Fabre, M.; Bauer, I.; 
Caffa, I.; Magnone, M.; Sociali, G.; Quercioli, A., et al., Nicotinamide 
phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and 
 
238 
 
associated neutrophil infiltration in atherosclerotic mice. Thromb Haemost 2014, 111 (2), 
308-322. 
87. Doring, Y.; Drechsler, M.; Wantha, S.; Kemmerich, K.; Lievens, D.; Vijayan, S.; 
Gallo, R. L.; Weber, C.; Soehnlein, O., Lack of neutrophil-derived CRAMP reduces 
atherosclerosis in mice. Circ Res 2012, 110 (8), 1052-1056. 
88. Chertov, O.; Ueda, H.; Xu, L. L.; Tani, K.; Murphy, W. J.; Wang, J. M.; Howard, 
O. M.; Sayers, T. J.; Oppenheim, J. J., Identification of human neutrophil-derived 
cathepsin G and azurocidin/CAP37 as chemoattractants for mononuclear cells and 
neutrophils. J Exp Med 1997, 186 (5), 739-747. 
89. Chertov, O.; Michiel, D. F.; Xu, L.; Wang, J. M.; Tani, K.; Murphy, W. J.; Longo, 
D. L.; Taub, D. D.; Oppenheim, J. J., Identification of defensin-1, defensin-2, and 
CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-
stimulated neutrophils. J Biol Chem 1996, 271 (6), 2935-2940. 
90. Sun, R.; Iribarren, P.; Zhang, N.; Zhou, Y.; Gong, W.; Cho, E. H.; Lockett, S.; 
Chertov, O.; Bednar, F.; Rogers, T. J., et al., Identification of neutrophil granule protein 
cathepsin G as a novel chemotactic agonist for the G protein-coupled formyl peptide 
receptor. J Immunol 2004, 173 (1), 428-436. 
91. Hartwig, H.; Silvestre Roig, C.; Daemen, M.; Lutgens, E.; Soehnlein, O., 
Neutrophils in atherosclerosis. A brief overview. Hamostaseologie 2015, 35 (2), 121-127. 
92. Soehnlein, O., Multiple roles for neutrophils in atherosclerosis. Circ Res 2012, 
110 (6), 875-888. 
93. Stemme, S.; Faber, B.; Holm, J.; Wiklund, O.; Witztum, J. L.; Hansson, G. K., T 
lymphocytes from human atherosclerotic plaques recognize oxidized low density 
lipoprotein. Proc Natl Acad Sci U S A 1995, 92 (9), 3893-3897. 
 
239 
 
94. Lee, T. S.; Yen, H. C.; Pan, C. C.; Chau, L. Y., The role of interleukin 12 in the 
development of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 
1999, 19 (3), 734-742. 
95. Whitman, S. C.; Ravisankar, P.; Daugherty, A., Interleukin-18 enhances 
atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ 
Res 2002, 90 (2), E34-38. 
96. Whitman, S. C.; Ravisankar, P.; Elam, H.; Daugherty, A., Exogenous interferon-
gamma enhances atherosclerosis in apolipoprotein E-/- mice. Am J Pathol 2000, 157 
(6), 1819-1824. 
97. Tedgui, A.; Mallat, Z., Cytokines in atherosclerosis: pathogenic and regulatory 
pathways. Physiol Rev 2006, 86 (2), 515-581. 
98. Gupta, S.; Pablo, A. M.; Jiang, X.; Wang, N.; Tall, A. R.; Schindler, C., IFN-
gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 1997, 99 (11), 
2752-2761. 
99. Lahoute, C.; Herbin, O.; Mallat, Z.; Tedgui, A., Adaptive immunity in 
atherosclerosis: mechanisms and future therapeutic targets. Nat Rev Cardiol 2011, 8 (6), 
348-358. 
100. von Boehmer, H.; Daniel, C., Therapeutic opportunities for manipulating T(Reg) 
cells in autoimmunity and cancer. Nat Rev Drug Discov 2013, 12 (1), 51-63. 
101. Foks, A. C.; Lichtman, A. H.; Kuiper, J., Treating atherosclerosis with regulatory 
T cells. Arterioscler Thromb Vasc Biol 2015, 35 (2), 280-287. 
102. Lin, J.; Li, M.; Wang, Z.; He, S.; Ma, X.; Li, D., The role of CD4+CD25+ 
regulatory T cells in macrophage-derived foam-cell formation. J Lipid Res 2010, 51 (5), 
1208-1217. 
 
240 
 
103. Tiemessen, M. M.; Jagger, A. L.; Evans, H. G.; van Herwijnen, M. J.; John, S.; 
Taams, L. S., CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of 
human monocytes/macrophages. Proc Natl Acad Sci U S A 2007, 104 (49), 19446-
19451. 
104. George, J.; Schwartzenberg, S.; Medvedovsky, D.; Jonas, M.; Charach, G.; Afek, 
A.; Shamiss, A., Regulatory T cells and IL-10 levels are reduced in patients with 
vulnerable coronary plaques. Atherosclerosis 2012, 222 (2), 519-523. 
105. Robertson, A. K.; Rudling, M.; Zhou, X.; Gorelik, L.; Flavell, R. A.; Hansson, G. 
K., Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest 
2003, 112 (9), 1342-1350. 
106. Pinderski Oslund, L. J.; Hedrick, C. C.; Olvera, T.; Hagenbaugh, A.; Territo, M.; 
Berliner, J. A.; Fyfe, A. I., Interleukin-10 blocks atherosclerotic events in vitro and in vivo. 
Arterioscler Thromb Vasc Biol 1999, 19 (12), 2847-2853. 
107. Mallat, Z.; Gojova, A.; Marchiol-Fournigault, C.; Esposito, B.; Kamate, C.; Merval, 
R.; Fradelizi, D.; Tedgui, A., Inhibition of transforming growth factor-beta signaling 
accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ 
Res 2001, 89 (10), 930-934. 
108. Mor, A.; Planer, D.; Luboshits, G.; Afek, A.; Metzger, S.; Chajek-Shaul, T.; Keren, 
G.; George, J., Role of naturally occurring CD4+ CD25+ regulatory T cells in 
experimental atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27 (4), 893-900. 
109. Maganto-Garcia, E.; Tarrio, M. L.; Grabie, N.; Bu, D. X.; Lichtman, A. H., 
Dynamic changes in regulatory T cells are linked to levels of diet-induced 
hypercholesterolemia. Circulation 2011, 124 (2), 185-195. 
 
241 
 
110. van Puijvelde, G. H.; van Es, T.; van Wanrooij, E. J.; Habets, K. L.; de Vos, P.; 
van der Zee, R.; van Eden, W.; van Berkel, T. J.; Kuiper, J., Induction of oral tolerance to 
HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis. 
Arterioscler Thromb Vasc Biol 2007, 27 (12), 2677-2683. 
111. Ait-Oufella, H.; Salomon, B. L.; Potteaux, S.; Robertson, A. K.; Gourdy, P.; Zoll, 
J.; Merval, R.; Esposito, B.; Cohen, J. L.; Fisson, S., et al., Natural regulatory T cells 
control the development of atherosclerosis in mice. Nat Med 2006, 12 (2), 178-180. 
 
242 
 
List of publications  
(from Ph.D studies) 
 Naha PC, Lau KC, Hsu JC, Hajfathalian M, Mian S, Chhour P, Uppulari L, 
MacDonald, ES, Maidment ADA, Cormode DP. (2016) Gold silver alloy 
nanoparticles (GSAN): an imaging probe for breast cancer screening with dual 
energy mammography or computed tomography. Nanoscale. 8, 13740-13754 
 Chhour P, Kim J, Benardo B, Tovar A, Mian S, Litt HI, Ferrari VA, Cormode DP. 
(2016) Effect of gold nanoparticle size and coating on labeling monocytes for CT 
tracking. Bioconjugate Chemisty. 28(1), pp 260–269 (Chapter 3) 
 Chhour P, Cheheltani R, Naha PC, Litt HI, Ferrari VA, Cormode DP. (2016) 
Nanoparticles for Cardiovascular Imaging with CT. Book Chapter in Design and 
Applications of Nanoparticles in Biomedical Imaging. Springer. ISBN 978-3-319-
42169-8, pp 357-384. (Chapter 1) 
 Cheheltani R, Ezzibdeh RM, Chhour P, Chandrika K, Jurcova M, Hsu JC, 
Blundell C, Litt HI, Ferrari VA, Allcock HA, Sehgal CM, Cormode DP. (2016) 
Tunable, biodegradable gold nanoparticles as contrast agents for computed 
tomography and photoacoustic imaging. Biomaterials. (102), 87-97. (Chapter 2) 
 Chhour P, Naha PC, O’Neill SM, Litt HI, Reilly MP, Ferrari VA, Cormode DP. 
(2016) Labeling monocytes with gold nanoparticles to track their recruitment in 
atherosclerosis with computed tomography. Biomaterials. (87), 93-103. (Chapter 
4) 
 Chhour P, Naha PC, Cheheltani R, Benardo B, Mian S, Cormode DP. (2015) 
Gold nanoparticles for biomedical applications: synthesis and in vitro evaluation. 
 
243 
 
Book Chapter in Nanomaterials in Pharmacology. Springer Protocols. ISBN 978-
1-4939-3121-7, pp 87-111 
 Teraphongphom NT, Chhour P, Naha PC, Witschey WRT, Jablonowski L, 
Opasanont B, Cormode DP, Wheatley MA. (2015) Nanocrystal loaded polymeric 
microbubbles as contrast agents for multimodal imaging. Langmuir. 31(43): 
11858-11867 
 Naha PC, Chhour P, Cormode DP. (2015) Systematic in vitro toxicological 
screening of gold nanoparticles designed for nanomedicine applications. 
Toxicology in Vitro. 29(7):1445-1453 
 Naha PC, Al-Zaki A, Hecht E, Chorny M, Chhour P, Blankemeyer E, Yates DM, 
Witschey WRT, Litt HI, Tsourkas A, Cormode DP. (2014) Dextran coated 
bismuth–iron oxide nanohybrid contrast agents for computed tomography and 
magnetic resonance imaging. Journal of Materials Chemistry B. 2, 8239-8248 
 Chhour P, Gallo N, Cheheltani R, Williams D, Al-Zaki A, Paik T, Nichol JL, Tian 
Z, Naha PC, Witschey WRT, Allcock HR, Murray CB, Tsourkas A, Cormode DP. 
(2014) Nanodisco Balls: Control over Surface versus Core Loading of 
Diagnostically Active Nanocrystals into Polymer Nanoparticles. ACS Nano.  8 
(9):9143–9153 (Chapter 2) 
 
